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African animal trypanosomosis is a devastating disease affecting livestock mainly found in 
sub-Saharan Africa. This disease is known as nagana and is transmitted by the trypanosome 
parasite from the tsetse fly vector to a mammalian host. There are three African 
trypanosomes namely Trypanosoma vivax, T. congolense and T. brucei brucei that are the 
causative agents responsible for this disease in African cattle. This disease is serious since it 
not only affects livestock but also has a negative impact on the sub-Saharan African 
economy. There is, therefore, a great demand for better control methods of the disease and 
suitable diagnostic methods.  
 
Current control measures such as the use of trypanocidal drugs, tsetse fly eradication 
methods and trypanotolerant cattle have become inadequate. The defence mechanism of the 
trypanosome to continuously change its surface coat by a process of antigenic variation has 
made it impossible to produce a suitable vaccine. Therefore, chemotherapy is still one of the 
key approaches for control of this wasting disease. The long existence of the current 
trypanocidal drugs has allowed the development of drug resistance. The development of new 
chemotherapeutic drugs is focused on targeting the pathogenic factors such as parasite 
cysteine peptidases that contribute to the disease. 
 
Vivapain is the main cysteine peptidase of T. vivax and shares high sequence identity with 
congopain, the main cysteine peptidase of T. congolense, which was previously shown to be 
a pathogenic factor contributing to trypanosomosis. Vivapain, thus, has potential as a target 
for chemotherapeutic drug design. Hence, the first part of this study involved the 
recombinant expression and enzymatic characterisation of vivapain for future production of 
new synthetic inhibitors for the use in new trypanocidal drugs.  
 
The catalytic domain of vivapain (Vp) was recombinantly expressed in the Pichia pastoris 
yeast expression system and enzymatically characterised. The main finding from this study 
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was that Vp was only able to hydrolyse a substrate if the P2 position was occupied by either a 
hydrophobic Phe or Leu residue. Vp was also found to be active close to physiological pH 
and was inhibited by the reversible cysteine peptidases, leupeptin, antipain and chymostatin 
and the irreversible cysteine peptidases L-trans-epoxysuccinyl-leucylamido (4-guanidino) 
butane (E-64), iodoacetic acid (IAA) and iodoacetamide (IAN). 
 
A further important aspect of controlling trypanosomosis is the diagnosis of the disease. 
Clinical, parasitological, molecular and serological techniques have been applied and used to 
diagnose trypanosomosis. One of the most promising serological techniques has proven to be 
the enzyme-linked immunosorbent assay (ELISA), more specifically the antibody and 
antigen detection ELISAs. The main requirement for this technique is a readily available and 
reproducible antigen such as that produced by recombinant expression. 
 
While there are recombinant antigens that are available to be used to detect T. congolense, T. 
brucei brucei and even T. evansi infections, there are none available to detect T. vivax 
infections. In the second part of this study, a mutant inactive full length form of vivapain 
(∆FLVp) was expressed in a bacterial expression system for the detection of T. vivax 
infections. Antibodies against this antigen were produced in both chickens and mice. Both 
the chicken IgY and mice sera were able to detect the recombinant ∆FLVp in western blots. 
The mice sera were also able to detect native vivapain in a T. vivax lysate, which is very 
promising for future use of the ∆FLVp antigen and the corresponding antibodies in diagnosis 
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1. LITERATURE REVIEW                                                                                                                 
1.1 AFRICAN ANIMAL TRYPANOSOMOSIS 
African animal trypanosomosis is a serious haemoparasitic endemic disease caused by the 
transmission of parasites known as trypanosomes from a tsetse fly vector, Glossina species, 
to a mammalian host. Tsetse-transmitted trypanosomosis is mainly found in sub-Saharan 
Africa distributed over an area of between 8 and 11 million km2 (Hursey 2001; Krafsur 
2003; Antoine-Moussiaux et al. 2009). The distribution of trypanosomes correlates to the 
distribution of tsetse flies in sub-Saharan Africa (Van den Bossche 2001). This location of 
tsetse flies is known as the tsetse fly belt (Fig. 1.1).  African trypanosomes that affect cattle 
are Trypanosoma congolense, T. vivax and to a lesser extent T. brucei brucei, causing a 
disease known as nagana. The symptoms of nagana are anaemia, weight loss, decline in 
productivity and sometimes even death (Lalmanach et al. 2002). This disease affects 
approximately 46 million cattle and causes a staggering economic loss of US $4.5 billion 
annually for sub-Saharan Africa (Swallow 2000; Antoine-Moussiaux et al. 2009).  
The control measures for African animal trypanosomosis include tsetse fly eradication, the 
use of trypanocidal drugs and livestock that have acquired the genetic trait of resistance to 
trypanosomosis (trypanotolerant cattle) (Naessens et al. 2002; Aksoy 2003; Holmes et al. 
2004). Attempts to eradicate tsetse fly populations involve the use of trypanocidal sprays, 
which is a problem since it has a negative impact on the environment (Allsopp and Hursey 
2004). The use of trypanotolerant cattle is a good approach; however, their small size and 
low productivity has led to farmers using them less often (Murray et al. 2004). The 
trypanocidal drugs used for African animal trypanosomosis include isometamidium 
chloride, homidium and diminazene aceturate. These very expensive drugs have been 
around for over five decades and the greatest problem associated with their use is the 
emergence of drug resistance (Anene et al. 2001).  
With this in mind there is a great demand for new control measures. Chemotherapy is still 
the key approach and it is based on targeting the pathogenic factors that cause the disease    
(Antoine-Moussiaux et al. 2009). Peptidases, more importantly cysteine peptidases of the 
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parasite, have vital functions in trypanosomosis, including the invasion of host cells and 
tissues, the breakdown of mediators involved in the host immune response and the 
hydrolysis of host proteins in order to sustain the nutritional needs of the parasite 
(Rosenthal 1999). Since these cysteine peptidases contribute to the pathogenesis of the 
disease it is likely that they would be good targets for chemotherapeutic drugs (Robertson 
et al. 1996). 
 
 
Figure 1.1 Illustration of the distribution of cattle and tsetse flies in Africa.  Acquired from the University 
of Liverpool www.genomics.liv.ac.uk/tryps/index accessed on 17.12.08. The area occupied by the tsetse flies 
is known as the tsetse fly belt, which corresponds to the area of infected cattle.  
1.2 TRYPANOSOMES  
Trypanosomosis was first discovered by Sir David Bruce in 1894, who found a correlation 
between nagana, a disease affecting cattle, the tsetse fly and trypanosomes, while 
investigating the deaths of many cattle in the Zululand region of South Africa (Duggan 
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1977). T. congolense, T. vivax and T. b. brucei are the major causative agents of bovine 
trypanosomosis in sub-Saharan Africa (Lalmanach et al. 2002; Stevens and Brisse 2004).  
T. vivax and T. evansi are also transmitted mechanically by biting insects, such as tabanids 
and stomoxes, in areas outside the tsetse belt as well as in South and Central America and 
Asia (Nantulya 1990; Osório et al. 2008), while T. equiperdium is transmitted sexually and 
have a wider geographic distribution (Nantulya 1990; Brun et al. 1998). Infections by these 
trypanosome species are not confined to cattle since they infect a wide range of domestic 
animals such as horses, camels, donkeys, mules, water buffalo, pigs, goats and dogs 
(Nantulya 1990; Brun et al. 1998; Uilenberg et al. 1998; Stevens and Brisse 2004). African 
trypanosomes also affect humans, causing sleeping sickness or human African 
trypanosomosis. These parasites are T. b. gambiense found mainly in West Africa and T. b. 
rhodesiense located mainly in East Africa (Baltz et al. 1985; Barrett et al. 2003; Stevens 
and Brisse 2004). The direct effect of trypanosomosis on humans and cattle, is the death of 
more than 100 people and 10 000 cattle daily (Hursey 2001). The South American 
trypanosome known as T. cruzi is transmitted by triatomas, and causes Chagas disease in 
humans (Cazzulo et al. 1997). Dogs and cats have recently been shown to be associated in 
the transmission of T. cruzi (Gürtler et al. 2006) 
1.3 CLASSIFICATION OF TRYPANOSOMES  
The classification of trypanosomes has been based solely on medical and veterinary 
features, which is represented in Fig. 1.2. The unicellular trypanosome parasites belong to 
the order Kinetoplastida due to the presence of a kinetoplast at the base of the flagellum 
(Uilenberg et al. 1998; Stevens and Brisse 2004). This kinetoplast contains the 
mitochondrial DNA of the parasite (Vickerman 1985). The family Trypanosomatidae is  
 






subdivided into Trypanosoma and Leishmania genera, which are classified according to 
their morphology and range of hosts the parasites infect (Momen 2001). 
The Trypanosoma genus is further subdivided into two sections, namely the Stercoraria and 
Salivaria, based on how the parasites are transmitted from the insect vector to the 
mammalian host once the parasite has completed its cyclic development (Uilenberg et al. 
1998). In the Stercoraria section, the metacyclic trypanosomes develop in the hindgut and 
are transmitted via the faeces of the insect vector. The Salivarian parasites develop into the 
metacyclic stage in the anterior part of the digestive tract of the tsetse fly and they are 
inoculated via the saliva into the mammalian host (Stevens and Brisse 2004). A striking 
feature of the salivarian species is that they contain and express variable surface 
glycoproteins (VSGs); therefore, they are able to change their surface coats by a process 
known as antigenic variation (Donelson 2003; Stevens and Brisse 2004). Salivaria are 
further divided into four subgenera namely, Duttonella, Nannomonas, Trypanozoon and 
Pycnomonas. The Duttonella genus has a principle species known as Trypanosoma vivax 
and a morphologically similar, but smaller species known as T. uniforme. T. vivax parasites 
mainly infect mammalian hosts in Africa and Latin America. The presence of a terminally 
situated kinetoplast in T. vivax is the distinguishing feature that separates the Duttonella 
genus from the Salivarian trypanosomes (Stevens and Brisse 2004).  
1.4 BIOLOGY OF TRYPANOSOMES  
1.4.1 Morphology of African trypanosomes  
Trypanosomes are unicellular streamlined elongated organisms that vary in size from 8-50 
µm, with T. vivax ranging between 18-31 µm (Uilenberg et al. 1998; Osório et al. 2008).  
These parasites are tapered on either end and they contain a highly organised microtubule 
cytoskeleton, which gives the parasite its shape (Fig. 1.3)  (Uilenberg et al. 1998; Matthews 
2005). The extremely flexible outer layer of the trypanosome cytoplasm is called the 
pellicle. This flexible pellicle allows for the free movement of the parasite but at the same 
time it also maintains the rigid structure of the trypanosome. The pellicle and the cytoplasm 
together form the undulating membrane (Uilenberg et al. 1998). The flagellar pocket is 
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situated at the posterior end of the parasite arising from the parabasal body. A single 
flagellum arises and it spans the length of the parasite. Since the flagellar pocket is the 
point of exit for the flagellum, it is known as the site of endo- and exocytosis (Matthews 
2005). The parasite uses both the flagellum and the undulating membrane for mobility 
(Branche et al. 2006). There is only a single mitochondrion present, which is elongated and 
runs from the posterior to the anterior end of the trypanosome. The posterior end of the 
mitochondrion contains a specialised area, known as the kinetoplast that contains between 
10-20% of the parasite’s DNA (Matthews 2005). The structure of T. vivax differs from that 
of T. congolense since T. vivax contains a larger kinetoplast, free flagellum (3-6 µm in 
length) and its posterior end is more club-shaped and the anterior end tends to taper off 
(Fig. 1.4). T. vivax also contains a distinctive vibrating and quick movement, which can be 
used to diagnose the presence of the parasite in the host (Osório et al. 2008).  
  
Figure 1.3 Diagrammatic representation of the morphology of a trypanosome. Acquired from 





Figure 1.4 Blood smear of T. vivax (Osório et al. 2008). The T. vivax parasite contains a larger kinetoplast, 
and a free flagellum. 
 
1.4.2 Genetic organisation  
To date, the T. brucei genome has been completely sequenced 
(www.sanger.ac.uk/Project/T.brucei) (Berriman et al. 2005). Therefore the knowledge of T. 
vivax and T. congolense genomes are based on the information of the T. brucei genome 
(Melville et al. 2004). The T. brucei African trypanosome has a 35 Mb (3.5 x 107 bp) 
genome, which is approximately the same size as the genomes of Plasmodium falciparum 
(2.5-3.0 x l07 bp) (Dame et al. 1996), Leishmania major (3.2 x 107 bp) (Ivens et al. 2005) 
parasites. T. cruzi genome (4.3 Mb) is much smaller than the T. brucei genome (Agüero et 
al. 2000). The genome of the African trypanosome is divided into two sections. One section 
is within the nucleus and the other is within the kinetoplast (Donelson 2003; Melville et al. 
2004). Two thirds of the nuclear genome has a single copy sequence and is thus relatively 
low in complexity while the remainder is made up of highly repetitive sequences (Melville 
et al. 2004). The nuclear genome is diploid, but the VSG genes, the VSG expression sites 
and the minichromosomes are not (El-Sayed et al. 2000). The kinetoplast contains two 
types of DNA circles, namely maxicircles and minicircles, with the latter keeping the 
maxicircles together in a network (Vickerman and Coombs 1999). 
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1.4.3 Antigenic variation  
Trypanosomes are able to evade the immune system of their mammalian host by regularly 
changing their surface coat by a phenomenon known as antigenic variation                           
(Borst and Rudenko 1994; Donelson 2003; McCulloch 2004). The entire cell surface of the 
blood stream and metacyclic trypanosomes; including the flagellum, are covered by the 
variant surface glycoprotein (VSG) coat (Barry and Carrington 2004). The role of this VSG 
coat is to protect the parasites from the host immune responses (Donelson 2003; McCulloch 
2004). Each change in the VSG coat is known as a distinct variable antigen type (VAT) 
(Barry and Carrington 2004).  This coat is highly immunogenic and results in high antibody 
titre in the mammalian host. Antibodies that were made against older VATs would be able 
to target these parasites; however, parasites with a new VAT will survive and can produce a 
new wave of parasitaemia. These different VATs do not all occur together but rather spread 
out throughout the infection and the switch from one VAT to the next is spontaneous. This 
event occurs in such a way that the new VAT is generated before the antibody attack on the 
trypanosomes of the old VAT occurs (Barry and Carrington 2004). This phenomenon of 
antigenic variation has therefore made it very hard to develop a VSG-based vaccine for 
trypanosomosis (Vickerman 1978).  
1.4.4 Life cycle of trypanosomes 
Trypanosomes are transmitted by both male and female tsetse flies of all 23 species of the 
Glossina genus (Uilenberg et al. 1998; Aksoy 2003). The transmission of the 
trypanosomes, such as T. b. brucei, T. congolense and T. vivax, by tsetse flies are cyclical 
(Fig. 1.5). However, mechanical transmission of T. vivax and T. evansi also occurs outside 
the tsetse belt of Africa by biting flies, such as tabanids (Vickerman et al. 1993; Uilenberg 
et al. 1998). 
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Figure 1.5 Life cycle of T. brucei showing the different morphological changes that occurs during the 
different stages in the vector and mammalian host. Adapted from 
pathmicro.med.sc.edu/lecture/trypanosomiasis.htm accessed on 24.10.09. The life cycle of T. vivax differs 
since the morphological changes in the vector only occur in the proboscis. 
The life cycle of the trypanosome is divided into two phases, one of which occurs in the 
insect vector and the other in the mammalian host (Fig. 1.5) (Uilenberg et al. 1998). The 
life cycle begins when the tsetse fly takes a blood meal from an infected host as short 
stumpy non-diving trypomastigotes. During this time the parasite lacks the glycoprotein 
surface coat and is not infective to mammals (Baltz et al. 1985; Vickerman et al. 1988). 
The parasite migrates to the midgut of the fly, where it transforms into the procyclic 
trypomastigote form. The procyclics then travel anteriorly to a region of the midgut, where 
they begin to divide and increase in number. It is the migration of the trypanosomes from 
the midgut to its next destination that differs between T. b. brucei and T. congolense 
species. T. b. brucei migrates from the midgut to the salivary glands and T. congolense 
from the midgut to the proboscis of the tsetse fly where they transform into long slender  
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epimastigotes (Uilenberg et al. 1998; Aksoy 2003). Thereafter, the epimastigotes transform 
into the metacyclic form, where they regain their glycoprotein surface coat (Baltz et al. 
1985). The metacyclics are the non-dividing infective form of the parasite (Aksoy 2003). 
The T. vivax life cycle differs from that of T. b. brucei and T. congolense since 
development occurs only in the proboscis of the tsetse fly with no events taking place in the 
midgut or the salivary glands of the vector (Matthews et al. 2004). The time period between 
the ingestion of the blood stream trypomastigotes from the mammalian host and the 
conversion into the metacyclics varies from three to five weeks for T. b. brucei and ten days 
for T. congolense and T. vivax (Vickerman et al. 1988).  
When the fly is takes its next blood meal it injects the infective metacyclics into its host. 
The parasites get deposited at the site of infection into the host’s dermal connective tissue, 
where the parasites divide by binary fission and develop into long slender trypomastigotes 
(Uilenberg et al. 1998). This leads to a local inflammatory reaction and a chancre develops 
in the skin at the site of infection (Vickerman 1985). The dividing trypanosomes can be 
found within the chancre, between collagen fibres and within dermal spaces. The parasites 
are then released into the host’s bloodstream from lymph nodes via lymph vessels. While 
the parasites are in the bloodstream they differentiate into rapidly dividing long slender 
trypomastigotes, which migrate to different organs of the host via the bloodstream 
(Vickerman et al. 1988). A portion of the trypomastigotes transform into a short, stumpy 
form, which is infective for the tsetse fly and can be picked up by the next fly taking a 
blood meal from the host (Uilenberg et al. 1998).  
 
1.5 PATHOGENESIS OF AFRICAN ANIMAL TRYPANOSOMOSIS 
African trypanosomes are the cause of three disease states, which are; nagana                         
(caused by T. b. brucei, T. congolense and T. vivax in cattle), surra (caused T. evansi in 
equines, water buffaloes and camels) and dourine (caused by T. equiperdium in horses) 
(Clair 1988). These pathogenic parasites can be divided into haematic and humoral 
trypanosomes, based on their distribution in tissues. The haematic trypanosomes, T. 
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congolense and T. vivax, are found in the blood vessels (intravascular) and the humoral 
trypanosomes, T. b. brucei, T. evansi and T. equiperdium, are present in the extravascular 
compartment and in tissues (Uilenberg et al. 1998; Lonsdale-Eccles and Grab 2002; Taylor 
and Authié 2004). The humoral trypanosomes are the causative agents of neurological 
disease since they can break through the blood-brain barrier (Antoine-Moussiaux et al. 
2008). Even though these trypanosomes are located in different areas, anaemia is a 
principal symptom in both groups (Prowse 2005).  
Interestingly, pathogenicity may differ within species of trypanosomes based on their 
geographical region. Some T. vivax trypanosomes from East Africa may cause an acute 
haemorrhagic disease in cattle, whereas T. vivax trypanosomes from West Africa may result 
in a milder non-haemorrhagic disease (Taylor and Authié 2004). There has also been 
evidence of a correlation between the biological vector species and the level of virulence of 
T. vivax isolates. The G. pallipides from central Kenya transmits a T. vivax isolate that 
causes acute disease and eventually leads to death in approximately one month in 70% of 
infected cattle, whereas the G. fuscipes transmits an isolate in Nyanza (a province located in 
the south west of Kenya), that causes a chronic infection and eventually leads to death in 
100 to 160 days post infection  (Osório et al. 2008).  
In bovine trypanosomosis, T. vivax seems to be the most pathogenic followed by T. 
congolense and to a lesser extent T. b. brucei (Taylor and Authié 2004). Even though        
T. vivax is less virulent than T. congolense it is responsible for over 50% of mortalities in 
cattle (Prowse 2005). T. congolense and T. b. brucei have a relatively low parasitaemia 
when compared to T. vivax, which is usually 108 trypanosomes/mL of blood) (Taylor and 
Authié 2004). 
During bovine trypanosomosis three successive stages in infection may occur, namely 
acute, stabilisation and chronic; however, death can occur at any stage. The initial stage is 
the acute phase of the disease, which may contain clinical signs such as enlarged lymph 
nodes and spleen, weakness, lethargy, abortion and reduced milk production. The acute 
phase is characterised by a continuous drop in the haematocrit value (packed red blood cell 
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volume, PCV), haemoglobin concentration and red blood cell numbers. Death of the animal 
may occur in the first weeks or months of the infection due to the acute phase. If cattle 
survive the acute phase, infection tends to stabilise after six to eight weeks, characterised by 
stabile PCV values, typical of the stabilisation phase.  The animal then enters the third or 
chronic phase of infection during which the animal may develop cachexia, intermittent 
parasitaemia and may become stunted, wasted and infertile. This chronic infection may lead 
to the death of the animal by congestive heart failure due to prolonged anaemia, damage to 
the heart muscles and increased vascular permeability. The haemorrhagic T. vivax isolates 
from East Africa cause a hyperacute disease that shows symptoms of high parasitaemia, 
severe anaemia and haemorrhages. These cattle either die in two weeks or self-cure under 
favourable conditions after two months (Taylor and Authié 2004). 
1.6 DIAGNOSIS OF AFRICAN ANIMAL TRYPANOSOMOSIS 
African bovine trypanosomosis can be diagnosed by an array of techniques some of which 
are based on clinical, parasitological, molecular and serological methods. The key reason 
for diagnosis is to ensure application of the most appropriate therapeutic methods. 
Diagnostic techniques should be suitable for field diagnosis under resource poor conditions 
(Luckins 1992). The diagnostic techniques used need to give rapid diagnostic results, since 
the response time for cattle that are treated earlier on in the acute phase of infection is rapid 
as compared to cattle treated during the chronic phase of infection, during which time the 
treatment is slow and cattle may even die (Taylor and Authié 2004). Other reasons for 
diagnosis are to monitor tsetse fly control and eradication methods, and gain insight into the 
efficacy of chemotherapy and the development of trypanocidal drug resistance (Eisler et al. 
2004).   
Clinical diagnosis of African bovine trypanosomosis is usually the favoured technique for 
field conditions since it is exclusively based on a physical examination of the animal. 
However, the clinical signs of bovine trypanosomosis described in Section 1.5 are not 
specific for the disease and the results obtained could pertain to other tropical diseases  
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(Nantulya 1990). In some cases trypanocidal drugs are administered to the cattle that show 
the clinical signs and a positive response to the drugs confirms the diagnosis (Eisler et al. 
2004). 
Parasitological examination techniques involve viewing wet blood films as well as Giemsa-
stained thick and thin fixed blood films with a light microscope. This technique varies in 
sensitivity and it is usually very low during the chronic phase of the disease (Magona et al. 
2003; Eisler et al. 2004). Since there is a high level of morphological similarity between the 
trypanosome species, it is difficult to use this technique to diagnose the different 
trypanosomal species infections. The sensitivity of this technique was improved by 
haematocrit centrifugation, which results in three layers forming after centrifugation: a red 
blood cell layer, the buffy coat layer, which contains the white blood cells and the 
trypanosomes, and a plasma layer. This concentration method allows for the analysis of the 
trypanosomes in the buffy coat layer, which is a more sensitive method of detection, with 
as low as 2.5 x 102 T. congolense, 5 x 102 T. vivax and 5 x 103 T. brucei being diagnosed 
(Luckins 1992). The problem with this technique is that it is difficult to perform in the field 
because fresh blood, a haematocrit centrifuge and microscopes are needed. Therefore, more 
reliable, sensitive and specific techniques were developed. These methods were based on 
molecular techniques and serological immunological techniques.   
A more recent molecular biology tools used for the diagnosis of bovine trypanosomosis is 
the polymerase chain reaction (PCR). PCR seems to be a promising technique since it 
allows for species-specific detection of the trypanosomes and it is a more sensitive 
technique (Solano et al. 1999; Desquesnes and Davila 2002). This technique is very costly 
since specialised equipment is needed. 
Serological techniques include complement fixation, indirect haemagglutination, indirect 
fluorescent antibody test and enzyme-linked immunosorbent assay (ELISA). Complement 
fixation has been used to diagnose T. equiperdium in North America. This test is not very 
reliable since problems such as reagent preparation, standardisation and anticomplementary  
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activity in the sera (removal of complement from the sera) occurred (Eisler et al. 2004). 
The indirect haemagglutination test was used to diagnose T. evansi infection, but was 
unreliable in detecting T. vivax infections (Clarkson et al. 1971).  
The indirect fluorescent antibody primary binding assay test was regarded as one of the 
most significant improvements for diagnostics. This test is used to directly measure the 
interaction between the antigen and the antibody. This was achieved by allowing the test 
sera (containing the antibody) to interact with the antigens fixed on a microscope slide. The 
antigens are fixed on a microscope slide using fixatives such as acetone and formalin 
(Nantulya 1990; Luckins 1992). The antibodies that bind to the antigen are then visualised 
by using anti-host species immunoglobulins conjugated to a fluorescent dye. The antigen 
and antibody interaction can be observed by using a fluorescence microscope. The indirect 
fluorescent antibody test has been shown to be very sensitive and specific in detecting 
trypanosome antibodies (Aquino et al. 1999). The problem with this method is that it is not 
species-specific and as a result there is high cross reactivity between the different 
trypanosome species. Another disadvantage of this technique is that it requires an 
expensive fluorescence microscope. 
Two types of ELISAs that can be used for the diagnosis, namely; the antibody-detection 
ELISA (Hopkins et al. 1998; Rebeski et al. 1999) and the antigen-detection ELISA                    
(Nantulya and Lindqvist 1989). The antibody-detection ELISA allows for the detection of 
specific antibodies in sera from trypanosome infected cattle. This particular test possesses 
the same problem of cross-reactivity between species. Therefore, in the diagnosis of bovine 
trypanosomosis antibodies have to be screened against all three trypanosome species; 
namely, T. congolense, T. vivax, T. brucei, to increase the sensitivity (Eisler et al. 2004). 
One of the drawbacks of this test is that the presence of the antibodies does not confirm an 
active infection. This is due to the fact that the antibodies may persist in the mammalian 
host much longer than the infectious agent. Antibodies may be present in the host between 
6-13 months after the infection has cleared (Luckins 1992; Van den Bossche et al. 2000). 
Another disadvantage is that it usually takes 8-12 days for antibody detection in the host,  
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therefore, this could lead to a false negative result (Greiner et al. 1997). For these reasons 
the antibody detection test has been used more as epidemiological tools for mapping and 
quantifying the prevalence and risk of trypanosomosis rather than for diagnostics (Eisler et 
al. 2004). 
An alternative approach to the antibody-detection ELISA is known as the antigen-detection 
ELISA. This technique involves detecting the presence of the parasite antigens in the blood 
of the infected cattle. This results in a good indication of an active infection (Nantulya 
1990). Modifications of the antigen-detection ELISA allowed for the detection of antigens 
in the host within 10-14 days of T. congolense and T. evansi infection. These antigens 
disappeared within 21 days of administering trypanocidal drugs after diagnosis (Rae and 
Luckins 1984). In this sandwich ELISA method, the wells of a 96 well polystyrene 
microtitre plate are coated with polyclonal antibodies made against crude recombinant 
antigen. The test serum is added and the antigen present in the sera binds to the antibody. 
The antibody-antigen interaction is detected using the same antibody, used to coat the plate, 
conjugated with an enzyme in the presence of a suitable substrate (Eisler et al. 2004). 
The major problem for both the antibody and the antigen-detection ELISA is the lack of 
availability of recombinant trypanosome antigens for the detection and production of anti-
trypanosome antibodies. Thus far, the ELISAs for both antibody and antigen detection have 
relied on native antigens prepared from whole parasite lysate; therefore, this had made it 
difficult to optimise and standardise the tests (Greiner et al. 1997; Eisler et al. 2004; Tran et 
al. 2009). 
1.7 CONTROL OF AFRICAN ANIMAL TRYPANOSOMOSIS  
1.7.1 Vector control 
Trypanosomosis is dependent on the transmission of the trypanosome from a single insect 
vector; therefore, the key form of control would be to target the vector (Aksoy 2003). The 
control of trypanosomosis has relied heavily on the control of the tsetse fly vector due to 
the absence of suitable vaccines and affordable drugs (Aksoy 2003; Donelson 2003; 
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Holmes et al. 2004). The main strategies for vector control include; ground and aerial 
insecticide spraying, sterile insect technique and the latest development of the bait 
technique, which involves applying insecticide on live bait such as cattle (Allsopp 2001; 
Allsopp and Hursey 2004; Vale and Torr 2004). 
The insecticide spraying approach seemed to be very successful; however, the major 
problem was the negative impact of the insecticides on the environment. The chemical 
compounds that are used in the successful eradication of tsetse flies are organochlorides 
such as dichlorodiphenyltrichloroethane (DTT) and dieldrin and the endosulfan group of 
compounds, such as the synthetic pyrethroids (Allsopp and Hursey 2004). Even though 
insecticidal spraying has been able to eradicate the tsetse fly vectors, there is the problem of 
the tsetse flies reinvading the area. Due to this problem, care has to be taken to ensure 
complete elimination of the tsetse fly population in that area or protect the area that has 
been cleared (Allsopp 2001). 
The sterile insect technique involves the release of sterile male flies into the wild 
population. These insects are sterilised by irradiation. With time, this procedure leads to a 
drastic decrease in the number of fertile males, which leads to a decrease in the number of 
successful matings. As the sterile flies are continually introduced into the wild, the tsetse 
fly population may slowly become eliminated. This technique was successful in eradicating 
the screwworm fly in the USA, the Mediterranean fruit fly and G. austeni from Zanzibar 
(Aksoy 2003). An organisation known as the Pan African Tsetse and Trypanosomosis 
Eradication Campaign (PATTEC) had introduced a large-scale tsetse control project based 
on the sterile insect technique and insecticide treated cattle (Torr et al. 2005). This 
approach to eradicate tsetse flies over the large area occupied by tsetse flies in sub-Saharan 
Africa raise some doubt as to the feasibility of the project (Rogers and Randolph 2002).   
1.7.2 Trypanotolerant Cattle  
 Trypanotolerant cattle breeds have developed the genetic capacity to manage the effects of 
trypanosomosis (Naessens et al. 2002). These cattle still develop trypanosomal infections;  
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however, they are able to limit parasitaemia and control anaemia (Lalmanach et al. 2002).  
Bos taurus, which includes the N’Dama, Mutura and the Dahomey cattle breeds, are 
trypanotolerant. These cattle are able to survive in areas that have a high infestation with 
tsetse flies and are mainly found in West and Central Africa (Authié 1994; Murray et al. 
2004). Zebu (Bos indicus) are susceptible to trypanosomosis and would die in the areas of 
high tsetse challenge (Authié 1994). Bos taurus cattle, in particular the N’Dama are much 
smaller in size compared to the Zebu and as a consequence have lower productivity and are 
not used as much as the larger, more susceptible cattle. For this reason, trypanotolerant 
cattle only make up one third of the cattle present in the tsetse infected areas of Africa 
(Murray et al. 2004). 
1.7.3 Vaccines  
There is a demand for vaccine development due to the problems of drug resistance and 
toxicity of prophylactic drugs. The greatest obstacle for vaccine development is the 
phenomenon of antigenic variation (Borst and Rudenko 1994; Donelson 2003; McCulloch 
2004). A new approach that has gained popularity over the past two decades is the 
development of an anti-disease vaccine that targets the pathogenic factors that are the 
causative agents of the disease, rather than the parasite itself (Playfair et al. 1990; Antoine-
Moussiaux et al. 2009). The concept of an anti-disease vaccine was first developed and is 
currently being worked on to combat malaria (Playfair et al. 1990; Authié 1994; 
Matuschewski 2006; Schofield 2007). Vaccination with pathogenic factors leads to the 
production of antibodies against these factors that reduce the symptoms of the disease. 
These pathogenic factors are either actively secreted when the parasite is alive or  released 
upon death of the parasite (Tizard et al. 1978). One of the major pathogenic factors 
associated with trypanosomes are the parasites’ proteolytic enzymes; more importantly the 
cysteine peptidases, which can potentially become components for an anti-disease vaccine 




Chemotherapy is still the most widely used form of control for bovine trypanosomosis in 
the 37 Sub-Saharan countries dominated by the endemic disease (Geerts and Gryseels 
2000; Holmes et al. 2004). The chemotherapeutic control of trypanosomosis relies on the 
use of three trypanocidal drugs that have been available on the market for over five 
decades; namely, isometamidium chloride (Samorin®), homidium (bromide and chloride) 
(Novidium®) and diminazene aceturate (Berenil®). Isometamidium chloride is most 
commonly used as a prophylactic and both homidium and diminazene aceturate are used as 
therapeutic agents.  Homidium also has partial prophylactic properties (Anene et al. 2001; 
Holmes et al. 2004). Only thirty five million doses of the drugs are used in Africa each year 
with an estimated 50-70 million cattle at risk (Geerts and Gryseels 2000).  
The greatest concern and risk of using these drugs is the development and spread of drug 
resistance, rendering the drugs ineffective. In 13 out of the 37 countries where 
trypanosomosis is prevalent, signs of resistance to one or more of the drugs have been 
reported (Geerts and Gryseels 2000; Holmes et al. 2004). Another downfall of using the 
current drugs is that they are provided to African countries by European pharmaceutical 
countries at great cost to the end-user. For this reason, there are a few generic forms of the 
drugs available in Africa but they are of poorer quality. This leads to a decrease in 
confidence in trypanocidal drugs, which may prevent farmers from using the drugs 
(Holmes et al. 2004). 
There is thus an urgent need for the development of cheap, novel and effective drugs  
(McKerrow 1999; Caffrey et al. 2000). One of the key chemotherapeutic targets are the 
cysteine peptidases since they play important roles in the parasite and the pathogenesis of 
the disease (Antoine-Moussiaux et al. 2009).  
During the last decade studies have shown that synthetic peptidyl inhibitors of cysteine 
peptidases improve the health of infected animals, reduce and even cure Plasmodium, 
Leishmania and Trypanosoma infections (McKerrow et al. 1999). Therefore, 
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characterisation of the substrate specificity of cysteine peptidases would assist in producing 
a synthetic peptide inhibitor.  
The cysteine peptidase inhibitors that have potential as trypanocidal agents are the 
irreversible peptide inhibitors with vinyl sulfones and the peptidyl ketones, namely; 
chloromethylketones, diazomethylketones and fluromethylketones groups attached 
(Troeberg et al. 1999; Anene et al. 2001; Vicik et al. 2006). In vitro studies showed that 
these inhibitors were trypanocidal at low micromolar concentrations against blood stream 
forms of T. b. brucei with trypanopain-Tb being the major target (Troeberg et al. 1999). 
The chloromethylketones, Z-Phe-Phe-CMK was the most trypanocidal methylketone with 
an IC50 value of 3.6 µM whereas the diazomethylketone, Z-Phe-Ala-CHN2, killed the blood 
stream forms of T. b. brucei (Scory et al. 1999; Troeberg et al. 1999). An important feature 
of these diazomethylketones was the fact that they were non-toxic to mammalian cells 
(Scory et al. 1999). These peptidyl diazomethylketones were also inhibitory to congopain 
(trypanopain-Tc) from T. congolense. The inhibitors that worked the best were Z-Leu-Leu-
Met-CHN2, Z-Leu-Met-CHN2 and Z-Leu-Lys-CHN2. Inhibitors became trypanocidal after 
incubation for 24-48 h with the cultured T. congolense parasites (Mbawa et al. 1992). 
Fluromethylketones Z-Ala-Phe-CH2F and Z-Ala-Imidazoyl-norvalyl-CH2F lysed 
trypomastigote forms of T. cruzi and blood stream forms of T. b. brucei but at high 
concentrations (Ashall et al. 1990). Incubation of T. cruzi (amastigotes) with Z-Phe-Ala-
CH2F and Z-Phe-Arg-CH2F prevented their transformation to trypomastigotes (Harth et al. 
1993). Diazomethylketone inhibitors used at lower concentrations were able to prevent 
differentiation of T. cruzi epimastigotes to trypomastigotes (Bonaldo et al. 1991).  
Vinyl sulfones were introduced as irreversible inhibitors due to their low toxicity to the 
mammalian host (Caffrey et al. 2000). Troeberg et al. (1999) demonstrated that the vinyl 
sulfone methylpiperazin-urea-Phe-homoPhe-VS killed 50% T. b. brucei parasites in culture, 
while Engel et al. (1998) showed that the Mu(morpholine urea)-Phe-homoPhe-VS was able 
to prevent cell division of T. cruzi epimastigotes resulting in  the death of the parasites after 
five days (Engel et al. 1998).  
20 
 
Trypanopain-Tb was also inhibited by a group of reversible inhibitors, i.e. chalcones, acyl 
hydrazides and related amides. Micromolar concentrations of these inhibitors were able to 
reduce the growth of bloodstream forms of T. b. brucei in culture (Troeberg et al. 2000). 
 
In vivo studies were also performed using inhibitors such as the vinyl sulfones and 
diazomethylketones. The vinyl sulfone, N-Me-Pip-Phe-homoPhe-VS, proved to be a 
promising inhibitor for T. cruzi infections (Engel et al. 1998; McKerrow et al. 1999). T. b. 
brucei infected mice were treated with the diazomethylketone, Z-Phe-Ala-CHN2 from day 
three post-infection. This resulted in a decrease in parasitaemia to points where they were 
undetectable (Scory et al. 1999). 
 
A study on the dipeptidyl inhibitors, Z-Phe-Tyr-CHO, Z-Phe-Tyr(OtBu)-CHN2 and 1-
NapSO2-Ile-Trp-CHO, against trypanopain from T. b. brucei (Nkemgu et al. 2003) showed 
that they were more effective than the inhibitors described by Troeberg et al (1999) and 
Scory et al. (1999). The IC50 values of these inhibitors were between 18-126 nM which was 
much lower than the IC50 of the commercially available trypanocidal drugs such as 
suramin, at 130-/360 nM  and diminazene aceturate at 20-100 nM (Nkemgu et al. 2003). 
 
An important question raised regarding the activity of cysteine peptidase inhibitors on the 
parasite is whether the inhibitory effect is due to the inhibition of the targeted cysteine 
peptidase or whether it is due to unrelated effects (McKerrow et al. 1999). A number of 
studies provided evidence that the inhibitors were acting on the target cysteine peptidase. 
The first study showed that despite the chemistry of the inhibitor, the same morphological 
deformities were present in the parasite e.g. when T. cruzi was reacted with vinyl sulfones 
and fluromethylketones, both inhibitors led to an accumulation of the unprocessed 
cruzipain in the Golgi apparatus, which changed the morphology of the organelle and 
decreased the normal trafficking of the cysteine peptidase to the lysosomes (Engel et al. 




inhibitor with biotin, which proved that trypanopain was the target cysteine peptidase 
(McKerrow et al. 1999; Troeberg et al. 1999).                                                                                                        
 
The design of these synthetic inhibitors based on targeting cysteine peptidases could be a 
promising chemotherapeutic application; however, care must be taken when choosing an 
inhibitor against the cysteine peptidases since the mammalian host affected by 
trypanosomosis also contains their own cysteine peptidases. For this reason, the inhibitor 
chosen should be able to differentiate between the mammalian and parasite targets and have 
a low toxicity in the host (Pink et al. 2005). Inhibitors such as vinyl sulfones  and 
diazomethylketones could be used since they were shown to have low toxicity to the host 
(Caffrey et al. 2000). Studies have shown that the vinyl sulfones were not toxic to infected 
hosts such as mice, rats and even dogs. A possible explanation for this is that the host 
cysteine peptidases are present in higher concentrations than those of the parasites, 
therefore there is no evidence of toxicity in the host (McKerrow 1999).  Even though 
parasite cysteine peptidases may be homologous to their mammalian hosts they have 
distinctive structural and biochemical properties such as pH optimum and stability, domain 
extensions (C-terminal extensions), diverse substrate specificity and cellular location (Sajid 
and McKerrow 2002). These differences could be advantageous when designing an 
inhibitor.  
1.8 PEPTIDASES  
1.8.1 Characterisation of proteolytic enzymes 
Proteolytic enzymes or peptidases are a collection of enzymes that have the ability to 
catabolise proteins and polypeptides by cleavage of the peptide bonds giving rise to 
peptides and free amino acids (North et al. 1990; Rosenthal 1999).  The active site 
(catalytic site) of the enzyme is often located in a groove that is found at the surface of the 
enzyme or buried slightly. The substrate binding sites are located near the active site and 
their properties contribute to substrate specificity. The substrate binding sites have a 
specific geometry which allows the substrate to fit into the binding groove. The specific  
22 
 
geometry can be explained using the nomenclature of Schechter and Berger (1967), where 
the binding sites adjacent to the active site are numbered   S1, S2, Sn from the active site 
towards the amino-terminus and S1′, S2′, Sn′ from the active site towards the carboxy-
terminus (Fig. 1.6). The scissile bond is the peptide bond hydrolysed by the enzyme. The 
corresponding substrate positions are numbered P1, P2, Pn  N-terminal to the scissile bond 
and P1′, P2′, Pn′ C-terminal to the scissile bond (Fig. 1.6)  (Schechter and Berger 1967). 
Even though only a single peptide bond is cleaved by the enzyme, the presence of a number 
of amino acid residues on either side of the scissile peptide bond is important for the 












Figure 1.6 Representation of the nomenclature for the action of an enzyme on a substrate. (Adapted 
from Schechter and Berger, 1967). S1, S2, Sn and P1, P2, Pn are on the amino side of the scissle bond on the 
enzyme and substrate, respectively.  
 
Proteolytic enzymes either hydrolyse the protein within the polypeptide chain 
(endopeptidase activity) or from the amino or carboxyl end (exopeptidase activity) known 
as an amino- or carboxypeptidases (Sajid and McKerrow 2002).  
      P2                     P1                    P1′          P2′   
 













Based on the active site residues, six classes of peptidases are distinguished, i.e. serine, 
threonine, aspartate, metallo, glutamic and cysteine peptidases (Table 1.1) (Rawlings and 
Barrett 1999; Sajid and McKerrow 2002; Rawlings et al. 2008). Some peptidases may only 
hydrolyse particular amide bonds, while others only hydrolyse a certain peptide bond that is 
found in a specific protein. Peptidases may even be able to hydrolyse many peptide bonds 
that have similar sequences or conformations.  
Table 1.1 Six main classes of peptidases divided according to their catalytic 
mechanisms.  [Adapted from: (Barrett 1994; Rosenthal 1999; Rawlings et al. 2008)] 
 
1.8.2 General mechanism of hydrolysis by cysteine peptidases 
The active site of all cysteine peptidases contains a catalytic triad of Cys25, His159, and 
Asn175. The presence of a cysteine residue with its thiol group in the active site is 
important for the hydrolysis of the substrate. The thiol group becomes deprotonated by the 
presence of the His residue in the active site. This mechanism improves the nucleophilicity 
of the thiol-group. The sulfhydryl (-SH) group of the Cys side chain interacts with the 
Peptidase Active site residues Example 
Aspartate Asp33, Asp213 Digestive enzymes, intracellular acid peptidases, 
extracellular regulatory peptidases, pepsin a, HIV 
I peptidase 
 
Cysteine Cys25, His159, Asn175 Papain, cathepsins B and L, congopain, vivapain, 
cruzipain, trypanopain 
 




Metallo His387, Glu388, His391, Glu410, 
Tyr476 
 
Aminopeptidases, Matrix metallopeptidases 
Serine Asp102, Ser195, His57 Trypsin, chymotrypsin, oligopeptidase B 
 




imidazole present in the His residue, giving rise to a thiolate-imidazolium charged diad.  
The thiolate cysteine attacks the carbonyl carbon of the scissile bond present in the 
substrate forming a tetrahedral intermediate (Fig. 1.7). This complex becomes stabilised by 
the presence of the Asn in the active site. The presence of a conserved Glu in the proximity 
of the active site creates an oxyanion hole, creating an electrophilic centre, which leads to 
further stabilisation of the tetrahedral intermediate during the process of hydrolysis. The 
tertrahedral intermediate is transformed into an enzyme-substrate thiol ester with the 
release of the C-terminal section of the substrate by a process known as acylation. The 
enzyme-substrate thiol ester is hydrolysed by water forming a second tertrahedral 
intermediate. This intermediate undergoes deacylation resulting in a free enzyme and an N-
terminal section of the substrate (Lecaille et al. 2002; Sajid and McKerrow 2002; Barrett 
and Rawlings 2004). Trypanosomal cysteine peptidases have a wide range of substrate 
specificities, which provides an advantage for developing inhibitors for the enzymes, but it 
can also be a disadvantage because it makes it difficult to develop inhibitors that will be 




Figure 1.7 Scheme representing the steps involved in the catalysis of cysteine peptidases (Dunn 2001)  
1.8.3 Classification of cysteine peptidases 
There are over 400 types of cysteine peptidases, many of which are responsible for 
important functions in and survival of parasites. They are also believed to be involved in 
the disease process (Mottram et al. 2003). These cysteine peptidases can be divided into 10 
clans, which include: CA, CD, CE, CF, CH, CL, CM, CN, CO and C- (Rawlings et al. 
2008). Cysteine peptidases belong to the papain superfamily of peptidases. They belong to 
Clan CA and subfamily C1A (Barrett and Rawlings 2004). This group of cysteine 
peptidases is the most widely studied (Barrett and Rawlings 2004; Caffrey and Steverding 
2009). The family contains papain (the plant cysteine peptidase) and the mammalian 
lysosomal cysteine peptidases: cathepsins B, C, K, L and S; parasite cysteine peptidases: 
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congopain (T. congolense), cruzipain (T. cruzi), falcipains (Plasmodium falciparum) and 
CPA, CPB and CPC (Leshmania mexicana). The C1 family is characterised by the presence 
of a Cys25, His159 and Asn175 (papain numbering) catalytic triad in the active site. All clan 
CA cysteine peptidases are irreversibly inhibited by L-trans-Epoxysuccinyl-leucylamido (4-
guanidino) butane (E-64) and their substrate specificity is determined by binding to the S2 
pocket (Sajid and McKerrow 2002; Barrett and Rawlings 2004; Rosenthal 2004; Caffrey 
and Steverding 2009). All the members of this family have very similar sequences and a 
common mechanism for hydrolysis (Fig. 1.7) (Barrett and Rawlings 2004). The majority of 
the cysteine peptidases are lysosomal enzymes, they often act at an acidic pH. However, 
there are some members of the papain family that act extracellularly (Rosenthal 1999). 
1.8.4 Parasitic cysteine peptidases  
A wide range of cysteine peptidases have been found in protozoan parasites namely,         
P. falciparum (Rosenthal 2004), T. cruzi (Martinez et al. 1991), T. congolense (Authié et 
al. 1992; Mbawa et al. 1992; Mendoza-Palomares et al. 2008), L. mexicana (Sanderson et 
al. 2000), Entamoeba histolytica (Quintas-Granados et al. 2009; Youn 2009), Fasciola 
hepatica  (Prowse et al. 2002; Beckham et al. 2009) and Toxoplasma gondii (Youn 2009). 
The cysteine peptidases are associated with assisting the parasite in pathogenesis of the 
disease by differentiation at the different stages of the life cycle, invading the host by 
parasite migration through tissue barriers and altering the host immune defence, degrading 
haemoglobin and other blood proteins and activation of inflammation (Chagas et al. 1997; 
McKerrow et al. 2006). The diverse functions of the peptidases in the parasite could be due 
to the fact that they have a unique nucleophilicity, i.e. they are able to hydrolyse many 
different substrates and they are stable in different biological environments (Sajid and 
McKerrow 2002). 
The trypanosomal cysteine peptidases include congopain from T. congolense, trypanopain 
from T. b. brucei, cruzipain from T. cruzi and vivapain from T. vivax. These cysteine 
peptidases are expressed mainly during the parasite life cycle stages that are involved in 
infecting the mammalian host. This leads to alterations of the host’s immune defences and 
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cysteine peptidases are, therefore, regarded as immunodominant antigens                  
(Chagas et al. 1997). The cysteine peptidase activity of T. congolense, T. b. brucei and T. 
vivax are confined to lysosomal organelles. The cysteine peptidases of T. congolense and T. 
cruzi have also been found on the cell surface; with the cysteine peptidases of T. cruzi also 
located in flagellar pocket (Mbawa et al. 1991a; Cazzulo et al. 1997). Substrate specificity 
is determined by the P2/S2 interaction. The cysteine peptidases prefer large aromatic 
residues in P2 (Lalmanach et al. 2002; Lecaille et al. 2002). These lysosomal cysteine 
peptidases have broad substrate specificity and mostly prefer an acidic pH (Rosenthal 
1999). However, parasite peptidases are more stable at neutral pH, whereas the mammalian 
lysosomal cysteine peptidases are relatively unstable at neutral pH                                
(Sajid and McKerrow 2002). The pH optimum of lysosomal cysteine peptidases may also 
be affected by the assay conditions used, where the pH optima were shown to be higher in 
acetate-4-morpholineethane sulfonic acid (MES)-Tris buffers of constant ionic strength 
(Dehrmann et al. 1995). 
1.8.5 Primary structure of trypanosomal cysteine peptidases 
Congopain (Serveau et al. 2003), trypanopain (Troeberg et al. 1999) and cruzipain              
(Cazzulo et al. 1997) are cathepsin L-like cysteine peptidase of T. congolense, T. b. brucei 
and T. cruzi, respectively. All three peptidases are synthesised in an inactive precursor 
form. Each enzyme has a pre-region, pro-region and a catalytic domain. The pre-region is 
usually hydrophobic and serves as a signal peptide (North et al. 1990). The pro-region may 
contribute to a number of functions. It can assist in protein folding because this region can 
take on the role of an intramolecular chaperone. This region may also regulate peptidase 
activity since it can act as an endogenous inhibitor and may even act as a signal that enables 
the peptidase to travel to its intracellular location (Sajid and McKerrow 2002).  
These three enzymes also contain an unusual C-terminal extension that is not present in 
their mammalian homologues (Authié et al. 2001). The C-terminal extension of cruzipain 
and congopain is made up of 130 amino acid residues and the C-terminal extension of 
trypanopain is 110 amino acids in length. The C-terminal extension is connected to the 
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catalytic domain of the enzyme via sequence motifs that either contain threonine, proline or 
serine residues, which may form a flexible region that could be easily accessible to 
proteolytic cleavage (Robertson et al. 1996). Congopain’s C-terminal extension is linked to 
the catalytic domain by a stretch of proline residues, while that of cruzipain is linked to the 
catalytic domain by several threonine residues (Chagas et al. 1997) (Fig. 1.8). The function 
of the C-terminal extension is unknown. However, it could potentially play a role in 
altering the host’s immune defences since this region is extremely immunogenic.  
Recombinant forms of T. cruzi and T. b. brucei cysteine peptidases expressed in 
Escherichia coli, that did not have the C-terminal extension, were active which proved that 
the presence of the C-terminal extension is not vital for enzyme activity (Robertson et al. 
1996). 
A cathepsin B-like cysteine peptidase was identified in T. congolense (Mendoza-Palomares 
et al. 2008). There are 13 genes coding for the peptidase, which are grouped into three 
evolutionary groups. The groups include; TcoCBc1 to TcoCBc5, TcoCBc6 and TcoCBs7 to 
TcoCBs13. The first two groups have the conventional Cys, His, Asn catalytic triad and the 
third group has Ser, Xaa, Asn in the active site, where Xaa could be any amino acid. The 
structure of cathepsin B-like cysteine peptidase contains an occluding loop, signal peptide, 
pro-peptide region and catalytic domain but the trypanosomal cathepsin B-like cysteine 
peptidases do not contain a C-terminal extension as do their cathepsin L-like counterparts 
(Mendoza-Palomares et al. 2008).   
Sequence alignment (Fig. 1.8) reveals that vivapain has a high sequence identity to 
trypanopain and congopain. Therefore, the enzyme characteristics of trypanopain and 
congopain should theoretically be a good indication of those of vivapain. The red box in the 
sequence alignment indicates the N-terminus of the mature enzyme for all three peptidases. 
The C-terminal extension for the enzymes is indicated by the blue boxes. The C-terminal 
domain of trypanopain and congopain are proline rich and the C-terminal domain of 
vivapain is threonine rich. The pink boxes indicate the amino acids that are part of the 
catalytic domain; Cys25, His159 and Asn175 (papain numbering). There are multiple genes 
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coding for congopain (Lalmanach et al. 2002) and even cruzipain (Mottram et al. 1998) 




Figure 1.8 The sequences of trypanopain, congopain and vivapain. Representing sequence identity (grey boxes), the beginning of the mature enzyme 
(red box), the amino acids present in the catalytic site; C, H, N (pink boxes) and the C-terminal extension (blue boxes). (Adapted from Nicola Biteau,  
University Victor Segalen, Bordeaux, France).
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1.9 OBJECTIVES OF THE PRESENT STUDY 
In the present study a cysteine peptidase, vivapain, from T. vivax was studied in order to 
develop chemotherapeutic drugs and a diagnostic assay for T. vivax induced 
trypanosomosis . Both the catalytic domain of vivapain (Vp) and the full length mutant 
form of vivapain (∆FLVp) were examined. The reason for studying vivapain is that it could 
potentially be a pathogenic factor contributing to the disease caused by T. vivax. This 
assumption can be made since the cysteine peptidase, congopain from T. congolense, which 
has a high sequence identity to vivapain (Fig. 1.8), was shown to be a pathogenic factor in 
trypanosomosis (Authié et al. 2001). The key reason for pursuing this study is that T. vivax 
is responsible for over 50% of mortality rates in cattle (Prowse 2005) and vivapain could be 
a potential pathogenic factor. To date, there has been no published data on the expression 
and characterisation of Vp; hence, congopain was used as a positive control in the 
experiments.  
This study can be divided into two main parts. The first part involved the recombinant 
expression of the catalytic domains of vivapain (Vp) and congopain (C2) in a yeast 
expression system. The recombinant proteins were then purified and extensive enzymatic 
characterisation studies were performed (Chapter 2). This information will, in future, be 
useful for the potential development of a new chemotherapeutic drug based on synthetic 
inhibitors. The second part of the study involved the cloning and expression of a full length 
mutant form of vivapain, termed (∆FLVp) in both yeast and bacterial expression systems 
and antibodies against ∆FLVp were made in both chickens and mice for future use in 
diagnostic tests (Chapter 3). The basis for the production of the recombinant ∆FLVp was to 
provide a vital tool that could be used for diagnostic tests in T. vivax infections. All the 
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ABSTRACT 
Trypanosoma vivax is one of the three main trypanosomes responsible for African bovine 
trypanosomosis. Vivapain is the cathepsin L-like cysteine peptidase of T. vivax and is 
believed to be a promising target for chemotherapeutic drug design. The main aim of this 
study was to express and enzymatically characterise the catalytic domain of vivapain (Vp) 
in order to gain information for future work in chemotherapeutic drug design. Vp was 
successfully recombinantly expressed in a Pichia pastoris yeast expression system and 
purified by three phase partitioning (TPP) and molecular exclusion chromatography 
(MEC). The catalytic domain of congopain (C2) was also expressed in the P. pastoris yeast 
expression system for use as a positive control since there has been no published work on 
the characterisation of Vp. Vp was expressed as a glycosylated active form, represented as 
a double band on SDS-PAGE gel at 29 and 33 kDa. The recombinant Vp was active against 
a range of synthetic substrates, which was comparable to other parasite cysteine peptidases. 
An interesting finding was that the substrate specificity of Vp was primarily based on the 
presence of a hydrophobic residue in P2. The best substrates for hydrolysis by Vp were Z-
Phe-Arg-AMC and D-Val-Leu-Lys-AMC. Vp was also inhibited by the classical cysteine 
peptidase inhibitors such as the reversible leupeptin, chymostatin and antipain and the 
irreversible E-64, iodoacetic acid and iodoacetamide.  Vp has a pH optimum of 7 when 
assayed in constant ionic strength buffers. The information obtained from the present study 




African bovine trypanosomosis is a deadly disease which is causing an enormous strain of              
US$ 45 billion on the sub-Saharan African economy (Antoine-Moussiaux et al. 2009). 
Trypanosoma vivax seems to be the most pathogenic parasite causing trypanosomosis in 
African livestock (Taylor and Authié 2004). This parasite is also responsible for over 50% 
of mortality rates in cattle (Prowse 2005). Therefore, there is a great demand for the control 
of this disease especially the infections caused by T. vivax.  
Current control measures include the use of trypanocidal drugs, attempts to eradicate tsetse 
fly populations and the use of trypanotolerant cattle. These methods have become 
insufficient (Naessens et al. 2002; Aksoy 2003; Allsopp and Hursey 2004; Holmes et al. 
2004; Murray et al. 2004). The trypanocidal drugs currently available for bovine 
trypanosomosis are isometamidium chloride, homidium and diminazene aceturate. These 
drugs are not as effective as they used to be since parasites have developed drug resistance 
because the drugs have been in use for over five decades and there is thus a need to develop 
new drugs (Anene et al. 2001).  
Chemotherapy is still the principal approach for the control of trypanosomosis. This 
approach is purely based on targeting the pathogenic factors contributing to the disease in 
the hopes of identifying new synthetic inhibitors for the production of new drugs. The 
parasite peptidases, especially the cysteine peptidases from parasites such as P. falciparum 
(Rosenthal 2004), T .cruzi (Martinez et al. 1991), T. congolense (Authié et al. 1992; 
Mbawa et al. 1992), L. mexicana (Sanderson et al. 2000) and Fasciola hepatica (Prowse 
2005), seem to be a good option as targets for drug design since they play essential roles in 
the parasite. They also contribute to and assist in the survival of the parasite (McKerrow 
1999).  
Since T. vivax contributes significantly to the number of infected cattle in Africa, there is a 
need to study the cysteine peptidase associated with this parasite in the hope that it could 
become a potential drug target. This particular cysteine peptidase has been termed vivapain. 
Vivapain has a high sequence identity to congopain and trypanopain (Fig 1.8, Section 
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1.8.5) and vivapain is likely to be a pathogenic factor in T. vivax since congopain acts as a 
pathogenic factor in T. congolense (Authié et al. 2001) .  
To date, there has been no published work on the recombinant expression and 
characterisation of vivapain and, consequently, congopain was used as a positive control in 
the present study. The most important aspect of characterising the cysteine peptidase is 
determining substrate specificity since it can be used to discover anti-peptidase inhibitors, 
which could be lead compounds for the development of anti-disease drugs. This is a good 
approach since many cysteine peptidase inhibitors can disrupt the life cycle of the parasite 
without leading to the production of major side effects in the host (Troeberg et al. 1999; 
Caffrey et al. 2000; Serveau et al. 2003).  
In the present study, the catalytic domains of vivapain (Vp) and congopain (C2) were 
recombinantly expressed in a Pichia pastoris yeast expression system. This was followed 
by purification of the two recombinant proteins. The enzymatic characteristics of both Vp 
and C2 were studied extensively. These studies involved testing substrate specificity using 
peptides with different amino acid residues in P1-P3 and kinetics of the effect of reversible 
and irreversible inhibitors on the hydrolysis of two peptide substrates by Vp and C2.  
 
2.2 MATERIALS AND METHODS  
2.2.1. Materials 
P. pastoris expression: A glycerol stock of P. pastoris containing recombinant pPic9-Vp 
was obtained from Professor Theo Balts (University Victor Segalen, Bordeaux, France). A 
glycerol stock of P. pastoris containing recombinant pPic9-C2 was obtained from Dr Alain 
Boulangé (University of KwaZulu-Natal, Pietermaritzburg).  
Purification and quantification: Sephacryl S-300 was purchased from Sigma (Munich 
Germany). BCA™ Protein Assay kit (Pierce, Rockford, IL, USA). Nunc-ImmunoTM 96-well 
plates and the Nunc Black 96-well were purchased from Nunc Intermed (Denmark). The plates 
were read in a FLUORStar Optima Spectrophotometer (BMG Labtech, Germany). 
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Antibodies: Polyclonal antibody raised in rabbits against the bacterial-expressed central 
domain of congopain and the Chicken anti rabbit IgY Horse radish peroxidase (HRPO) 
conjugate (Dr Alain Boulangé, University of KwaZulu-Natal).  
Peptide substrates and inhibitors: The peptide substrates H-D-Val-Leu-Lys-7-amino-4-
methylcoumarin (AMC), H-D-Ala-Leu-Lys-AMC, succinyl (Suc)-Leu-Tyr-AMC, Suc-Ala-
Phe-Lys-AMC, H-Ala-Phe-Lys-AMC, H-Pro-Phe-Arg-AMC, methoxy-succinyl         
(MeoSuc)-Asp-Tyr-Met-AMC, butyloxycarbonyl (Boc)-Leu-Arg-Arg-AMC,                
Boc-Leu-GLy-Arg-AMC, H-Leu-AMC, H-Gly-AMC were obtained from Bachem (King of 
Prussia, PA, USA). Benzyloxycarbonyl (Z)-Phe-Arg-AMC, Z-Gly-Pro-Arg-AMC, Z-Gly-
Gly-Arg-AMC, Z-Arg-AMC, Z-Arg-Arg-AMC, Z-Gly-Arg-Arg-AMC, Z-Ala-Arg-Arg-
AMC, L-trans-epoxysuccinyl-leucylamido(4-guanidino)butane (E64), leupeptin, 
chymostatin, antipain, bestatin, ethylenediaminetetra-acetic acid (EDTA), pepstatin A, 
iodoacetic acid (IAA), iodoacetamide (IAN), phenylmethylsulfonylfluoride (PMSF), N-
tosyl-L-lysyl chloromethylketone (TLCK) and N-tosyl-L-phenylalanyl chloromethylketone 
(TPCK) were obtained from Sigma (Munich, Germany)  
 
2.2.2 Expression of Vp (catalytic domain of vivapain) and C2 (catalytic domain of 
congopain) in Pichia pastoris 
The P. pastoris strain GS115 glycerol stocks containing pPic9-Vp and pPic9-C2 were 
streaked on yeast extract peptone dextrose (YPD) plates [1% (w/v) yeast extract, 2% (w/v) 
peptone, 2% (w/v) dextrose (glucose) and 20 g/l bacteriological agar] containing ampicillin 
(50 µg/mL). A single colony from the YPD plate was inoculated into 100 mL YPD liquid 
medium [1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose (glucose)] 
containing ampicillin (50 µg/mL) to prevent contamination of the cultures. The YPD 
culture was grown at 30oC (in a 1 L baffled flask) in an orbital shaking incubator for two to 
three days. The culture was transferred into a 2 L baffled flask and the culture volume was 
made up to 1 L with buffered complex glycerol medium (BMGY) [1% (w/v) yeast extract,       
2% (w/v) peptone, 100 mM potassium phosphate buffer, pH 6.5, and 1.34% (w/v) yeast 
nitrogen base (YNB)]. The culture was grown for a further two days at 30oC in a shaking 
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incubator until an OD600 of 2-6 was reached. The BMGY medium was used since the 
combination of yeast extract and peptone in the medium allow for an increase in the 
biomass of cells and better cell growth. Cells were harvested by centrifugation (2000 g, 10 
min, 4oC) and resuspended in 500 mL of buffered minimal medium (BMM) [100 mM 
potassium phosphate buffer, pH 6.5, 1.34% (w/v) YNB, 0.00004% (w/v) biotin and            
0.5% (v/v) methanol] The BMM culture was placed in 2 L baffled flasks and incubated at 
30oC in a shaking incubator for four to six days. Methanol (0.5%) was added daily to the 
cultures in order to maintain induction of expression of the protein of interest. The cells 
were harvested by centrifugation (5000 g, 10 min, 4oC) once again, however this time the 
supernatant was retained since the P. pastoris strain used secretes the protein being 
expressed into the medium. The supernatant was stored in plastic bottles at -20oC until 
further use.  
2.2.3 Purification of Vp and C2  
Three phase partitioning (TPP)  
Three phase partitioning (TPP) was the initial method used for purification and 
concentration of Vp and C2. This method was conducted according to  Pike and Dennison 
(1989). The Vp and C2 supernatants (500 mL) were thawed and filtered through Whatman 
No 1 filter paper. The pH of the respective supernatants was lowered to pH 4.2 with 
phosphoric acid in order to process the peptidases into mature proteins. Tertiary butanol 
[30% (v/v)] was added to the culture supernatant and both Vp and C2 were precipitated out 
of solution with ammonium sulfate (NH4)2SO4 [40% (w/v) of the total volume i.e. culture 
supernatant and tertiary butanol]. The amount of (NH4)2SO4 to be used was determined by 
optimising TPP using 10, 20, 30 and 40% (NH4)2SO4 on a crude supernatant sample of Vp 
to which 30% (v/v) tertiary butanol had been added. Thereafter, the mixture was 
centrifuged (6000 g, 10 min, 4oC) in a swing out rotor. The centrifugation led to the 
successful separation of the three layers: a tertiary butanol layer, a precipitated protein layer 
and an aqueous layer. The precipitated protein layer for Vp and C2 was retained and 
dissolved in phosphate buffered saline (PBS) dialysis buffer [100 mM  Na2HPO4, 2 mM 
KH2PO4,      2.7 mM KCl and 137 mM NaCl, pH 7.2 ]. The proteins were then dialysed in a 
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10 kDa cut-off dialysis bag (Thermo Scientific Snakeskin® pleated dialysis tubing) 
overnight at 4oC against PBS, pH 7.2 in order to eliminate any residual tertiary butanol and 
(NH4)2SO4. The dialysed protein samples were concentrated by dialysis against solid 
polyethylene glycol (PEG) (Mr 20 000) until the volume in the dialysis bag was brought 
down to 5 mL. Analysis of the C2 sample after TPP revealed that the protein was pure, 
therefore no further steps of purification were required.  
 
Molecular exclusion chromatography (MEC)  
The Vp sample was further purified by molecular exclusion chromatography (MEC) using 
a Sephacryl-300 (Sigma) HR column (25 x 840 mm; flow rate of 25 mL/ hour, 4oC). The 
resin used has a fractionation range of 10 to 1500 kDa (Dennison 1999). The column was 
equilibrated with one column volume of MEC buffer [100 mM sodium acetate buffer,      
pH 7.0, 0.02% (w/v) NaN3). Thereafter, the column was calibrated with blue dextran (2000 
kDa), phosphorylase b (97 kDa), bovine serum albumin (66 kDa), ovalbumin (45 kDa), 
carbonic anhydrase (34.3 kDa), and soybean trypsin inhibitor (25 kDa). The proteins (12.5 
mg each) were dissolved and made up to 5 mL with MEC buffer. The determination of the 
void volume (Vo) of the column was based on the elution volume (Ve) of blue dextran. 








Where, Kav = availability constant 
     Ve = elution volume 
 Vo = void volume 
                                          Vt = total column volume (Dennison 1999) 
The Kav values were then subsequently used to produce a plot of Kav vs log Mw (results not 
shown), which was used to approximate the Mw of the eluted proteins. The Vp sample 
obtained after TPP (5 mL) was applied to the column and eluted using the MEC buffer. The 
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amount loaded on a MEC column should always be between 2 and 5% of the total column 
volume. Eluted fractions were analysed by measuring their absorbance at A280 as well as 
their activity against a synthetic substrate, Z-Phe-Arg-AMC.  
 
2.2.4 Recombinant protein quantification 
2.2.4.1 Quantification of Vp 
The purified Vp sample was quantified by two methods; namely, BCA™ Protein Assay kit 
(Pierce, Rockford, IL, USA) and by direct comparison of the Vp sample against known 
concentrations of BSA samples on a reducing SDS-PAGE gel. The BCA test was 
performed by combing reagent B with reagent A in a 1:20 ratio. The working reagent    
(200 µl) was mixed with bovine serum albumin (BSA) standards (0.025 – 2 mg/mL) and 
placed in a Nunc® 96 well microtitre plate. A dilute purified Vp sample was treated in the 
same manner. The plate was covered and incubated at 37oC for 30 min. This test was based 
on the presence of bicinchoninic acid in the working reagent, which interacts with the 
proteins to produce a purple coloured product. The absorbance of each sample was 
measured at 562 nm. A standard curve of A562 vs BSA standard concentrations was 







Figure 2.1 Standard curve of absorbance (A562) vs BSA concentrations for determination of protein 
concentration. Bovine serum albumin (BSA) standards (0.025 – 2 mg/mL) were used to construct a standard 
curve for the BCA assay. The equation of the trend line is y=0.0003x, with a correlation coefficient of 0.940. 
Microsoft excel 2007 was used to construct the plot.  
 
The second method of Vp quantification involved running equal volumes of BSA standards 
(0.025 – 2 mg/mL) and a purified Vp sample of unknown concentration on a 12.5% 
reducing SDS-PAGE gel. The protein bands were visualised by staining the gel with 
Coomassie blue R-250 [0.125% (w/v) Coomassie blue R-250, 50% (v/v) methanol and 
10% (v/v) acetic acid] followed by destaining in destain solution I [50% (v/v) methanol, 
10% (v/v) acetic acid] overnight and then in destain solution II [5% (v/v) methanol, 7% 
(v/v) acetic acid] to allow for complete destaining.. The concentration of the Vp was 
estimated by comparing the protein band intensity of the BSA standards with the Vp 































Figure 2.2 Analysis by 12.5% SDS-PAGE for the estimation of the concentration of Vp by direct 
visualisation. The BSA standards (0.025 – 2 mg/mL) were resolved on the gel alongside the Vp sample of 
unknown concentration. Lane 1, molecular weight marker; lanes 2-9, BSA standards (0.025 – 2 mg/mL)     
(2.5 µl); lane 10, purified Vp sample (2.5 µl). The samples loaded on the gel were mixed with an equal 
volume of reducing treatment buffer and boiled for 2 minutes. The gel was stained with Coomassie blue       
R-250.  
 
2.2.4.2 Quantification of C2 
The purified C2 was quantified by a method described by Bradford (1976), known as the 
Bradford dye-binding assay. This method is based on the binding of Coomassie Brilliant 
Blue G-250 dye to a protein sample. This interaction leads to a change in the absorbance 
maximum of the dye from 365 to 595 nm that is used to determine the concentration of a 
sample of unknown concentration (Bradford 1976). A micro assay was performed to 
quantify the purified C2 sample. Briefly, this method involved combining the dye reagent 
(950 µl) [0.01% (w/v) Coomassie Brilliant Blue G-250, 88% (v/v) phosphoric acid and 
99.5% (v/v) ethanol] with BSA standards (50 µl), ranging from 1-5 ng. The reaction 
mixture was left to stand for approximately two minutes after inversion. The C2 sample 
was diluted and treated under the same conditions as the BSA standards. The absorbance at   
595 nm was read for each sample. A standard curve of A595 vs BSA protein standards was 
constructed (Fig. 2.3). The concentration of C2 was determined by using the equation 
generated by the linear regression analysis of the standard curve and the absorbance at    












Figure 2.3 Bradford standard curve of absorbance (A595) vs BSA standard concentrations for 
determination of unknown protein concentration. Bovine serum albumin (BSA) standards (1-5 ng) were 
used to construct a standard curve for the Bradford micro assay. The concentration of the C2 sample was 
determined by using the standard curve. The equation of the trend line is y=0.0289x + 0.0012, with a 
correlation coefficient of 0.9964. Microsoft excel 2007 was used to construct the plot. 
 
2.2.5 SDS-PAGE gel analysis of proteins 
Analysis of recombinant protein samples were performed by a method described by        
Laemmli (1970). This was achieved by using a discontinuous Tris-Glycine buffer and gel 
system. Samples were combined with an equal volume of reducing treatment buffer       
[125 mM Tris-HCl, 4% (w/v) SDS, 20% (v/v) glycerol and 10% (v/v) 2-mercaptoethanol, 
pH 6.8]. The SDS in this buffer binds tightly to the protein sample resulting in a negatively 
charged rod-like protein complex. Disulfide bonds are reduced by 2-mercaptoethanol 
allowing the resulting subunits to also bind to SDS, which opens the protein structure even 
further. Once an electric field passes through the system a separation of the protein takes 
place based solely on the size of the protein and/or subunits. The proteins are first resolved 
through a stacking gel with small pore sizes in a 500 mM Tris-HCl buffer, pH 6.8 and 
thereafter through a running gel of large pore sizes in a 1.5 M Tris-HCl buffer, pH 8.8. 
Electrophoresis was conducted at 18 mA per gel for approximately 1.5 - 2 hours using a 


















relative migration distance of proteins on a gel has an inversely proportional relationship 
with the molecular weight of the protein. A standard curve of log Mw of proteins of known 
molecular weight vs distance travelled (relative mobility) was constructed (Fig. 2.4). The 
curve generated was used to determine the molecular weight of the protein of unknown 
size.    
 
Figure 2.4 Standard curve of log Mw against relative mobility for the estimation of protein Mw by 
SDS-PAGE. The low range marker is made up of phosphorylase B (97 kDa), bovine serum albumin           
(66 kDa), ovalbumin (45 kDa), carbonic anhydrase (31 kDa), soybean trypsin inhibitor (21Da) and lysozyme 
(14 kDa). The equation of the trend line is   y= -6.3012x + 13.239, with a correlation coefficient of 0.9864. 
Microsoft excel 2007 was used to construct the plot. 
 
Following electrophoresis, proteins were visualised by incubating the gel in a Coomassie 
blue R-250 stain for four hours followed by destaining in destain solution I overnight and 
then in destain solution II to allow for complete destaining. The detection of the Coomassie 
blue stain ranges from approximately 50-100 ng of protein. When a more sensitive protein 
detection was required, a silver stain method was used as described by Blum et al. (1987). 
This detection method limit is approximately 1-10 ng of protein. The silver staining method 
has to be carried out in extremely clean glassware to decrease the chance of background 
staining and all the steps must be carried out on an orbital shaker.  Briefly, the silver 




























solution [50% (v/v) methanol, 12% (v/v) acetic acid, 0.5% (v/v) formaldehyde] for 1 hour 
or overnight at room temperature (RT). The gel was incubated in 50% (v/v) ethanol (3 x 20 
min). This was followed by soaking of the gel in pretreatment solution                         
[0.4% (w/v) Na2S2O3.5 H2O] for 1 min. The gel was washed in distilled water (3 x 20 sec). 
This was followed by soaking the gel in impregnation solution [0.2% (w/v) AgNO3, 0.75% 
(v/v) 37% formaldehyde] for 20 min. Once again, the gel was washed in distilled water (3 x 
20 sec) and, thereafter, incubated in developing solution [6% (w/v) Na2CO3, 0.5% (v/v) 
37% formaldehyde, 2% (v/v) pretreatment solution (0.4% (w/v) Na2S2O3.5 H2O)] until the 
first protein band became evident. Once this occurred, the gel was immediately placed in 
distilled water until sufficient bands appeared. The development of the bands was stopped 
by placing the gel in a stopping solution [50% (v/v) methanol, 12% (v/v) acetic acid] for 10 
min. The gel was washed in 50% (v/v) methanol and stored in polythene zip-seal bags.  
2.2.6 Western Blot analysis of proteins 
Western blots were carried out in order to confirm the expression of the recombinant 
proteins. Proteins were separated on a Laemmli SDS-PAGE gel and transferred from the 
SDS-PAGE gel onto a nitrocellulose membrane, using a wet blotter (BioRad Hercules, CA, 
USA) in the presence of blotting buffer [45 mM Tris-HCl buffer, pH 8.3, 173 mM glycine 
and 0.1% (w/v) SDS] for 16 hours at 200 mA (Towbin et al. 1979; Gershoni and Palade 
1982). Following transfer of the proteins, the nitrocellulose membrane was stained with 
Ponceau S [0.1% (w/v) Ponceau S in 1% (v/v) glacial acetic acid]. Once the protein bands 
became visible, the positions of the molecular weight markers were marked with a pencil. 
Thereafter, the nitrocellulose membrane was destained with distilled water. The unoccupied 
sites on the nitrocellulose membrane were blocked with low fat milk powder solution     
[5% (w/v) low fat milk powder in Tris buffered saline (TBS) (20 mM Tris-HCl buffer,    
pH 7.4, 200 mM NaCl) for one hour at RT. The membrane was subsequently washed with 
TBS (3 x 5 minutes) and incubated in primary antibody diluted in 0.5% (w/v) BSA-TBS for 
two hours at RT. This was followed by washing the membrane in TBS (3 x 5 minutes). The 
membrane was then incubated in enzyme labelled secondary antibody diluted in 0.5% (w/v) 
BSA-TBS for one hour at RT. Lastly, the membrane was washed in TBS (3 x 5 minutes) 
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and placed in substrate solution [0.06% (w/v) 4-chloro-1-naphthol, 0.0015% (v/v) hydrogen 
peroxide (H2O2), 0.1% (v/v) methanol, in TBS]. The blot was left in the dark until the 
appearance of protein bands became evident.  
2.2.7 Enzymatic characterisation 
2.2.7.1 Gelatin SDS-PAGE analysis of Vp and C2 
This method involved running a standard Laemmli 12.5% SDS-PAGE gel with 
modifications as described by Heussen and Dowdle (1980). These modifications include 
running the samples under non-reducing conditions i.e. the samples are combined with an 
equal volume of non-reducing treatment [125 mM Tris-HCl buffer pH 6.8, 4% (w/v) SDS 
and 20% (v/v) glycerol] and a gelatin solution [1% (w/v)] is added to make the 12.5%  
SDS-PAGE running gel buffer (Heussen and Dowdle 1980). After electrophoresis the 
running gel is soaked in two changes of Triton X-100 solution [2.5% (v/v)] over a one hour 
period at RT to remove the SDS, which allows for the renaturation of the recombinant 
protein. The gel is subsequently incubated in congopain assay buffer [100 mM Bis-Tris 
buffer, pH 6.5, 4 mM Na2EDTA, 0.02% (w/v) NaN3 and 8 mM DTT] for three hours at 
37oC. The gel was then stained with amido black solution  [0.1% (w/v) amido black,     
30% (v/v) methanol, 10% (v/v) glacial acetic and 60% (v/v) distilled water] for one hour at 
RT and destained in 30% (v/v) methanol, 10% (v/v) glacial acetic and 60 % (v/v) distilled 
water until clear bands became evident, which is an indication of proteolytic activity of the 
recombinant peptidase.  
2.2.7.2 Effect of endoglycosidase H (Endo H) on Vp 
The action of Endo H on Vp was conducted according to Caffrey et al. (2001). Vp (50 µl), 
5 M NaCl (1.5 µl), 5% (w/v) SDS and 10% of 2-mercaptoethanol were combined and 
boiled for 5 minutes. The preparation was allowed to cool and 0.5 M sodium citrate buffer 
(pH 5.5); (6 µl) was added and the preparation was divided into two. Endo H (500 U) was 
added to one of the preparations and the other was used as a control. The two preparations 
were incubated at 37oC for 3 hours. Thereafter an equal volume of reducing treatment 
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buffer was added to each preparation and boiled for 5 minutes. The samples were 
electrophorised on 12.5% reducing SDS-PAGE gel as described by Section 2.2.5.  
2.2.7.3 Active site titration of Vp and C2  
Active site titration with the irreversible inhibitor, E-64, was conducted on Vp and C2 
according to Barrett et al. (1982) in order to determine the active concentration of both 
cysteine peptidases. The enzyme (25 µl) [1 µM diluted in 0.1% (w/v) Brij-35] was 
incubated with E-64 [0.1 – 1 µM diluted in 0.1% (w/v) Brij-35] in the presence of 
congopain assay buffer (50 µl) at 37oC for 30 minutes. The DTT was added to the buffer 
just before use. Thereafter, 10 µl aliquots of the incubated mix were combined with 25 µl 
of Z-Phe-Arg-AMC synthetic substrate solution [20 µM, diluted in distilled water]. This 
step was performed in triplicate for each E-64 concentration. The fluorescence (activity of 
the enzyme against the substrate) was measured (excitation, Ex360nm and emission, Em460nm) 
using a FLUORStar Optima spectrophotometer (BMG Labtech, Offenburg, Germany). The 
active concentration of the enzyme was determined by plotting fluorescence against the    
E-64 concentrations (0.1-1 µM).  
2.2.7.4 Effect of pH on both Vp and C2 
The determination of the pH optimum for Vp and C2 using constant ionic strength acetate-
MES-Tris (AMT) buffer [100 mM Na-acetate, 200 mM Tris-HCl, 100  mM MES, 8 mM 
DTT, 4 mM Na2EDTA] was conducted according to Ellis and Morrison (1982). The AMT 
buffer was aliquoted and titrated from pH 4 to 9 with either HCl or NaOH. The enzyme 
[1.5 ng active enzyme (25 µl) diluted in 0.1 % (w/v) Brij-35] was incubated separately with 
AMT buffers of pH 4-9 (50 µl) for 15 minutes at 37oC. This was performed in triplicate for 
each buffer (pH 4-9). The enzyme and buffer mix (75 µl) and Z-Phe-Arg-AMC (25 µl)    
[20 µM, diluted in distilled water] was placed in black Nunc® 96 well microtitre plate and 
the fluorescence was measured (Ex360nm, Em460nm) using a FLUORStar Optima 
spectrophotometer (BMG Labtech, Offenburg, Germany). The optimum pH of the 
recombinant protein was determined by plotting fluorescence against the pH.  
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2.2.7.5 Determination of kinetic constants and parameters 
AMC standard curve 
In order to quantify the amount of product formed in the hydrolysis of synthetic peptide by 
the enzyme, an AMC calibration curve was constructed. A range of AMC concentrations 
(50 µl) [5 x 10-3 – 15 µM] were incubated with pre-warmed congopain assay buffer (50 µl) 
and the fluorescence (Ex360nm, Em460nm) measured using a FLUORStar Optima 
spectrophotometer (BMG Labtech, Offenburg, Germany). The standard AMC curve was 
constructed from a plot of AMC concentrations versus fluorescence (Fig. 2.5). The slope of 
this curve was used to convert the fluorescence units acquired from the synthetic substrate 
assays and inhibitor assays into concentration.    
 
Figure 2.5 Standard curve relating the amount of AMC to fluorescence (Ex360nm, Em460nm). The equation 
of the trend line is given by y = 3.356x + 445.06, with a correlation coefficient of  0.9978. Microsoft excel 
2007 was used to construct the plot.  
Peptidolytic specificity  
 
The substrate specificity of a particular enzyme is analysed by measuring the following 
parameters: Michaelis-Menten constant, Km, and the maximum velocity of an enzyme 
catalysed reaction, Vmax. Km indicates the affinity of the enzyme for the substrate and it is 
independent of enzyme concentration (Palmer 1995). The lower the Km the more the 
enzyme prefers the substrate. Vmax describes the maximum number of substrate particles 
that can be converted to products per molecule of enzyme per unit time. Vmax is dependent 

































available, the active amount of enzyme can be determined. This value is known as [E]o. 
When this value is known, Vmax can be converted to kcat, which is the turnover number of 
the enzyme (Palmer 1995). The relationship between these values are represented in the 






(Salvesen and Nagase 1989) 
 
The apparent second order rate constant, kcat / Km, describes the catalytic efficiency of the 
reaction. Therefore, it is used to describe the specificity of the enzyme for the substrate. 
This value can be used to compare different substrates for a particular enzyme. 
The kinetic constants of a reaction can be determined from single-substrate-enzyme 
catalysed reactions. This determination is based on measuring the initial velocity (vo) over a 
range of substrate concentrations [S]. The Km, Vmax, [S] and vo are related by the Briggs and 





(Briggs and Haldane 1925) 
Vmax and Km, are determined from the direct plot of vo versus [S]. 
The hydrolysis of the synthetic fluorogenic substrate by Vp and C2 were performed using 
the same method. Briefly, the enzyme [1.5ng (0.56 nM) active Vp and (0.56 nM) active C2] 
was made up to 25 µl with Brij [0.1 % (w/v)] and activated in congopain assay buffer (50 
µl) for 10 min at 37oC. Thereafter, substrate (25 µl) (ranging from 2.5 – 50 µM final 
concentration) was added. The fluorescence (Ex360nm, Em460nm) was monitored continuously 
for 10 min using the FLUORStar Optima spectrophotometer (BMG Labtech, Offenburg, 
Germany). The initial steady state velocity (vo) was determined over the range of substrate 
concentrations. The kinetic constants Vmax and Km were determined by hyperbolic 
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regression analysis of the kinetic data using the Hyper32© software data package (1991-
2003, J.S. Easterby, University of Liverpool, UK).  
50 mM Substrate stock solutions: Z-Phe-Arg-AMC (3.25 mg), H-D-Val-Leu-Lys-AMC 
(1.03 mg), H-D-Ala-Leu-Lys-AMC (2.44 mg), Suc-Leu-Tyr-AMC (2.76 mg),                                 
Suc-Ala-Phe-Lys-AMC (3.68 mg), H-Ala-Phe-Lys-AMC (2.61 mg), H-Pro-Phe-Arg-AMC 
(2.88 mg), Z-Gly-Pro-Arg-AMC (3.28 mg), Z-Gly-Gly-Arg-AMC (3.08 mg), Z-Arg-AMC 
(2.51 mg), Z-Arg-Arg-AMC (3.11 mg), Z-Gly-Arg-Arg-AMC (3.33 mg), Z-Ala-Arg-Arg-
AMC (3.40 mg), Meosuc-Asp-Tyr-Met-AMC (3.49 mg), Boc-Leu-Arg-Arg-AMC (3.69 
mg), Boc-Leu-Gly-Arg-AMC (3.01 mg), H-Leu-AMC (1.44 mg), H-Gly-AMC (1.57 mg) 
were dissolved separately in DMSO (100 µL). 
1 mM Working substrate solutions:  50 mM stock solutions (20 µL) was dissolved in 
distilled water (980 µL). Substrates were diluted from this 1 mM working solution with 
distilled water to four times the appropriate final concentration, which allows for the 
dilution in the assay. 
 
Assay for the effect of reversible inhibitors on Vp and C2 
The inhibition kinetic constant (Ki) was determined for reversible inhibitors according to 
Salvesen and Nagase (1989). Firstly, the uninhibited rate of substrate hydrolysis (vo) was 
determined. Briefly, the enzyme [0.15ng (0.056 nM) active Vp and (0.056 nM) active C2] 
was made up to 25 µl with 0.1 % (w/v) Brij and incubated with 50 µl congopain assay 
buffer for 10 min at 37oC to allow for activation of the enzyme. Substrate (25 µl) of 20 µM 
Z-Phe-Arg-AMC or D-Val-Leu-Lys-AMC (final concentration) was added. This substrate 
concentration was used since it allowed for less than 5% hydrolysis, which is vital since 
this ensures that the substrate concentration is kept constant. The fluorescence (Ex360nm, 
Em460nm) was monitored continuously for 5 min using the FLUORStar Optima 
spectrophotometer (BMG Labtech, Offenburg, Germany). Inhibitor was added at a 
concentration range at least 20-fold molar excess over the enzyme concentration. The 
volume of inhibitor added did not exceed 5% of the total assay volume. Fluorescence 
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(Ex360nm, Em460nm) was monitored continuously using the FLUORStar Optima 
spectrophotometer (BMG Labtech, Offenburg, Germany) until a new steady state velocity 
was obtained in the presence of the inhibitor (vi). Under these conditions the apparent 
inhibition constant in the presence of substrate (Ki(app)) is given by the following equation: 




(Salvesen and Nagase 1989) 
1/ Ki(app) is the slope from the plot of vo/ vi against [I]. 










 Assay for the effect of irreversible inhibitors on Vp and C2 
The effect of irreversible inhibitors on Vp and C2 activity was determined under pseudo 
first-order conditions, where the inhibitor concentration is 50 times greater than the enzyme 
concentration ([I] > 50[E]) (Salvesen and Nagase, 1989). Briefly, the enzyme [0.15ng 
(0.056 nM) active Vp (1.56 µl) and (0.056 nM) active C2 (1 µl)] was made up to 97.5 µl 
with 1 % (w/v) Brij and activated with 1.95 mL congopain assay buffer. The inhibitor    
(880 µl; the volume added allowed for the final concentration to be 50 x > enzyme 
concentration) was added to buffered enzyme solution and incubated at 37oC. Aliquots    
(75 µl) were removed at 5 min time intervals for 1 hour and the residual activity was 
determined against 25 µl of substrate (20 µM final concentration of Z-Phe-Arg-AMC or   
D-Val-Leu-Lys-AMC). The kobs was determined from a plot of the ln (natural logarithm) of 
residual enzyme activity against time.  
The slope of this plot gives -kobs (pseudo first-order rate constant), which allows for the 







    (Salvesen and Nagase 1989), 
where [I] is the inhibitor concentration. The time required for the free enzyme to decrease 
by 50% (half-time, t1/2) during the reaction of the enzyme with the irreversible inhibitor is 
given by: 




(Salvesen and Nagase 1989) 
 
 
2.3 RESULTS  
2.3.1 Expression of the catalytic domains of vivapain (Vp) and congopain (C2) 
Vp and C2 were recombinantly expressed in P. pastoris by methanol induction. Fig. 2.6 A 
and 2.6 B show the recombinant expression supernatant of Vp on day two and day five of 
expression and of C2 on day five of expression. Vp was observed as two bands at 
approximately 29 kDa and 33 kDa (Fig. 2.6 A, lanes 2 and 3). C2 also has two bands at 
approximately 27 kDa and 33 kDa (Fig. 2.6 B, lane 2). The reason for the 33 kDa C2 band 





















Figure 2.6 Analysis by 12.5% SDS-PAGE of the expression of Vp and C2 in P. pastoris. Panel A, silver 
stained gel showing the expression of Vp after day two and day five. Lane 1, molecular weight markers;            
lane 2, supernatant of culture from day 2 of expression (25 µl); lane 3, supernatant of culture from day 5 of 
expression (25 µl). Panel B, Coomassie stained gel showing the expression of C2 on day five.                          
Lane 1, molecular weight markers; lane 2, supernatant of culture from day 5 of expression (25 µl). Expression 
for both Vp and C2 were induced with 0.5% (v/v) methanol in BMM. Each of the Vp and C2 supernatants 
were mixed with an equal volume of reducing treatment buffer and boiled for 2 minutes prior to loading. 
2.3.2 Purification of Vp and C2 
Three phase partitioning (TPP) was used as the initial step to both concentrate and purify 
the recombinantly expressed proteins from the culture supernatant. TPP was optimised on a 
crude supernatant of Vp and the optimal amount of (NH4)2SO4 was determined to be 40% 
(results not shown). The arrows in Fig 2.7 panel A indicate two prominent bands present in 
each lane corresponding to Vp at 29 kDa and 33 kDa (Fig 2.7, lanes 2 and 3). TPP was also 
performed on the C2 culture supernatant using 40% (NH4)2SO4. Once again, the protein 
precipitated efficiently out of the supernatant which can be seen by the prominent band 
present in panel B (Fig 2.7, lane 2). The 33 kDa band that was present in the C2 culture 
supernatant before TPP (Fig 2.6 B, lane 2) has disappeared after TPP; however, the 33 kDa 
band that was present in the Vp culture supernatant before TPP (Fig 2.6 A, lane 2) is still 
present after TPP and at the same intensity as the 29 kDa band. This 33 kDa band could 
potentially be glycosylated.       


































Figure 2.7 Analysis by 12.5% SDS-PAGE of the precipitation of Vp and C2 from the culture 
supernatant using TPP. Panel A: Precipitation of Vp from the expressed culture supernatant using 40% 
(NH4)2SO4. Lane 1, molecular weight markers; lanes 2 and 3, different Vp fractions after TPP, dialysis and 
concentration (10 µl). Panel B: Precipitation of C2 from the expressed culture supernatant using 40% 
(NH4)2SO4. Lane 1, molecular weight markers; lane 2, C2 fractions after TPP, dialysis and concentration  (10 
µl). The samples loaded on the respective gels were mixed with an equal volume of reducing treatment buffer 
and boiled for 2 minutes. The gel was stained with Coomassie blue R-250. The arrows indicate the 
precipitated protein bands representing Vp (Panel A) and C2 (Panel B).  
 
A western blot was performed in order to verify that Vp and C2 were expressed (Fig. 2.8). 
Both Vp and C2 were detected using rabbit anti-central domain of congopain IgG. This 
antibody is specific for C2; however, it had a good chance of detecting Vp because of the 
high sequence identity between Vp and C2 (Fig. 1.8, Section 1.8.5). The antibody 
recognised bands at 29 and 33 kDa (lanes 2 and 3), which correspond to the sizes of the two 
bands present in Vp and it also detected C2 at 27 kDa (lane 4) that was used as a positive 
control. The blot also shows multiple contaminating bands in lanes 2 and 3 that are larger in 




































Figure 2.8 Western blot analysis of Vp and C2 expression. Proteins were electrophoresed on a 12.5% 
SDS-PAGE gel and electroblotted onto a nitrocellulose membrane. Transferred protein was incubated with 
rabbit anti-central domain of congopain IgG (1: 1000). Secondary antibody was goat anti-rabbit HRPO-
conjugated (1: 2000). Reaction was developed with 4-chloro-1-naphthol/H2O2. Lane 1, molecular weight 
markers; lane 2 and 3, Vp (10 µg) after TPP and lane 4, of C2 after TPP (5 µg).  
 
The SDS-PAGE gel (Fig 2.7 A, lanes 2 and 3) and the western blot (Fig 2.8, lanes 3 and 4) 
showed the presence of higher molecular weight contaminants in the Vp sample after TPP. 
Vp was further purified using Sephacryl S-300 molecular exclusion chromatography 
(MEC). Two elution peaks were observed after the MEC purification (Fig 2.9). The first 
peak corresponds to the higher molecular weight contaminants. The second peak 
corresponds to Vp. This was further verified by performing an activity assay using the 
substrate Z-Phe-Arg-AMC. This showed that the proteins eluting in the first peak have no 
activity in contrast to the proteins in the second peak which showed Vp activity. A silver 
stain, which was performed on the fractions present in the second peak (Fig. 2.10) revealed 
two bands corresponding to the expected size of Vp at 29 and 33 kDa. These fractions were 












Figure 2.9 Purification of Vp by molecular exclusion chromatography using Sephacryl-300. The column 
has dimensions of 25 x 840mm with a flow rate of 25ml/hour. Fractions (5 mL) were collected. The 
absorbance at A280 was taken () as well as the activity against Z-Phe-Arg-AMC ().Microsoft excel 2007 









Figure 2.10 Silver stained 12.5% reducing SDS-PAGE gel indicating fractions eluted during MEC of 
Vp. Panel A: lane 1, molecular weight markers; lanes 2-10, MEC fractions 50-58. Panel B: lane 1, molecular 
weight markers; lanes 2-10, MEC fractions 59-67.  
The western blot (Fig. 2.11) represents the progression of purification of Vp, which shows 
that the majority of the contaminants present after TPP were successfully eluted in the first 
peak of the MEC purification (Fig. 2.9) This is evident when comparing the Vp bands 
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contaminating bands present after TPP are not present after MEC. The primary antibody 
used for the western blot was rabbit anti-central domain of congopain IgG. Because of the 
congopain and vivapain amino acid sequence identity (Fig. 1.8 Chapter 1), the western blot 













Figure 2.11 Analysis of the purification of the Vp after TPP and MEC. Panel A: 12.5% Reducing SDS-
PAGE and panel B: western blot. Lane 1, molecular weight markers; lane 2, culture supernatant before 
purification (10 µl); Lane 3, Vp after TPP (10 µl) and Lane 4, Vp after MEC (10 µl). For panel A: the 12.5% 
SDS-PAGE gel each sample was mixed with an equal volume of reducing treatment buffer and boiled for 2 
minutes and the gel was stained with Coomassie blue R-250. For panel B: proteins were electrophoresed on a 
12.5% SDS-PAGE gel and electroblotted onto a nitrocellulose membrane. Transferred protein was incubated 
with rabbit anti-central domain of congopain IgG (1: 1000). Secondary antibody was goat anti-rabbit HRPO-
conjugated (1:2000). Reaction was developed with 4-chloro-1-naphthol/H2O2.The arrows indicate the bands 
representing vivapain in lanes 2-4 in both A and B. 
 
The purification of Vp and C2 is represented in Table 2.1. The activity of Vp was measured 
before and after TPP and after MEC and the activity of C2 was only measured before and 
after TPP, since C2 did not have any contaminating bands after TPP (Fig. 2.7 B). The 
activity was determined by assaying the hydrolysis of Z-Phe-Arg-AMC. Therefore the 
values for activity were calculated from the total activity obtained from the hydrolysis of 
the substrate. The specific activity of Vp increased 22 -fold after TPP and a further 18-fold 
after MEC. The Vp yield after TPP and MEC was 95% and 143% respectively. The 




















Table 2.1 Purification of Vp (A) and C2 (B). Activity was measured on Vp samples 
before and after TPP as well as after MEC and on C2 samples before and after TTP. 



















Supernatant 730 1.3 949 35166 37.06 1 100
TPP 8 5.2 41.6 33421 803.39 21.68 95



















Supernatant 100 0.06 5.6 31153 5563 1 100




2.3.3 Enzymatic characterisation of Vp 
In order to assess the activity of the recombinantly expressed Vp and C2 against a protein 
substrate, both the purified samples were electrophoresed on a 12.5% SDS-PAGE gel 
containing 1% (w/v) gelatin under non-reducing conditions. The digestion of the gelatin by 
the Vp and C2 samples corresponds to the respective positions of their protein bands on the 
gel (Fig. 2.12). The bands in each lane associated with Vp are at approximately at 35 kDa 
and 50 kDa (Fig. 2.12, lanes 2 and 3). The area where C2 digested the gelatin is at 



















Figure 2.12 Analysis by non-reducing 12.5% SDS-PAGE gel containing 1% gelatin showing the 
endoproteolytic activity of Vp and C2. Proteins were not boiled and reduced. Lane 1, Spectra™ Multicolour 
Broad Range Protein Ladder; lanes 2 and 3, Vp 0.5 µg and 1 µg; lane 4, C2 (5 µg). (B) Gels were stained with 
Amido black. 
 
Vp was observed on both the reducing (Fig. 2.6 A, 2.7 A, 2.10 A and B and 2.11 A) and 
non-reducing (Fig 2.12) SDS-PAGE gels as a double band. The presence of the two bands 
suggests that vivapain could be glycosylated. This was investigated by conducting 
endoglycosidase H (Endo H) digestion of Vp, which cleaves glycosylated areas of a protein 
and assessing the cleavage products on SDS-PAGE (Fig. 2.13). In comparison to the 
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29 kDa and at 33 kDa (lane 3), the 33 kDa band disappeared in the presence of Endo H 



















Figure 2.13 Analysis by a reducing 12.5% SDS-PAGE of endoglycosidase H treatment of Vp. Lane 1, 
molecular weight markers; lane 2, Vp (15 µg) treated with 500 units endoglycosidase H; lane 3, control-Vp 
without endoglycosidase H (15 µg). The Vp samples were boiled with 2-mercaptoethanol before the addition 
of endoglycosidase H since the enzyme is only able to work on the reduced sample. Vp and Endo H were 
incubated for 3 hours at 37oC. The gel was stained with Coomassie blue R-250. 
 
Active site titration was carried out on the recombinant purified Vp and C2 by using E-64 
as the active site titrant. This gives an indication of the concentration of the active enzyme 
present from the total concentration of Vp and C2. Both preparations of Vp (Fig. 2.14) and 
C2 (results not shown) were shown to be 20% active, which translates into active 

























Figure 2.14 Percentage of active vivapain in the presence of differing concentrations of E-64. A constant 
amount of vivapain (1 µM) was reacted with different concentrations of E-64 (ranging from 0.1-1 µM) and 
the hydrolysis of Z-Phe-Arg-AMC was measured. Microsoft excel 2007 was used to construct the plot.   
 
The pH optima for maximal activity of Vp and C2 were determined in the presence of a 
constant ionic strength AMT buffer ranging from pH 4-9. The pH profiles for Vp and C2 
are shown in (Fig. 2.15). The activity of Vp against Z-Phe-Arg-AMC was optimal at        
pH 7.0. Vp is active over a narrower pH range (from pH 6-9) than C2. The pH optimum for 






































































Figure 2.15 Effect of pH on Vp (A) and C2 activity (B) against Z-Phe-Arg-AMC. Vivapain (1.5 ng active 
enzyme) and C2 (1.5 ng active enzyme) were used and their activity against Z-Phe-Arg-AMC was tested at 
37oC. The AMT buffers of constant ionic strength was used over a pH range from pH 4-9. The error bars 
represent the mean fluorescence ± SD (n=3). Microsoft excel 2007 was used to construct the plot. 
 
Both the recombinantly expressed purified Vp and C2 were reacted with an array of 
endopeptidase and exopeptidase synthetic substrates. The kinetic constants, namely Km, kcat 





6.78 µM, respectively) and a high kcat/Km (22.57 s
-1mM-1 and 149.59 s-1mM-1, respectively) 
for hydrolysis of Z-Phe-Arg-AMC.  
Table 2.2 Kinetic constants for the hydrolysis of synthetic substrates by purified 
recombinant Vp and C2. The various substrate concentrations used ranged from           
2.5-50 µM with 1.5 ng enzyme. All incubation steps were carried out at 37oC. Assays were 
performed in congopain assay buffer [100 mM Bis-Tris, pH 6.5, 4 mM EDTA, 0.02% (w/v) 
NaN3, 8 mM DTT]. The Km values were calculated based on the AMC standard curve 
(y=3.356x) from the means of triplicate values. Km values and the Michaelis-Menten plots 
were calculated using the Hyper® 32 software (J.S Easterby). 
Substrate  Enzyme  a Km 
(µM) 
kcat (s
-1) kcat/Km     
(s-1mM-1) 
Z-Phe-Arg-AMC Vp 9.61 0.22 22.57 
  C2 6.78 1.01 149.59 
 
H-D-Val-Leu-Lys-AMC Vp 14.23 0.55 38.61 
  C2 1.78 2.36 1324.96 
 
H-D-Ala-Leu-Lys-AMC Vp 14.97 0.33 21.74 
  C2 1.55 2.75 1772.17 
 
Suc-Leu-Tyr-AMC Vp 186.1 0.04 0.22 
  C2 728.5 0.90 1.24 
 
Suc-Ala-Phe-Lys-AMC Vp 83.03 0.01 0.14 
  C2 131.5 0.48 3.66 
 
H-Ala-Phe-Lys-AMC Vp 88.06 0.05 0.52 
  C2 33.26 1.19 35.82 
 
H-Pro-Phe-Arg-AMC Vp 61.63 0.11 1.81 
  C2 17.92 1.37 76.31 
No activity was detected against  Z-Gly-Pro-Arg-AMC, Z-Gly-Gly-Arg-AMC, Z-Arg-AMC, Z-Arg-Arg-
AMC, Z-Gly-Arg-Arg-AMC, Z-Ala-Arg-Arg-AMC, Meosuc-Asp-Tyr-Met-AMC, Boc-Leu-Arg-Arg-AMC, 
Boc-Leu-Gly-Arg-AMC, H-Leu-AMC, H-Gly-AMC, after one, two, three and four hours of incubation at 
37oC. 




This shows that Z-Phe-Arg-AMC is a good substrate for Vp and C2; however, results show 
that it is not the best substrate. The best substrate for Vp is H-D-Val-Leu-Lys-AMC. Vp has 
a Km of 14.23 µM and a kcat/Km of 38.61 s
-1mM-1 when reacted with H-D-Val-Leu-Lys-
AMC. Even though the Km is higher than for the hydrolysis of Z-Phe-Arg-AMC by Vp, a 
comparison of the kcat/Km values (catalytic efficiency constants) determines the best 
substrate for a particular enzyme. Since the reaction between Vp and H-D-Val-Leu-Lys-
AMC yields a higher kcat/Km value, it is the better substrate. The results also show that D-
Ala-Leu-Lys-AMC is also a good substrate for Vp. The best substrates for C2 are H-D-Val-
Leu-Lys-AMC and H-D-Ala-Leu-Lys-AMC since the Km values are low (1.78 µM and 1.55 
µM respectively) and their kcat/Km are exceptionally high (1324.96 s
-1mM-1 and 1772.17 s-
1mM-1 respectively). It is also interesting to note that both these cysteine peptidases, Vp and 
C2, have endopeptidase and exopeptidase activity as shown by the hydrolysis of Z-Phe-
Arg-AMC, which has a N-terminal blocking group and H-D-Val-Leu-Lys-AMC and H-D-
Ala-Leu-Lys-AMC, which do not have blocking groups. The following substrates: Z-Gly-
Pro-Arg-AMC, Z-Gly-Gly-Arg-AMC, Z-Arg-AMC, Z-Arg-Arg-AMC, Z-Gly-Arg-Arg-
AMC, Z-Ala-Arg-Arg-AMC, MeoSuc-Asp-Tyr-Met-AMC, Boc-Leu-Arg-Arg-AMC,                             
Boc-Leu-Gly-Arg-AMC, H-Leu-AMC,  H-Gly-AMC, were not hydrolysed by Vp or C2. 
 
The inhibition of recombinant Vp and C2 by competitive, low molecular weight reversible 
inhibitors is shown in Table 2.3. Both the enzymes seemed to follow the same trend when 
they reacted with the inhibitors in the presence of either Z-Phe-Arg-AMC or                     
D-Val-Leu-Lys-AMC. The best inhibitor for both recombinant Vp and C2 was leupeptin 
since the lowest Ki value was obtained for this inhibitor when comparing it to the values 
obtained for the other inhibitors. There is no significant difference between the reactions of 
chymostatin and antipain with the recombinant Vp in the presence in                                       
D-Val-Leu-Lys-AMC and C2 in the presence of Z-Phe-Arg-AMC. Chymostatin seems to 
be a better inhibitor than antipain for Vp in the presence of Z-Phe-Arg-AMC since a lower 
Ki value is obtained. Chymostatin is the better inhibitor of the two for the reaction with 
recombinant C2 in the presence of D-Val-Leu-Lys-AMC since a lower Ki is obtained. Other 
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low molecular weight reversible inhibitors such as bestatin, EDTA and pepstatin A did not 
inhibit either Vp or C2.  
 
Table 2.3 Inhibition of recombinant Vp and C2 by competitive reversible inhibitors. 
Assays were performed in congopain assay buffer [100 mM Bis-Tris, pH 6.5, 4 mM 
EDTA, 0.02% (w/v) NaN3, 8 mM DTT]. All incubation steps were at 37
oC. The Ki values 
were calculated based on the AMC standard curve (y=3.356x) from the means of triplicate 
values.  
No inhibition was observed with bestatin (10 µM), EDTA (10 mM) or pepstatin A (1 µM)  
 
The inhibition of recombinant Vp and C2 by competitive, low molecular weight 
irreversible inhibitors is shown in Table 2.4. The reaction of both Vp and C2 with IAA and 
IAN shows very similar kinetic values in the presence of either Z-Phe-Arg-AMC or                                                 
D-Val-Leu-Lys-AMC. The action of IAA and IAN on Vp seems to better in the presence of 
D-Val-Leu-Lys-AMC since a higher kass values of 17.86 mM
-1.s-1 and 12.5 mM-1.s-1 are 
obtained and the t1/2 values are much lower for these reactions. The action of IAA on C2 
seems to better in the presence of Z-Phe-Arg-AMC since a higher kass value of                     







 Z-Phe-Arg-AMC  D-Val-Leu-Lys-AMC Z-Phe-Arg-AMC  D-Val-Leu-Lys-AMC 
Inhibitor 
Ki (µM)                
( x103) 
Ki (µM)                                 
( x103) 
Ki (µM)                     
( x103) 
Ki (µM)                             
( x103) 
Leupeptin 4.46 4.35  5.45  102.1 
Chymostatin 9.77 18.07  9.62  240 
Antipain 13.32 11.4  8.5  434.9  
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for C2 in the presence on D-Val-Leu-Lys-AMC due to the higher kass value of                      
16.08 mM-1.s-1 is and t1/2 is much lower (1593 s) for this reaction. The low molecular weight 
irreversible inhibitors such as PMSF, TLCK and TPCK did not inhibit Vp or C2. 
 
Table 2.4 Inhibition of recombinant Vp (A) and C2 (B) by competitive irreversible 
inhibitors. All incubation steps were at 37oC. Assays were performed in congopain assay 
buffer [100mM Bis-Tris, pH 6.5, 4mM EDTA, 0.02% (w/v) NaN3, 8mM DTT]. The kass 






























No inhibition was observed with PMSF, TLCK and TPCK
 
a Standard deviation  
b 
28 nM inhibitor concentration 
A Vp 












IAA b 10.71 ± 0.01 2311 17.86 ± 5.04 1386 
IAN  b 7.14 ± 0.01 3466 12.5 ± 7.58 1980 
B C2 









                                   
(mM-1.s-1) 
t1/2 (s) 
IAA b 14.29 ± 0.01 1732 10.72 ± 5.06 2309 
IAN  b 10.72 ± 5.06 2309 16.08 ± 2.52 1539 
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2.4 DISCUSSION  
In the present study, the catalytic domain of vivapain (Vp) was expressed in a yeast 
expression system. This decision was based on the fact that the catalytic domain of 
congopain (C2) had been previously expressed at high functional levels in the 
methylotrophic Pichia pastoris yeast expression system (Boulangé A, University of 
KwaZulu-Natal, personal communication). The use of the methylotrophic P. pastoris yeast 
expression system had become very popular due to the simplicity of the expression 
technique (Cereghino and Cregg 2000). This system is also able to express high levels of 
foreign proteins either extracellularly or intracellularly. Most importantly, this system is 
capable of producing multiple eukaryotic post translational modifications; namely: 
disulfide bond formation, glycosylation, protein folding and proteolytic processing 
(Cereghino and Cregg 2000; Macauley-Patrick et al. 2005). The occurrence of the post 
translational modifications obviates the need for the renaturation of the protein after 
expression (Aloulou et al. 2006). Another key feature of this system, for extracellular 
expression, is that most P. pastoris expression vectors contain a Saccharomyces cerevisiae 
MAT-α-prepro signal peptide sequence, which directs the expressed protein out of the yeast 
cells and into the culture medium. This serves as an initial step for purification (Cereghino 
and Cregg 2000; Cereghino et al. 2002). The methylotrophic P. pastoris yeast expression 
system has become a highly successful expression system for the expression of many 
heterologous proteins such as cathepsin B from L. major (Chan et al. 1999), rhodensain, a 
cysteine peptidase from T. b. rhodesiense (Caffrey et al. 2001), cathepsin B-like cysteine 
peptidase from T. congolense (Mendoza-Palomares et al. 2008) and multiple isoforms of 
cathepsin B-like cysteine peptidases from Trichobilharzia regent (Dvořák et al. 2005). 
The catalytic domain of vivapain (Vp) was successfully expressed as an active mature 
enzyme resulting in a double band corresponding to 29 kDa and 33 kDa on reducing SDS-
PAGE. These bands were also recognised by the polyclonal antibody raised in rabbits 
against bacterial-expressed central domain of congopain (Boulangé et al. 2001). Since the 
bacteria-expressed congopain was not re-natured before antibody production it is expected 
that the serum will recognise mainly linear epitopes. Therefore, it was likely that Vp would 
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be detected by this antibody especially due to the high sequence identity between 
congopain and vivapain (Fig. 1.8, Section 1.8.5). The recombinant Vp sample is observed 
as a double band on a reducing/non-reducing SDS-PAGE gel since the peptidase is 
glycosylated. This was confirmed by endoglycosidase H (Endo H) analysis. In the presence 
of Endo H, the 29 kDa band remained and the 33 kDa band disappeared. Therefore, it can 
be deduced that the 29 kDa band represents the non-glycosylated form, while the 33 kDa 
form is glycosylated. An interesting finding was that the double band was still observed in 
the Vp sample before and after activation at pH 4.2, which suggests that the mature enzyme 
has a glycosylation site. This was verified by using a prediction program; NetNGlyc 1.0 
Server (www.cbs.dtu.dk/services/NetNGlyc), which showed that Vp has a possible 
glycosylation site at Asn288 in the mature region of the protein.  This feature of Vp is unlike 
that of cruzipain and rhodensain where the pro-enzyme of these peptidases are glycosylated 
with glycosylation sites present at Asn113 for cruzipain (Eakin et al. 1993) and at Asn295 in 
rhodensain (Caffrey et al. 2001). Therefore, it can be concluded that the Vp that is present 
in the P. pastoris supernatant does not obtain the pro-enzyme and both the glycosylated and 
unglycosylated mature enzyme is present before and after activation at pH 4.2.  
The catalytic domain of congopain (C2) was also successfully expressed as shown by the 
presence of a 27 and a 33 kDa band on reducing SDS-PAGE. This double band was only 
present in the P. pastoris expression supernatant and upon activation at pH 4.2 the 33 kDa 
band disappeared, which indicates that this was the pro-enzyme form of C2. The mature 
enzyme form of C2 has a Mr of 27000 (Boulangé et al. 2001). This band was detected by 
the polyclonal antibody raised in rabbits against the bacterial-expressed central domain of 
congopain. 
The digestion of gelatin at both 35 and 50 kDa for Vp and at 39 kDa for C2 showed that 
both peptidases have endoproteolytic activity. This further validates the activity of both the 
glycosylated and unglycosylated forms of Vp. The reason why the bands of digestion are at 
a higher Mr than expected is that the gelatin gel is electrophoresed under non-reducing 
conditions. By analogy of C2, that it is known to be a dimer (Boulangé A, University of 
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KwaZulu-Natal, personal communication), the activity displayed by Vp at 35 and 50 kDa 
suggest that Vp is also a dimer.  
The initial purification step used for both Vp and C2 was three phase partitioning (TPP). 
This time saving technique is also cheap and easy to perform. The TPP technique as 
described by Pike and Dennison (1989) for the purification of cathepsin L from sheep liver 
was very successful in purifying and concentrating Vp and C2. In fact this technique was so 
successful for the purification of C2 that no further purification techniques had to be 
performed due to the purity of the sample after TPP. Molecular exclusion chromatography 
(MEC) was used to remove the higher molecular weight contaminating bands present in the 
Vp sample after TPP resulting in a homogenous 29 and 33 kDa preparation of Vp. The 
yield of Vp obtained after TPP and MEC and of C2 after TPP was greater than 100%. A 
similar trend was reported by Dennison and Lovrien (1997) for Bacillus subtilis peptidase, 
Saccharomyces cerevisiae invertase and Candida cylindracea lipase where yields for these 
proteins were 300, 100 and 900% respectively after purification. The unusually high yield 
could be due to the fact that inhibitors in the culture supernatants were being removed 
during the purification steps (Dennison and Lovrien 1997; Sharma and Gupta 2001) This 
could be a possible explanation for the high yield obtained for Vp and C2 after purification.   
The synthetic substrates revealed that Vp preferred the basic residues, Arg and Lys, are 
preferred in P1 only when P2 is occupied by Leu or Phe since Z-Arg-Arg-AMC, Z-Gly-Arg-
Arg-AMC, Z-Ala-Arg-Arg-AMC, Boc-Leu-Arg-Arg-AMC and Z-Arg-AMC are not 
hydrolysed. Neither Vp nor C2 tolerate other hydrophobic residues in P2 as shown by the 
absence of hydrolysis of Z-Gly-Pro-Arg-AMC, Z-Gly-Gly-Arg-AMC and Boc-Leu-Gly-
Arg-AMC. Papain, mammalian cathepsin L, cruzipain from T. cruzi and falcipain from 
Plasmodium falciparum  also prefer a hydrophobic residue in P2 (Brömme et al. 1989; 
Cazzulo et al. 1990; Wijffels et al. 1994; Serveau et al. 1996; Shenai et al. 2000; Salvati et 
al. 2001). The presence of either the smaller hydrophobic Ala or Val in P3 also proved to be 
preferred by Vp and C2 as evident by a 10-fold increase in kcat/Km as compared to the 
presence of other residues in P3. Consequently, the best substrates for Vp and C2 are Z-
Phe-Arg-AMC, H-D-Val-Leu-Lys-AMC and H-D-Ala-Leu-Lys-AMC. Peptides with a 
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hydrophilic Tyr in P1, though a Leu is present in P2, were poor substrates for both Vp and 
C2. Substrates such as H-Ala-Phe-Lys-AMC and Suc-Ala-Phe-Lys-AMC, which contain a 
basic amino acid Lys in P1, hydrophobic Phe in P2 and the hydrophobic Ala in P3 were 
poorly hydrolysed by Vp. This shows that when Lys is in P1 and Ala in P3, the preferred 
amino acid in P2 is Leu instead of Phe. When Leu is in P2 (H-D-Ala-Leu-Lys-AMC) the 
hydrolysis by Vp yields a kcat/Km that is approximately 42-fold higher than when Phe is in 
P2 (H-Ala-Phe-Lys-AMC). Suc-Ala-Phe-Lys-AMC is also poorly hydrolysed by C2. It is 
also interesting to note that C2 is able to hydrolyse H-Pro-Phe-Arg-AMC whereas Vp 
hydrolyses this substrate poorly. Another important feature to note is that both Vp and C2 
have endopeptidase and exopeptidase activity since they are able to hydrolyse Z-Phe-Arg-
AMC, which has a N-terminal blocking group and H-D-Val-Leu-Lys-AMC and                
H-D-Ala-Leu-Lys-AMC, which do not have blocking groups. There was no activity against 
H-Leu-AMC and H-Gly-AMC, which suggests that Vp and C2 has no aminopeptidase 
activity. This was further borne out by the lack of inhibition by the aminopeptidase 
inhibitor, bestatin. H-Leu-AMC is a key synthetic substrate for a leucyl aminopeptidase 
from Leishmania amazonesis, L. donovani and L. major (Morty and Morehead 2002). 
The Km of 6.78 µM obtained for the hydrolysis of Z-Phe-Arg-AMC by C2 is comparable to 
the Km values for native congopain of 1.5 µM (Chagas et al. 1997), 4.4 µM (Mbawa et al. 
1992) and 7.3 µM (Authié et al. 1992). The Km obtained for the hydrolysis of Z-Phe-Arg-
AMC, H-D-Val-Leu-Lys-AMC and H-D-Ala-Leu-Lys-AMC by Vp are 9.61 µM, 14.23 µM 
and 14.97 µM, respectively. The Km obtained for the hydrolysis of Z-Phe-Arg-AMC,                                  
H-D-Val-Leu-Lys-AMC and H-D-Ala-Leu-Lys-AMC by native trypanopain from T. b. 
brucei was 1.2 µM, 25 µM and 27 µM, respectively (Troeberg et al. 1996), which are 
comparable to the values obtained for Vp. The Km obtained for the hydrolysis of  Z-Phe-
Arg-AMC by  native and recombinant falcipain-2 from P. falciparum were 17.3 µM and 
9.13 µM, respectively (Shenai et al. 2000), 1.8 µM  and 0.96 µM  for native and 
recombinant cruzipain from T. cruzi (Cazzulo et al. 1990; Serveau et al. 1996), 2.8 µM for 
mammalian cathepsin L (Brömme et al. 1989), 46 µM for cathepsin L-like cysteine 
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peptidase from Fasciola hepatica (Wijffels et al. 1994), and 14 µM for a cysteine peptidase 
from L. infantum (Salvati et al. 2001). 
Both Vp and C2 were inhibited by the peptide aldehydes leupeptin, antipain and 
chymostatin. The action of these inhibitors on the enzyme involves the interaction of the 
aldehyde group from the inhibitor with the thiolate group of the enzyme. This interaction 
forms a tetrahedral hemithioacetate (Otto and Schirmeister 1997). Since both Z-Phe-Arg-
AMC and H-D-Val-Leu-Lys-AMC were good substrates for Vp, it was decided to test all 
the inhibitors in the presence of either substrate. Leupeptin seems to be the better inhibitor 
for Vp and C2 in the presence of Z-Phe-Arg-AMC and H-D-Val-Leu-Lys-AMC. This is 
evident from the low Ki values for leupeptin as compared to those obtained for chymostatin 
and antipain. This result is expected since the aldehyde group of leupeptin (N-acetyl-leucyl-
leucyl-arginal is present on the Arg residue in position P1 (the arginal group is essential for 
inhibition) (Umezawa 1976) and it was deduced from the synthetic substrate assays that Vp 
prefers an Arg residue in P1. A comparable Ki value of 1.12 x 10
-3 µM was obtained for the 
inhibition of papain with leupeptin (Schultz et al. 1989). Chymostatin seems to be a better 
inhibitor for Vp hydrolysis of Z-Phe-Arg-AMC than antipain, whereas there was no 
significant difference for C2. There were no comparable differences in the Ki values for the 
inhibition of Vp hydrolysis of H-D-Val-Leu-Lys-AMC, but chymostatin seems to be the 
better inhibitor for the hydrolysis of this substrate by C2. In most cases, chymostatin seems 
to be the better inhibitor which is not expected since, like leupeptin, antipain also has an 
aldehyde group on the Arg residue in position P1 (Umezawa 1976) and the aldehyde group 
of chymostatin is present on the Phe residue in position P1 (Burleigh et al. 1997). The 
metallo-peptidase inhibitor, EDTA, and the aspartic peptidase inhibitor, pepstatin A, did 
not inhibit Vp or C2. Studies have shown that both native and recombinant cysteine 
peptidases are also inhibited by these inhibitors; leupeptin, antipain and chymostatin. 
Native trypanopain from T. b. brucei (Troeberg et al. 1996), native cruzipain from T. cruzi 
(Cazzulo et al. 1990) are inhibited by leupeptin, antipain and chymostatin. Native 
congopain from T. congolense (Mbawa et al. 1992), native and recombinant falcipain-2 
from P. falciparum (Shenai et al. 2000) and recombinant cruzipain from T. cruzi (Eakin et 
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al. 1992) were shown to be inhibited by leupeptin. A cathepsin L-like cysteine peptidase 
from Fasciola hepatica (Wijffels et al. 1994) was inhibited by leupeptin and antipain.  
Both Vp and C2 were inactivated by the cysteine peptidase specific irreversible inhibitors; 
iodoacetic acid (IAA), iodoacetamide (IAN) and E-64. E-64 also inhibits the cysteine 
peptidases cathepsins B, H and L and papain (Barrett et al. 1982) and it is the trans-L-(S,S)-
epoxysuccinic acid reactive group present in E-64 that is responsible for the inhibition          
(Otto and Schirmeister 1997). In this study, E-64 was used as the active-site titrant, which 
gave an indication of the amount of active enzyme present in both the Vp and C2 
preparations. For both Vp and C2, 20% of the total peptidase concentration was 
enzymatically active. E-64 was also shown to inhibit native congopain from T. congolense                                                            
(Authié et al. 1992; Mbawa et al. 1992; Chagas et al. 1997), native and recombinant 
falcipain-2 (Shenai et al. 2000), native and recombinant cruzipain (Cazzulo et al. 1990; 
Eakin et al. 1992) and a cathepsin L-like cysteine peptidase from F. hepatica (Wijffels et 
al. 1994).  
 
Both IAA and IAN are sulfhydryl alkylating reagents. These inhibitors bind covalently to 
the active site Cys sulfhydryl group (Dickens 1933).The inhibition kinetic values obtained 
for IAA and IAN inhibition of the hydrolysis of either Z-Phe-Arg-AMC or D-Val-Leu-Lys-
AMC by Vp and C2 were very similar. When comparing the action of IAA on Vp in the 
presence of either Z-Phe-Arg-AMC or D-Val-Leu-Lys-AMC, better inhibition seems to be 
in the presence of D-Val-Leu-Lys-AMC since a higher kass value was obtained and the t1/2 
value for this reaction is almost two times less than that of the reaction in the presence of  
Z-Phe-Arg-AMC. This means that it takes a shorter time for the free enzyme concentration 
to decrease by 50% in the presence of D-Val-Leu-Lys-AMC. A similar trend is evident for 
the reaction of IAN on Vp in the presence of either Z-Phe-Arg-AMC or D-Val-Leu-Lys-
AMC, where the kass value in the presence of D-Val-Leu-Lys-AMC is higher and the t1/2 
value is almost two times less. For the action of IAA on C2 in the presence of either Z-Phe-
Arg-AMC or D-Val-Leu-Lys-AMC very similar kass values are obtained; however, the t1/2 
value is almost one and half times less than in the presence of Z-Phe-Arg-AMC. The kass 
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values for the reaction of IAN on C2 in the presence of D-Val-Leu-Lys-AMC is higher than 
in the presence of Z-Phe-Arg-AMC and the t1/2 value obtained in the presence of D-Val-
Leu-Lys-AMC is almost two times less. Literature has shown that papain is also inhibited 
by IAA (Light et al. 1964; Husain and Lowe 1968) and IAN (Blumberg and Ogston 1957). 
IAA was also shown to inhibit the cathepsin L-like cysteine peptidase from F. hepatica 
(Wijffels et al. 1994). The low molecular weight irreversible serine peptidase inhibitors 
PMSF, TLCK and TPCK did not inhibit Vp or C2.  
 
The pH optimum obtained for C2 of 6.5, is comparable to the value of pH 6 obtained from 
earlier studies for native congopain (Mbawa et al. 1992). The pH optimum obtained for Vp 
was 7 and almost no activity remained at pH 4, which is not expected since it is a lysosomal 
peptidase. The pH optimum obtained for native trypanopain from T. b. brucei was  pH 5.7 
(Troeberg et al. 1996), and similar near basic pH optima were reported for native and 
recombinant falcipain-2 (pH 6 and pH 5, respectively) (Shenai et al. 2000), native cruzipain 
(pH 6) (Serveau et al. 1996),  a cathepsin L-like cysteine peptidase from F. hepatica       
(pH 7.5) (Wijffels et al. 1994), mammalian cathepsin L (pH 6) (Brömme et al. 1989) and 
for papain (pH 7.0) (Wijffels et al. 1994). Therefore, these cysteine peptidases could 
possibly be contributing to the pathology of the diseases due to their pH optima being so 
close to physiological pH. 
 
In this study, Vp was successfully expressed in the P. pastoris yeast expression system and 
purified using TPP and MEC. Substrate assays revealed that Vp preferred the hydrophobic 
amino acid residues Phe and Leu in P2 and a smaller hydrophobic residue in P3. Only when 
P2 is occupied by Phe or Leu, a basic residue is preferred in P1. Vp was also reversibly 
inhibited by leupeptin, chymostatin and antipain and irreversibly inhibited by IAA and IAN 
in the presence of Z-Phe-Arg-AMC or D-Val-Leu-Lys-AMC. Vp showed an optimum for 
catalytic activity at pH 7.0. The information required for the synthesis of synthetic peptide 
inhibitors lies in understanding which amino acid residues are preferred in P1, P2 etc. 
Therefore, future work would be based on using the information obtained from this study to 
construct synthetic peptide inhibitors with chemical groups, such as vinyl sulfones and the 
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peptidyl ketones attached and testing the effects of these irreversible                                        
inhibitors on Vp and T.vivax grown in culture.
73 
 
Appendix 1: Michaelis-Menten curves for Vp  
The plots generated by the Hyper® 32 software program appears to give an incorrect Vmax, however the Vmax value was verified 
by the GraphPad Prism® softeware program aswell. The Hyper® 32 software program does not allow for the addition of units to 
the axes. The units of v is µM.s-1 and of [S] is µM 
 
  
Z-Phe-Arg-AMC H-D-Val-Leu-Lys-AMC  









Appendix 2: Michaelis-Menten curves for C2 
The plots generated by the Hyper® 32 software program appears to give an incorrect Vmax, however the Vmax value was verified 
by the GraphPad Prism® softeware program aswell. The Hyper® 32 software program does not allow for the addition of units to 
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ABSTRACT 
The use of many diagnostic tests based on clinical, parasitological, molecular and 
serological techniques has made it possible to diagnose trypanosomosis, which allows for 
the proper treatment of the disease. One of the key diagnostic tests is the serological 
enzyme-linked immunosorbent assay (ELISA). This test can be based on antibody detection 
or on antigen detection. In both cases, the use of a recombinant antigen is required for the 
tests. There is no antigen available to detect T. vivax infections like there are for T. 
congolense and T. brucei infections. In this study, a mutant full length inactive form of 
vivapain (∆FLVp) was recombinantly expressed for potential use as an antigen for 
diagnostic tests. This antigen contains the   Ala25, His159 and Asn175 (papain numbering) in 
the active site instead of the conventional Cys25, His159 and Asn175 (papain numbering) 
rendering it inactive. The ∆FLVp was cloned into pTZ57R/T vector and sub-cloned into the 
pPic9 yeast and pET-32a yeast expression vectors. The ∆FLVp was only able to be 
expressed in a bacterial system as a 70 kDa protein. Attempts were made to renature the 
protein. Antibodies against this antigen were produced in both chickens and mice. These 
antibodies were able to detect the recombinant ∆FLVp in western blots. The mice serum 
was able to detect native vivapain in a T. vivax lysate in a western blot. This finding 
suggests that this antigen could possibly be useful in field diagnosis of T. vivax infections 
especially in its use in ELISAs.  
3.1 INTRODUCTION 
Trypanosoma vivax is the major causative agent of trypanosomosis in African livestock 
(Lalmanach et al. 2002). Control and therapeutic methods for this disease are required due 
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to the negative impact it has on the economy of sub-Saharan Africa (Antoine-Moussiaux et 
al. 2009). The diagnosis of trypanosomosis is one of the areas that can provide sufficient 
and accurate information of the disease to allow for appropriate therapeutic measures to be 
taken (Mattioli et al. 2001; Eisler et al. 2004). A range of diagnostic tests that are being 
used, include, clinical, parasitological, molecular and serological tests. Diagnostic 
techniques used should be appropriate for use in the field and for the level of technology 
available in developing countries (Luckins 1992; Eisler et al. 2004).   
The clinical diagnostic technique is dependent on the physical examination of cattle. The 
major problem with this technique is that the clinical signs are not specific for 
trypanosomosis (Nantulya 1990). The method involved in parasitological techniques are 
viewing of wet blood films and Giemsa-stained thick and thin fixed blood films with a light 
microscope. This technique varies in sensitivity due to the trypanosome species’ similarities 
in morphology (Magona et al. 2003). For this reason, a haematocrit centrifuge can be used 
to increase the sensitivity by separating the buffy coat containing the trypanosomes from 
the red blood cells and plasma. The disadvantage of using this technique especially in the 
field is that fresh blood, a haematocrit centrifuge and microscopes are needed (Luckins 
1992; Eisler et al. 2004). Polymerase chain reaction (PCR) is the molecular biology method 
used for the diagnosis of bovine trypanosomosis. PCR has shown to be a very sensitive 
method and it has the ability of species-specific detection of the trypanosomes (Solano et 
al. 1999; Desquesnes and Davila 2002). The problem of using this technique in the field is 
that it is very expensive since it involves the use of specialised equipment by an 
experienced technician.  
The most promising techniques, especially for diagnosing T. vivax infections, are the 
serological techniques; more importantly, the enzyme-linked immunosorbent assay 
(ELISA) (Osório et al. 2008). The advantage of the ELISA technique is that it can be 
adapted to field use, requiring only a simple ELISA plate reader. This technique also allows 
for the processing of a large number of samples due to automation of the equipment. 
ELISA is also a very sensitive technique (Hopkins et al. 1998). 
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There are two types of ELISAs that can be used for the diagnosis; namely, the antibody-
detection ELISA (Hopkins et al. 1998; Rebeski et al. 1999) and the antigen-detection 
ELISA (Nantulya and Lindqvist 1989). The absence of recombinant trypanosome antigens 
for the detection and production of anti-trypanosome antibodies is a major problem for both 
the antibody-detection ELISA and the antigen-detection ELISA. Thus far, ELISAs for both 
antibody and antigen detection have relied on crude preparation of whole parasite lysate 
and native antigens acquired from trypanosome culture; therefore, it is difficult to optimise 
and standardise the tests and a large volume of cultured trypanosomes is required (Greiner 
et al. 1997; Eisler et al. 2004; Tran et al. 2009). Due to this problem work increased on the 
identification and recombinant expression of antigens that showed promise for the detection 
of T. brucei (Tran et al. 2008), T. congolense (Davita 2009, MSc) and T. evansi               
(Verloo et al. 2001; Lejon et al. 2005; Tran et al. 2009) infections in the sera of infected 
animal species. There is no suitable antigen for the specific diagnosis of T. vivax infections 
(European Commission 6th Framework Research grant, Trypadvac2). For this reason, this 
study focused on producing a recombinant antigen that could potentially be used to detect 
T. vivax infections. This particular antigen was based on the T. vivax cysteine peptidase, 
vivapain. Due to high cross-reactivity observed between the trypanosome species in ELISA 
it is important to test infected sera using species-specific antigens; therefore, the production 
of this recombinant antigen specific to detecting T. vivax infections could potentially be 
used in conjunction with the existing recombinant antigens, such as the full length inactive 
mutant of congopain, to increase the sensitivity of the ELISA tests. Thus far the full length 
inactive mutant of congopain showed promise as a species-specific antigen for T. 
congolense detection (Dr Phillippe Büscher, Department of parasitology, Institute of 
Tropical Medicine, Antwerp, Belgium). 
In the present study, the full length inactive mutant form of vivapain, ∆FLVp, was cloned 
into pTZ57R/T vector and sub-cloned into bacterial (pET-32a) and yeast (pPic9) expression 
vectors. This was followed by recombinant expression of ∆FLVp in both bacterial and 
yeast systems. Antibodies were produced against the bacterial expressed recombinant 
∆FLVp, in both chickens and mice. The antibodies were tested in western blots to 
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determine if they would be able to detect the recombinant ∆FLVp used to produce the 
antibodies as well as native vivapain in T. vivax blood stream form lysates.   
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
Molecular Biology: EcoRI, NotI, SalI, SacI [reference for nomenclature see,               
(Roberts et al. 2003)] shrimp alkaline phosphatase (SAP), T4 DNA ligase, 10 mM dNTPs 
mix, X-gal, IPTG, pTZ57R/T vector, DNA high and middle range molecular marker mix, 
Fermentas Spectra™ multicolour Broad range protein ladder, GeneJetTM Plasmid 
Miniprep Kit and TranformAidTM Bacterial Transformation Kit were obtained from 
Fermentas (Vilnius, Lithuania). BsgI  and competent Escherichia coli JM 109 cells were 
obtained from New England Biolabs (Ipawitch, MA, USA). Taq polymerase, 10 x PCR 
reaction buffer and MgCl2 were from Solis Biodyne (Tartu, Estonia). The DNA clean and 
concentrator kit was purchased from ZymoResearch (Orange, CA, USA). The E.Z.N.A® 
gel extraction kit was purchased from PreQLab (Erlangen, Germany). The Pichia pastoris 
yeast strain (GS 115) and the pPic9 vector were obtained from were purchased from 
Invitrogen (Carlsband, CA, USA). pET-32a expression vector and the BL21 (DE3) 
electrocompetent cells were purchased from Novagen (Madison, WI, USA). 
P. pastoris expression: E. coli glycerol stock of the inactive mutant catalytic domain of 
vivapain fragment (∆CAVp) in pPic9 was obtained from Professor Theo Baltz (University 
of Victor-Segalen, Bordeaux, France). E. coli mutated C2 clone (H43W) in pPIC9 was 
obtained from Hlumani Ndlovu 2009, MSc (University of KwaZulu-Natal). 
Purification: His-select nickel affinity resin were obtained from Sigma (Munich, 
Germany). DEAE resin was purchased from Whatman International (England). 
Antibodies: IgY anti-congopain-N-terminus peptide antibody (affinity purified, 50 µg/mL) 
was raised against the 22 N-terminal residues of congopain (Mkhize, 2003). Horse anti-
mouse IgG Horse radish peroxidase (HRPO) conjugate was obtained from Southern Cross 
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Biotechnology, Vector Labs. Rabbit anti-IgY coupled to HRPO, Freund’s complete and 
incomplete adjuvants were obtained from Sigma (Munich, Germany). Nunc-ImmunoTM 
96-well plates were from Nunc Intermed (Denmark). 
3.2.2 Isolation of Trypanosoma vivax from infected mouse blood  
Two mice were infected with T. vivax Y486 stabilate (40 µl per mouse). The mice were 
bled on the third day post infection when parasitaemia peaked. Approval for procedures 
involving animals was obtained from the University of KwaZulu-Natal animal ethics 
committee, reference number 036/09/Animal. Half of the blood was used to make new 
stabilate and the other half was used to obtain the T. vivax parasites by purification 
according to Lanham and Godfrey (1970). Briefly, 5 g DEAE-50 resin was suspended in  
20 mL phosphate buffered saline (PBS) [100 mM Na2HPO4, 2 mM KH2PO4, 2.7 mM KCl 
and 137 mM NaCl, pH 8]. The resin was allowed to settle for approximately 30 min and the 
PBS removed. This step was performed three times to equilibrate the resin. The resin slurry 
was poured into the column (30 x 120 mm) (usually for 1 mL of mouse blood, 4 mL of 
packed resin is required) and the resin was washed with one column volume of PBS. 
Thereafter, the resin was equilibrated with one column volume of phosphate saline glucose 
(PSG) [57 mM Na2HPO4, 3 mM NaH2PO4, 42 mM NaCl, 50 mM glucose and 1 mM 
hypoxanthine]. The heparinised blood was added to the column. The column tap was 
opened, which allowed for the blood to settle, which took approximately 10 min. After a 
further 10 min, a drop of eluate was placed on a slide and analysed under a microscope. 
Once parasites were present in the eluate, collection of the T. vivax parasites occurred for 
approximately three column volumes or until no parasites were present when the elution 
drops were viewed under the microscope. Care had to be taken to ensure that the column 
did not run dry. This was done by continually adding PSG to the column (approximately 10 
mL at a time). The parasites were collected from the eluates by centrifugation                
(3000 g, 10 min, RT). The pellets were resuspended in 70% (v/v) PSG and 30% (v/v) 
glycerol and stored at -80oC until further use.  
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3.2.3 Extraction of T. vivax genomic DNA 
The extraction of T. vivax genomic DNA was performed according to the protocol from          
Medina-Acosta and Cross (1993). The parasites isolated as described in Section 3.2.2, were 
resuspended in PBS (1 mL) and centrifuged (1000 g, 10 min, RT). The supernatant was 
removed and the pellet was dissolved in 150 µl TELT [50 mM Tris-HCl buffer, pH 8,    
62.5 mM EDTA, pH 9, 2.5 M LiCl, 4% (v/v) TritonX-100]. This solution was incubated at 
RT for 5 min. Thereafter, 150 µl of phenol-chloroform [1:1 (v/v)] was added. The mixture 
was placed on a rocker for 5 min at RT. The two phases were separated by centrifugation 
(13000 g, 5 min, RT). The top phase was retained and to this 300 µl of absolute ethanol was 
added. This solution was centrifuged (13000 g, 5 min, RT) and the supernatant was poured 
out and 1 mL of absolute ethanol was added, followed by centrifugation (13000 g, 5 min, 
RT). Once again, the supernatant was removed and the pellet was incubated at 37oC for 10-
15 min. Thereafter, 100 µl TE buffer [100 mM Tris-HCl buffer, pH 7.5, 10 mM EDTA] 
was added as well as RNAse to a final of 2 mg/mL and incubated at 37oC for 45 min. The 
genomic DNA was stored at -20oC until further use. The extraction of the DNA was 
analysed by electrophoresis on a 1% (w/v) agarose gel in 1 x Tris-acetate-EDTA (TAE) 
buffer [40 mM Tris-HCl buffer pH 7.4, 20 mM  glacial acetic acid and 0.1 mM EDTA] at 
80 V for 30-40 minutes.  
3.2.4 Amplification of the FLVp gene from T. vivax genomic DNA  
The T. vivax genomic DNA (1 in 10 dilution) was used as the template for the amplification 
of the FLVp gene using specific full length vivapain primers (Table 3.1). The primers were 
designed to introduce EcoRI/NotI cloning sites at each extremity of the amplicon. 
EcoRI/NotI nomenclature according to Roberts et al (2003). The master mix for the PCR 
reaction contained FLVp Fw and Rv primers [0.25 µM for each], 1x PCR buffer, 2.5 mM 
MgCl2, 0.25 U Taq and 0.5 mM dNTPs in a total reaction volume of 25 µl. The 
amplification method used is known as touch-down-PCR, which was carried out by 
denaturing the genomic DNA at 95oC for 5 min, followed by 25 cycles of denaturing the 
DNA at 95oC for 1 min, primers annealed at 55oC for 1 min, decreasing by 1oC after every 
cycle until the temperature reached 45oC, elongation at 72oC for 2 min and finally an 
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elongation at 72oC for 7 min. The PCR product was analysed by electrophoresis on a 1% 
(w/v) agarose gel in 1 x TAE buffer at 80 V for 30-40 minutes. 
Table 3.1 Primers used for the amplification, cloning and screening of the FLVp and 
∆FLVp genes. The full length primers were used to amplify the FLVp gene from T. vivax 
genomic DNA. The C-term primers were used to confirm the presence of the FLVp gene in 
the pTZ57R/T vector (T vector). The restriction sites for EcoRI and NotI are highlighted in 
bold. 
Primer Sequence Tm 
(oC) 
Full length (FL) Vp Fw 5’-AAA GAA TTC TAC ATG GCG GTG CTG CGC GCG         
     GAG-3’ 
67 
Full length (FL) Vp Rv 5’-AAA GCG GCC GCC CTA CCC TCG ATG TTG TGC    




extension Fw  
5’-AAA GAA TTC TAC ATG ACA ACA ACA ACA ACA     
     ACA AC-3’ 
59 
       
 
3.2.5 Cloning of the full length vivapain (FLVp) gene into the pTZ57R/T vector  
The PCR product (1.3 kb) from the amplification of the FLVp gene was cut out of the 
agarose gel and purified using the E.Z.N.A gel extraction kit (PreQLab). The DNA was 
eluted in elution buffer (30 µl). The purified DNA was ligated into the pTZ57R/T vector (T 
vector) (Fig 3.1) in a 3:0.25 ratio in the presence of 10 x ligation buffer and T4 DNA ligase 
overnight at 4oC. The ligation mix (2.5 µl) was transformed into competent E. coli JM 109 
cells using the TransformAid™ bacteria transformation kit. The transformed cells (50 µl) 
were plated onto pre-warmed 2x YT  plates [1.6% (w/v) tryptone, 1% (w/v) yeast extract, 
0.5% (w/v) NaCl, 15g/l bacteriological agar] containing ampicillin (100 µg/mL) and 
incubated at 37oC overnight. Prior to plating of the cells, X-gal (20 µg/mL) and             
IPTG (10 µg/mL) were spread on the 2x YT plate and incubated at 37oC for 30 min. This 




Figure 3.1 Map of the pTZ57R/T vector (Fermentas). This vector has a multiple cloning site, f1 origin of 
replication [f1(IG)], ampicillin resistance gene [bla (ApR)] used for the selection of recombinants and a lacZ 
gene which allows for blue and white colony screening.  
Transformation revealed the presence of many more white colonies than blue colonies. The 
white colonies were screened by colony PCR using C-term Fw and FLVp Rv primers 
(Table 3.1). The colony PCR amplification method was carried out by denaturing the 
genomic DNA at 95oC for 5 min, followed by 25 cycles of denaturing the DNA at 95oC for 
1 min, primer annealing at 55oC for 1 min, elongation at 72oC for 2 min and finally an 
elongation at 72oC for 7 min. The amplification products were analysed by electrophoresis 
on a 1% (w/v) agarose gel in 1 x TAE buffer at 80 V for 30-40 minutes. The positive clones 
were grown in 2x YT liquid media (5 mL) [1.6% (w/v) tryptone, 1% (w/v) yeast extract, 
0.5% (w/v) NaCl] containing ampicillin (100 µg/mL) overnight at 37oC, with shaking. The 
plasmid DNA was isolated from the overnight cultures, using the GeneJet™ plasmid 
miniprep kit. DNA was eluted in elution buffer (50 µl). The plasmid DNA (20 µl) was sent 
for sequencing to the Segoli Ilri laboratory unit, International livestock research unit, 
Nairobi, Kenya.  
3.2.6 Subcloning of the full length inactive mutant vivapain (∆FLVp) gene into the 
pTZ57R/T vector  
The FLVp gene was cloned into the T vector to determine whether a natural mutation 
would occur in the catalytic domain of the gene, for the production of a full length inactive 
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mutant. This mutant is required for diagnostic tests for T. vivax. Sequencing of the FLVp 
gene cloned into the T vector revealed that only one out of the six clones matched up to the 
vivapain reference sequence on the database (Appendix 1). This clone contained the 
catalytic triad Cys25, His159 and Asn175 (papain numbering) in the active site; thus, 
representing the full length active form of vivapain. Therefore, a different approach was 
taken to obtain the ∆FLVp fragment. In order to obtain the ∆FLVp fragment the full length 
active vivapain fragment (FLVp) cloned into the T vector and an inactive mutant catalytic 
domain of vivapain fragment (∆CAVp) that was in pPic9 [obtained from Professor Theo 
Baltz (University of Victor-Segalen, Bordeaux, France) were used. The ∆CAVp fragment 
had an alanine substituted for cysteine in the catalytic triad. Therefore, the amino acids in 
the active site of ∆CAVp are Ala25, His159 and Asn175. Upon inspection of the gene 
sequence around that coding for the catalytic residues, Cys25, His159 and Asn175 (called 
CHN), in the FLVp clone and the Ala25, His159 and Asn175 (called AHN) in the ∆CAVp 
showed that these domains were flanked by two BsgI restriction sites. The double cutter 
restriction enzyme, BsgI (New England Biolabs), was used to excise the “CHN” coding 
fragment from the FLVp gene and the “AHN” coding fragment from the ∆CAVp inactive 
mutant catalytic domain of vivapain in the pPic9 vector. This “AHN” coding fragment was 
ligated with the cut FLVp gene (now without the CHN coding fragment), which rendered 
































Figure 3.2 Schematic representation of the action of BsgI restriction enzyme on the FLVp gene in T 
vector and the ∆CAVp in pPic9. The restriction site for the BsgI restriction enzyme is      




The plasmid DNA for the ∆CAVp in the pPic9 vector was obtained by streaking a glycerol 
stock of E. coli containing the pPic9-∆CAVp on a 2x YT plate containing ampicillin     
(100 µg/mL). The plate was incubated overnight at 37oC. A single colony was grown in   
2x YT liquid media, overnight at 37oC, with shaking. The plasmid DNA was isolated from 
the overnight cultures using the GeneJet™ plasmid miniprep kit. DNA was eluted in 50 µl 
elution buffer. The plasmid DNA for the ∆FLVp in the T vector was obtained from the 
remaining sample isolated for sequencing (Section 3.2.5). Both the plasmid DNA for FLVp 
in the T vector and pPic9-∆CAVp were restricted with BsgI (50 U). The resulting 
restriction revealed that the “CHN” coding fragment from FLVp and the “ANH” coding 
fragment for ∆CAVp were cut out (Fig. 3.2). Thereafter, the T vector without the “CHN” 
coding fragment was ligated to the “AHN” fragment in a 0.25:3 ratio in the presence of    
10 x ligation buffer and T4 DNA ligase overnight at 4oC. This ligation resulted in the 
∆FLVp in the T vector. The ligation mix (2.5 µl) was transformed into competent E. coli 
JM 109 cells using the TransformAid™ bacteria transformation kit. The transformed cells 
were plated on pre-warmed 2x YT plates containing ampicillin (100 µg/mL), X-gal         
(20 µg/mL) and IPTG (10 µg/mL). The plate was incubated overnight at 37oC. Colonies 
were screened for recombinants by colony PCR with the C-term Fw and FLVp Rv primers 
(Table 3.1). The colony PCR amplification method was carried out by denaturing the 
genomic DNA at 95oC for 5 min, followed by 25 cycles of denaturing the DNA at 95oC for 
1 min, primer annealing at 55oC for 1 min, elongation at 72oC for 2 min and finally an 
elongation at 72oC for 7 min. The results from the amplification were analysed by 
electrophoresis on a 1% (w/v) agarose gel in 1 x TAE at 80 V for 30-40 minutes. Positive 
clones were grown in 2x YT liquid media (5 mL) containing ampicillin (100 µg/mL) 
overnight at 37oC, with shaking. The plasmid DNA was isolated from the overnight 
cultures, using the GeneJet™ plasmid miniprep kit. DNA was eluted in elution buffer (50 
µl). In order to verify the presence of the “AHN” fragment and the entire ∆FLVp gene in 
the T vector, duplicates of the plasmid DNA from a positive clone was restricted with either 
BsgI or with EcoRI and NotI. Thereafter, both clones were sequenced Segoli Ilri laboratory 
unit, International livestock research unit, Nairobi, Kenya.  
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3.2.7 Subcloning of the ∆FLVp construct into bacterial (pET-32a) and yeast (pPic9) 
expression vectors 
The ∆FLVp clone containing the “AHN” fragment was cloned into expression vectors. The 
pET-32a and pPic9 expression vectors were prepared for transformation in the same 
manner. Briefly, the vector glycerol stock was streaked on a 2x YT plate containing 
ampicillin (100 µg/mL). The plate was incubated overnight at 37oC. A single colony was 
grown in 2x YT liquid media, overnight at 37oC, with shaking. The GeneJet™ plasmid 
miniprep kit was used to isolate the plasmid DNA. DNA was eluted in elution buffer (50 
µl). The plasmid DNA was restricted with EcoRI and NotI, which generated a linear 
plasmid and treated with SAP (1 U) to dephosphorylate the exposed ends of the plasmid. 
The plasmid DNA was concentrated using the ZymoResearch® DNA clean and 
concentrator kit and eluted in 30 µl of elution buffer. The ∆FLVp-T vector plasmid DNA 
was restricted with EcoRI and NotI in order to remove the ∆FLVp insert. This restriction 
was analysed by electrophoresis on a 1% (w/v) agarose gel in 1 x TAE buffer at 80 V for 
30-40 minutes. The ∆FLVp insert was cut out of the gel and purified using the E.Z.N.A gel 
extraction kit (PreQLab). The purified DNA was eluted in 30 µl of elution buffer. Both the 
purified pET-32a vector (EcoRI/NotI) (1 µl) and the ∆FLVp insert (EcoRI/NotI) (1 µl) 
were analysed on 1% (w/v) agarose gel in 1 x TAE buffer at 80 V for 30-40 minutes. This 
was done to determine the relative quantities of vector and insert. This was also performed 
with the purified pPic9 vector (EcoRI/NotI) (1 µl) and the ∆FLVp insert (EcoRI/NotI). The 
ligation of the ∆FLVp into pET-32a (Fig. 3.3 A) and pPic9 (Fig. 3.3 B) were performed in 
a 3:1 ratio into 10 x ligation buffer and T4 DNA ligase overnight at 4oC. The                
pET-32a-∆FLVp and pPic9-∆FLVp ligation mixes (2.5 µl) were transformed into 
competent E. coli JM 109 cells. This was performed using the TransformAid™ bacteria 
transformation kit. The transformed cells (50 µl) were plated onto pre-warmed 2x YT 
plates containing ampicillin (100 µg/mL) and incubated at 37oC overnight. The colonies for 
the pET-32a-∆FLVp transformation were screened using the C-term Fw and pET Rv 
primers and the pET Fw and Rv primers for the control (Table 3.2). The template for the 
control was the pET-32a-∆FLVp plasmid DNA. The colonies for the pPic9-∆FLVp were 
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screened using the C-term Fw and FLVp Rv primers (Table 3.2). The amplification 
conditions for both colony PCR reactions are represented in Table 3.3.  
 
 
Figure 3.3 Expression vector maps of A) pET-32a (5.9kb) (Novagen) and B) pPic 9 (8kb) (Invitrogen). 
A) The vector contains a multiple cloning site, f1 origin of replication, ampicillin resistance gene (Ap), lacI 
coding sequence (lacI) and a T7 promoter and transcription start. B) The vector contains the following 
features which assist in the expression process: ColE1 origin of replication (pBR322), 3’ AOX fragment (3’ 
AOX), a HIS4 gene, which is used for selection by complementation in the his4 yeast strain, c-myc epitope 
(TT), multiple cloning sites, α-factor secretion signal (S), 5’ AOX fragment (5’ AOX) and an ampicillin 





Positive colonies from each transformation, ∆FLVp into pET-32a and ∆FLVp into pPic9, 
were grown in 2x YT liquid media, overnight at 37oC, with shaking. The plasmid DNA of    
pET-32a-∆FLVp and pPic9-∆FLVp were obtained using the GeneJet™ plasmid miniprep 
kit. The DNA was eluted in 30 µl of elution buffer. Both the plasmid DNA for              
pET-32a-∆FLVp (10 µl) and pPic9-∆FLVp (10 µl) were restricted with EcoRI/NotI to 
verify the presence of the ∆FLVp insert. The result of this restriction was analysed on a 1% 
(w/v) agarose gel in 1 x TAE buffer at 80 V for 30-40 minutes. 
 
Table 3.2 Primers used for the amplification, cloning and screening of the ∆FLVp 
gene. The C-term primers were used to confirm the presence of the ∆FLVp gene in pPic9 
after transformation into the E. coli JM 109 cells. The C-term Fw and pET Rv primers were 
used to confirm the presence of the ∆FLVp gene in pET-32a after transformation into the E. 
coli JM 109 cells. The C-term Fw and AOX Rv primers were used to confirm the presence 
of the ∆FLVp gene in pPic9 after the transformation into the Pichia pastoris GS115 yeast 
cells. The AOX Fw and AOX Rv primers were used to confirm the presence of the C2 
(H43W) gene in pPic9 after transformation into P. pastoris GS115 yeast cells.  
Primer Sequence Tm 
(oC) 
Full length (FL) Vp Rv 5’-AAA GCG GCC GCC CTA CCC TCG ATG TTG TGC     
     ATC  GCA GGG CGG CG-3’  
78 
C-terminal (C-term) 
extension Fw  
5’-AAA GAA TTC TAC ATG ACA ACA ACA ACA ACA     
     ACA AC-3’ 
59 
pET Fw 5’-TAATACGACTCACTATAGGG-3’ 54 
pET Rv 5’-GCTAGTTATTGCTCAGCGG-3’ 57 
AOX Fw 5’-ACTGGTTCCAATTGACAAGC-3’ 50 






Table 3.3 Colony PCR conditions for the screening of pET-32a and pPic9 colonies. 
The master mix for the PCR reaction contained Fw and Rv primers [0.25 µM for each],    
1x PCR buffer, 2.5 mM MgCl2, 0.25 U Taq and dNTPs [0.5 mM]. PCR reactions were 






pET Fw/    
pET Rv 
C-term Fw/ 





Denaturation  95oC ; 1 min 95oC ; 1 min 95oC ; 1 min 95oC ; 1 min 95oC ; 1 min 
Renaturation  55oC ; 1 min 55oC ; 1 min 55oC ; 1 min 55oC ; 1 min 55oC ; 1 min 
Elongation 72oC ; 2 min  72oC ; 2 min  72oC ; 2 min  72oC ; 2 min  72oC ; 2 min  
Reaction 
Volume (µl) 25 25 25 100 100 
 
3.2.8 Expression of ∆FLVp in bacteria 
The pET-32a-∆FLVp plasmid DNA (1 µl) was combined with E. coli BL21 (DE3) 
electrocompetent cells. This mix was added to a gap vial and electroporated at                   
2.5 kV, 25 µF, 200 Ω (BioRad, Hercules, CA, USA). The cells were diluted in 2x YT liquid 
media, without ampicillin (100 µg/mL) and grown at 37oC for one hour, with shaking. The 
cells were pelleted by centrifugation (13000 g, 30-60 s). The supernatant was removed 
(approximately 800 µl) and the cells resuspended in the remainder of the supernatant and 
plated on pre-warmed 2x YT plates containing ampicillin (100 µg/mL) and incubated 
overnight at 37oC. 
A single colony from the transformation of pET-32a-∆FLVp in E. coli BL21 (DE3) cells 
was inoculated into terrific broth liquid media (800 µl) [1.2% (w/v) tryptone, 2.4 % (w/v) 
yeast extract, 0.4% (v/v) glycerol, 0.17 M KH2PO4, 0.72 M K2HPO4] containing ampicillin 
(100 µg/mL). A BL21 (DE3) non recombinant colony was also inoculated in terrific broth 
as a control. The glycerol in the media acts as a carbohydrate source. One of the advantages 
of using glycerol instead of glucose is that the glycerol does not ferment to acetic acid                           
(Tartof and Hobbs 1987). The terrific broth cultures were incubated overnight at 37oC with 
shaking. Thereafter, the cells were harvested by centrifugation (5000 g, 10 min, 4oC). The 
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cell pellets were resuspended in TE buffer. The cells were pelleted once again by 
centrifugation (5000 g, 10 min, 4oC) and resuspended in lysis buffer [50 mM Tris-HCl 
buffer, pH 7.5, 100 mM NaCl, 1mM DTT and 5% (v/v) glycerol]. Peptidase inhibitors; 
leupeptin, E-64, AEBSF and EDTA were added with a final concentration 1 µM. Lastly, 
lysozyme at pH 8 was added to the lysate to lyse cells by degrading the bacterial cell wall. 
The lysate was stored overnight -20oC.  The lysed cell pellet and supernatant were analysed 
on SDS-PAGE to determine if the ∆FLVp was expressed in the soluble fraction or as 
inclusion bodies.  
3.2.9 Solubilisation of the bacterial-expressed ∆FLVp 
The solubilisation of the recombinantly expressed ∆FLVp was performed according to 
Sijwali et al. (2001). The lysate was thawed and sonicated (8 x 15 s bursts) using a 
VirSonic 60 sonicator. This was followed by pelleting the lysed cells (inclusion bodies) by 
centrifugation (14000 g, 15 min, 4oC). The supernatant was discarded and the inclusion 
bodies were washed twice by a first wash buffer [2.0 M urea, 20 mM Tris-HCl buffer, pH 
8, 2.5% (v/v) Triton X-100] and by a second wash buffer [20% sucrose and 20 mM Tris-
HCl buffer, pH 8]. Following each wash, the inclusion bodies were pelleted by 
centrifugation (12000 g, 30 min, 4oC) and the supernatant was retained each time. The 
pelleted inclusion bodies were solubilised using solubilisation buffer [6 M guanidine-HCl, 
20 mM Tris-HCl buffer, pH 8, 250 mM NaCl, 20 mM imidazole].  
3.2.10 Purification of the bacterial-expressed ∆FLVp under denaturing conditions 
 
Preparation of His-select nickel affinity resin  
 
His-select nickel affinity resin (1 mL) was placed in a 15 mL conical centrifuge tube and 
centrifuged (800 g, 1 min, RT) to allow the resin to settle. The supernatant was removed 
and resin was resuspended by gentle tapping in 10 mL of sterile distilled water. The resin 
was allowed to settle by centrifugation (800 g, 1 min, RT). This step was performed twice 
and each time the supernatant was discarded. The resin was resuspended in 10 mL of the 
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solubilisation buffer (Section 3.2.9) and allowed to settle by centrifugation (800 g, 1 min, 
RT). This step was repeated with the removal of the supernatant after each step.  
Purification 
Two mL of the solubilised ∆FLVp (Section 3.2.9) was added to the prepared His-select 
nickel affinity column. The solubilised ∆FLVp was allowed to bind to the resin by end-
over-end mixing for 1 h at RT. The resin was allowed to settle by centrifugation            
(800 g, 1 min, RT) and the supernatant was retained for analysis on an SDS-PAGE gel.  
Thereafter, the resin was washed with 10 mL of solubilisation buffer and settled by 
centrifugation    (800 g, 1 min, RT). The resin was washed with a buffer containing 8 M 
urea, 20 mM Tris-HCl, pH 8, 0.5 M NaCl and allowed to settle by centrifugation (800 g, 1 
min, RT). This was followed by washing the resin with a buffer containing 8 M urea, 20 
mM Tris-HCl, pH 8, 0.03 M imidazole and the resin was allowed to settle by centrifugation 
(800 g, 1 min, RT). The resin was resuspended in 2 mL of elution buffer (8 M urea, 20 mM 
Tris-HCl, pH 8, 1 M imidazole) and transferred into a BioRad chromatography purification 
column. Fractions (100 µl) were collected and analysed on a reducing 12.5% SDS-PAGE 
gel. The supernatants from each wash step were also analysed on 12.5% SDS-PAGE gel. 
The resin was washed in 0.5 M NaOH (10 column volumes) and equilibrated in 
solubilisation buffer containing 20 mM imidazole and stored at 4oC. 
3.2.11 Renaturation of the bacterial-expressed ∆FLVp  
The renaturation of the recombinantly expressed ∆FLVp was performed according to 
Sijwali et al. (2002). Any insoluble material from the solubilisation of ∆FLVp (Section 
3.2.9) was removed by centrifugation (27000 g, 30 min, 4oC). The solubilised ∆FLVp was 
diluted 100 fold with renaturation buffer [100 mM Tris-HCl buffer, pH8, 1 mM EDTA, 
20% (v/v) glycerol, 1 M KCl, 1 mM GSH, 0.5 mM GSSG] added in small increments. The 
renaturation buffer and solubilised ∆FLVp were left for 20 h at 4oC without stirring. 
Following renaturation the sample was concentrated down to 1/10th of the original volume 
using ultrafiltration (Amicon PM 30, 62 mm filter). Thereafter, the volume was brought 
back to the original volume with ice cold sterile distilled water. Once again, the sample was 
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concentrated but this time the volume was brought down to 1 mL. DTT (2.5 mM) was 
added to the concentrated sample before incubation at RT for 40 min with gentle stirring. 
The sample was stored at -20oC until further use. The renatured samples were analysed by 
12.5% SDS-PAGE gel as described in section 3.2.14. The samples were analysed by 
electrophoresis under reducing and non-reducing conditions. 
3.2.12 Expression of ∆FLVp in yeast  
Transformation of pPic9-ΔFLVp and pPic9-C2 (H43W) into Pichia pastoris GS115 cells. 
An E. coli mutated C2 clone (H43W) in pPIC9 (Ndlovu 2009, MSc) was used as a positive 
control for transformation and expression of ∆FLVp in yeast. The transformation of   
pPic9-∆FLVp and pPIC9-C2 (H43W) was based on the work done by Wu and Letchworth 
(2004). The recombinant vectors were transformed into methylotrophic P. pastoris GS 115 
cells. A single GS 115 colony was grown in yeast extract peptone dextrose medium (YPD) 
(500 mL) [1% (w/v) yeast extract, 2% (w/v) peptone and 2% (w/v) dextrose (glucose)] at 
30oC overnight, with shaking until an OD600 of 2 was reached. The cells were pelleted by 
centrifugation (708 g, 20 min, 4oC). The pelleted cells were resuspended in 400 mL of 100 
mM lithium acetate, 10 mM DTT, 0.6 M sorbitol, 10 mM Tris-HCl buffer, pH 7.5 and 
incubated at RT for 30 min. This was followed by centrifugation (708 g, 20 min, 4oC). The 
pelleted cells were resuspended in 45 mL of ice cold 1 M sorbitol and centrifuged as 
before. This step was repeated three times. The cells were finally resuspended in 1.5 mL of 
ice cold sorbitol, giving a final concentration of 1010 cells/mL. The pPic9-∆FLVp and                    
pPIC9-C2 (H43W) plasmid DNA (10 µl of each) was linearised with SalI and SacI, 
respectively. The linearised DNA (2 µl) was mixed with 200 µl of the GS 115 cells and 
transferred to gap vials. The linearised DNA was transformed into GS115 cells by 
electroporation at 1.5kV, 25µF, 200Ω using an electroporator (BioRad, Hercules, CA, USA). 
Immediately after electroporation, 1 mL of ice cold 1 M sorbitol was added to the cells. 
Cells were plated on minimal dextrose (MD) plate [1.34% (w/v) YNB, 0.00004% (w/v) 
biotin, 2% (w/v) dextrose (glucose), 15g/l bacteriological agar] and grown for four days at 
30oC. Colony PCR was performed using the AOX primers for the pPIC9-C2 (H43W) 
transformation and C-term Fw and AOX Rv primers for pPic9-∆FLVp transformation 
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(Table 3.2). This was performed in order to confirm the presence of the foreign DNA in the 
P. pastoris genome. The AOX Fw and Rv primers could not be used for the pPic9-∆FLVp 
transformation since linearisation with SalI directs insertion of the DNA into the P. pastoris 
genome at the his4 gene; therefore, the insert will not be between the Fw and Rv AOX 
priming sites.     
Small Scale Expression of ∆FLVp  
The expression of both ∆FLVp and C2 (H43W) were performed using the same method 
described below. A single colony from the MD plate was inoculated into 10 mL YPD 
liquid media containing ampicillin (100 µg/mL) to prevent contamination of the culture. 
The YPD culture was placed in 250 mL baffled flasks and grown at 30oC in an orbital 
shaking incubator for two to three days. The culture was transferred into a 1 L baffled flask 
and the culture volume was made up to 100 mL with buffered complex glycerol media 
(BMGY) [1% (w/v) yeast extract, 2% (w/v) peptone, 100 mM potassium phosphate buffer, 
pH 6.5, and 1.34% (w/v) yeast nitrogen base (YNB)]. The culture was grown for a further 
two days at 30oC in a shaking incubator (until an OD600 of 2-6 was reached). The BMGY 
media was used to increase the biomass of cells as it allows for better growth of the cells. 
The cells were harvested by centrifugation (2000 g, 10 min, 4oC) and resuspended in 25 mL 
of buffered minimal media (BMM) [100 mM potassium phosphate buffer, pH 6.5, 1.34 % 
(w/v) YNB, 0.00004% (w/v) biotin and 0.5% (v/v) methanol] The BMM culture was 
placed in 1 L baffled flasks and grown at 30oC in a shaking incubator for four to six days. 
Methanol (0.5%) was added daily to the cultures in order to maintain induction of 
expression of the protein of interest. The cells were harvested by centrifugation (5000 g, 10 
min, 4oC) and the supernatant was retained. The supernatant was stored in plastic bottles at 




3.2.13 Purification of ∆FLVp and C2 (H43W) 
Three phase partitioning (TPP)  
Three phase partitioning (Pike and Dennison 1989) was used to concentrate and purify the 
ΔFLVp and C2 (H43W) samples. The supernatants (25 mL) were thawed and filtered 
through Whatman No 1 filter paper. Thereafter, tertiary butanol [30% (v/v)] was added to 
the culture supernatant. The peptidases precipitated with ammonium sulfate [40% (w/v) of 
the total volume i.e. culture supernatant and tertiary butanol]. The TPP sample was 
centrifuged (6000 g, 10 min, 4oC) in a swing-out rotor to separate the three layers: the 
tertiary butanol layer, the precipitated protein layer and an aqueous layer. The precipitated 
protein layer was retained and dissolved in dialysis buffer [phosphate buffered saline 
(PBS), pH 7.2]. The proteins were then dialysed overnight at 4oC against PBS, pH 7.2 in a 
10 kDa cut-off dialysis bag (Thermo Scientific Snakeskin® pleated dialysis tubing) in order 
to eliminate any residual tertiary butanol and (NH4)2SO4. The dialysed protein samples 
were concentrated against solid polyethylene glycol (Mr 20 000) until the volume in the 
dialysis bag was brought down to 5 mL.  
3.2.14 SDS-PAGE gel analysis of recombinant protein 
Analysis of recombinant protein samples was performed by SDS-PAGE according to      
Laemmli (1970) using a discontinuous Tris-Glycine buffer and gel system. Samples that are 
being resolved on a gel are combined with a reducing treatment buffer [125 mM Tris-HCl 
buffer, pH 6.8, 4% (w/v) SDS, 20% (v/v) glycerol and 10% (v/v) 2-mercaptoethanol] or 
non-reducing treatment buffer [125mM Tris-HCl buffer, pH 6.8, 4% (w/v) SDS and      
20% (v/v) glycerol] in a 1:1 ratio. The proteins were first resolved through a stacking gel 
containing [500 mM Tris-HCl buffer, pH 6.8] and thereafter through a running gel 
containing [1.5 M Tris-HCl buffer, pH 8.8]. Electrophoresis was conducted at 18 mA per 
gel for approximately 1.5 - 2 h in a tank buffer [250 mM Tris-HCl buffer, pH 8.3, 192 mM 
glycine, 0.1% (m/v) SDS]. The relative migration distance of proteins on a gel has an 
inversely proportional relationship with the molecular weight of the protein. A standard 
curve of log Mw of proteins of known molecular weight against distance travelled (relative 
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mobility) was constructed (Fig. 3.4). The plot generated was used to determine the 
molecular weight of the protein of unknown size.    
 
Figure 3.4 Standard curve of log Mw against relative mobility for the estimation of protein Mw by 
SDS-PAGE. The low range marker is made up of phosphorylase B (97 kDa), bovine serum albumin (66 
kDa), ovalbumin (45 kDa), carbonic anhydrase (31 kDa), soybean trypsin inhibitor (21Da) and lysozyme (14 
kDa). The equation of the trend line is   y= -0.60602 + 12.778, with a correlation coefficient of 0.988. 
Microsoft excel 2007 was used to construct the plot. 
 
The separated proteins were visualised by incubating the gel in a Coomassie blue R-250 
stain [0.125% (w/v) Coomassie blue R-250, 50% (v/v) methanol and 10% (v/v) acetic acid] 
for four hours followed by destaining in destain solution I [50% (v/v) methanol, 10% (v/v) 
acetic acid] overnight and then in destain solution II [5% (v/v) methanol, 7% (v/v) acetic 
acid] to allow for complete destaining. The detection limit of the Coomassie blue stain 
ranges from approximately 50-100 ng of protein (Laemmli 1970). 
 
3.2.15 Production of anti-∆FLVp antibodies in mice and chickens 
The solubilised ∆FLVp protein band (from section 3.2.9) separated on SDS-PAGE was cut 
from the gel (Fig. 3.5) and liquid nitrogen added. The gel piece was crushed into a fine 




























(5000 g, 2 min, RT) after each wash, followed by washing twice in 1 mL PBS and 














Figure 3.5 Analysis by a reducing 12.5% SDS-PAGE gel of recombinant solubilised ∆FLVp. Lane 1, 
Molecular weight markers; lane 2, pET-32a-∆FLVp (15 µl). White oval indicates the section of  ∆FLVp  that 
was cut out the gel and used for immunisation. The sample wad mixed with an equal volume of reducing 
treatment buffer and boiled for 2 minutes prior to loading. Proteins were stained with Coomassie R-250. 
 
 
For chicken immunisations the 1 mL ∆FLVp-PBS suspension was combined with 1 mL of 
Freund’s complete adjuvant (Sigma) and the mixture was triturated to give a stable water-
in-oil emulsion. Two chickens were immunised receiving 500 µl each (250 µl per breast 
muscle). Booster injections were administered at weeks 2, 4 and 6 using Freund’s 
incomplete adjuvant (Sigma). Eggs were collected before immunisation and during the 
immunisation period.  
 
For mice immunisation, 200 µl of the 1mL ∆FLVp-PBS suspension was combined with an 
equal volume of Freund’s complete adjuvant (Sigma). The mixture was triturated to give a 
stable water-in-oil emulsion. The immunogen was injected into two mice (100 µl per 







     1                 2 
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mouse). The mice received booster injections on weeks 3 and 6 using Freund’s incomplete 
adjuvant (Sigma). Mice were bled prior to and during the immunisation period.  
3.2.16 Isolation of IgY from egg yolk 
Chicken IgY antibodies were isolated from egg yolk by a PEG precipitation technique 
described by Polson et al. (1985). The precipitation technique is made up of three steps. 
The first step involves removing the vitellin and fat fractions and the second and third steps 
involves the precipitation of the antibodies. The egg yolk was separated from the egg white 
and the yolk gently rinsed under running tap water to remove any remaining egg white. The 
yolk was collected by puncturing the yolk sac and the volume of the yolk was determined. 
Two volumes of 100 mM sodium phosphate buffer, pH 7.6, containing 0.02% (w/v) NaN3 
was mixed with the yolk. PEG 6000 was added to the total volume (yolk volume plus the 
two column volumes of buffer) to a final concentration of 3.5% (w/v) and dissolved with 
gently stirring. The mixture was centrifuged (4 420 g, 30 min, RT), and the supernatant 
filtered through absorbent cotton wool.  The PEG 6000 concentration of the filtrate was 
increased to 12% (w/v) and dissolved once again by gentle stirring. The mixture was 
centrifuged    (12 000 g, 10 min, RT). The pellet was retained and dissolved in a volume of 
sodium phosphate buffer equal to the yolk volume and 12% (w/v) PEG 6000 added and 
dissolved by gentle stirring. The solution was centrifuged (12 000 g, 10 min, RT). The 
pellet was retained and dissolved in a sixth of the yolk volume of 100 mM sodium 
phosphate buffer, pH 7.6, but this time containing 0.1% (w/v) NaN3 and stored at 4°C. 
 
3.2.17 Enzyme-linked immunosorbent assays (ELISAs) 
The ELISA technique used in this study to evaluate the production of polyclonal antibodies 
in both mice and chickens was based on an original protocol (Huson et al. 2009). 
Recombinant ∆FLVp expressed in bacteria was used to coat the ELISA plate wells of 96 
well Nunc-ImmunoTM ELISA plates at a concentration of 1 µg/mL in PBS pH 7.2 (150 µl 
per well) overnight at 4oC. The coating antigen was removed and non-specific binding of 
the antibody was prevented by blocking the wells with 0.5% (w/v) BSA-PBS (200 µl per 
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well) for 1 h at 37oC. This was followed by washing the wells three times with 0.1% (v/v) 
PBS-Tween. Primary antibodies (chicken IgY or mice sera) were diluted appropriately with 
0.5% (w/v) BSA-PBS and incubated in the wells (100 µl per well) for 2 h at 37oC. Wells 
were washed three times with 0.1% (v/v) PBS-Tween. The HRPO-conjugated anti-species 
secondary antibody (rabbit anti-chicken IgY or horse anti-mouse IgG), diluted in              
0.5% (w/v) BSA-PBS, was added (120 µl per well) and incubated for 1 hour at 37oC. Wells 
were washed three times with 0.1% (v/v) PBS-Tween. This was followed by the addition of 
substrate solution [0.05% (w/v) ABTS and 0.0015% (v/v) H2O2 in 0.15 M citrate-phosphate 
buffer, pH 5.0] (150 µl per well) until colour developed in the dark. The A405 of each well 
was measured in a FLUORStar Optima spectrophotometer (BMG Labtech, Offenburg, 
Germany). 
 
3.2.18 Western blot analysis of recombinant proteins 
Western blots were carried out to verify the expression of the recombinant proteins and to 
test the anti-∆FLVp antibodies. Protein separated by SDS-PAGE (Section 3.2.14) were 
transferred onto a nitrocellulose membrane, using a wet blotter (BioRad Hercules, CA, 
USA) in the presence of blotting buffer [45 mM Tris-HCl buffer, pH 8.3, 173 mM glycine 
and 0.1% (w/v) SDS] for 16 hours at 200 mA (Towbin et al. 1979; Gershoni and Palade 
1982). The nitrocellulose membrane was transiently stained with Ponceau S [0.1% (w/v) 
Ponceau S in 1% (v/v) glacial acetic acid] and the molecular weight markers as well as the 
relevant protein bands marked with a pencil and the nitrocellulose membrane was destained 
with distilled water containing a drop of NaOH. The unreactive sites on the nitrocellulose 
membrane were blocked with low fat milk powder solution. [5% (w/v) low fat milk powder 
in Tris buffered saline (TBS) (20 mM Tris-HCl and 200 mM NaCl, pH 7.4)] for one hour at 
RT. The membrane was subsequently washed with TBS (3 x 5 minutes) and incubated in 
primary antibody diluted in 0.5% (w/v) BSA-TBS for 2 h at RT. This was followed by 
washing the membrane in TBS (3 x 5 minutes) and incubation in HRPO labelled secondary 
antibody diluted in 0.5% BSA TBS for one hour at RT. Lastly, the membrane was washed 
in TBS (3 x 5 minutes) and placed in substrate solution                                                 
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[0.06% (w/v) 4-chloro-1-naphthol, 0.1% (v/v) methanol, 0.0015 % (v/v) hydrogen peroxide 
H2O2 in TBS]. The blot was left in the dark until the protein bands developed.  
3.3 RESULTS 
3.3.1 Cloning of full length mutant of vivapain (∆FLVp) into the pTZ57R/T vector    
(T vector) 
The T. vivax parasites were purified from the blood of two mice infected with the Y486 T. 
vivax strain. The parasites were purified using a DEAE 50 cellulose column yielding       
4.7 x 107 parasites/mL. Genomic DNA was isolated from the parasites using a            
phenol/chloroform method and revealed a single band with no degradation products                  

















Figure 3.6 Agarose (1%) gel electrophoresis showing genomic DNA extracted from T. vivax parasites. 
Lane1, FastRuler™ DNA Ladder Middle Range; lane 2, T. vivax genomic DNA (1µl). Gel was stained with 
ethidium bromide.  
 
Genomic DNA (Fig. 3.6) was used as the template for the PCR amplification of full length 
vivapain. A touch down PCR was performed since this was found to be the best method for 
the amplification of the FLVp gene. Agarose gel analysis of the PCR product revealed a 
prominent band at approximately 1.3 kb (Fig. 3.7) which corresponds to the expected size 
of the FLVp gene.  




















Figure 3.7 Agarose (1%) gel showing the amplification product of the full length vivapain gene from     
T. vivax genomic DNA using full length primers in the touch down PCR. Lane1, FastRuler™ DNA 
Ladder Middle Range; lane 2, PCR product of the FLVp gene amplification (1 µl). Red box showing the 
FLVp PCR product. Gel was stained with ethidium bromide. 
The 1.3 kb fragment was cut out of the gel, purified and ligated into the pTZ57R/T vector 
(T vector). The ligation mix was transformed into E.coli JM109 cells. Blue-white colony 
selection was used to screen for transformants. Six white colonies were screened for 
recombinants by using colony PCR with specific C-term primers that were designed to 
amplify the C-terminal domain of the FLVp gene. All six colonies selected were 
recombinant due to the presence of a 350 bp product (Fig. 3.8, lanes 2-7) which 










Figure 3.8 Agarose (1%) gel showing the screening of the six recombinant clones (T vector-FLVp) after 
transformation into E. coli JM 109 cells using C-term primers. Lane1, FastRuler™ DNA Ladder Middle 
Range; lanes 2-7, PCR product for the screening of the six colonies (20 µl); lane 8, positive PCR control        
(1 in 10 dilution of T. vivax genomic DNA as template) (20 µl); lane 9: negative control (no DNA template) 
(20 µl). Gel was stained with ethidium bromide. 
The six recombinant T vector-FLVp plasmid DNA preparations were isolated and 
sequenced. The cloning of the FLVp gene into the T vector was performed to determine 
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which would have led to the production of a full length inactive mutant that could have 
been used in diagnostic tests for T. vivax. The sequencing results revealed that only one out 
of the six clones matched up to the vivapain reference sequence in the database    
(Appendix 1). This sequence contained the catalytic triad Cys25, His159 and Asn175 (papain 
numbering) in the active site. This meant that this particular clone’s sequence constituted 
the full length active form of vivapain. Since the full length inactive form of vivapain 
(∆FLVp) was required a different approach had to be taken.  
The ∆FLVp fragment was obtained from the full length active vivapain (FLVp) fragment 
cloned into the T vector and an already existing mutant catalytic domain of vivapain 
fragment (∆CAVp) cloned into a pPic9 vector. The ∆CAVp fragment had an alanine 
substituted for cysteine in the catalytic triad. Therefore, the amino acid residues in the 
active site of ∆CAVp are Ala25, His159 and Asn175 (papain numbering). The ∆FLVp 
fragment was obtained by using a unique double cutter restriction enzyme, namely BsgI, 
which was unique to both the full length active vivapain fragment cloned in T vector and 
the mutant catalytic domain of vivapain fragment (∆CAVp) in pPic9. The restriction sites 
for this enzyme were present on either side of the CHN domain of the FLVp clone and the 





























Figure 3.9 Agarose (1%) gel showing restriction with BsgI. A) full length active vivapain fragment cloned 
in T vector miniprep (CHN fragment) and B) mutant catalytic domain of vivapain fragment (∆CAVp) in 
pPic9 miniprep (AHN fragment) using BsgI. Lane 1, FastRuler DNA Ladder Middle Range; lane 2, uncut 
miniprep (control) and lane 3, cut miniprep. The gel was stained with ethidium bromide. The arrow in (A) 
represents the CHN fragment and the arrow in (B) represents the AHN fragment  
 
The AHN coding fragment was then ligated into the BsgI sites of the full length active 
vivapain coding fragment. The result of this ligation was DNA coding for a full length 
inactive mutant of vivapain. The ∆FLVp fragment in the T vector was transformed into 
E.coli JM 109 cells and colony PCR was performed to screen the white colonies with C-
term primers (Table 3.2). This colony PCR (Fig. 3.10) revealed that all of the 17 cones 
selected were recombinant due to the presence of a 360 bp band in all the lanes of the 






































Figure 3.10 Screening of the recombinant (T vector-∆FLVp) clones after transformation into E. coli  
JM 109 cells on 1% agarose gel. Lane1, FastRuler™ DNA Ladder High Range; lanes 2-18, PCR product for 
the screening of the 17 colonies (20 µl); lane 19, positive PCR control (T. vivax genomic DNA as template) 
(20 µl); lane 20, negative control (no DNA template) (20 µl). Gel was stained with ethidium bromide.  
 
Since the C-term primers were used in the colony PCR, a further test to prove that the AHN 
coding fragment was ligated into the T vector was performed. A miniprep was performed 
on clones 1 and 10 (Fig. 3.10 lanes 2 and 11) in order to obtain the plasmid DNA. This 
plasmid DNA was then subjected to restriction by EcoRI and NotI (Fig. 3.11 A) to ensure 
that the ∆FLVp coding fragment was present in the T vector and by BsgI I to ensure that 
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Figure 3.11 Analysis of restriction by EcoRI, NotI and BsgI using 1% Agarose gel. A) Restriction of 
clone one and ten by EcoRI and NotI. Lane 1, FastRuler™ DNA Ladder High Range; lane 2, clone one uncut 
plasmid DNA (1 µl); lane 3, clone one cut plasmid DNA (EcoRI/NotI) (10 µl); lane 4, clone 10 cut plasmid 
DNA (EcoRI/NotI) (10 µl); lane 5, clone ten uncut plasmid DNA (1µl). B) Restriction of clone one and ten by 
BsgI. Lane1, FastRuler™ DNA Ladder High Range; lane 2, clone one cut plasmid DNA (BsgI) (10 µl); lane 
3, clone 10 cut plasmid DNA (BsgI) (10 µl). Gel was stained with ethidium bromide.   
 
The sequencing of the clones revealed that the AHN coding fragment was successfully 
ligated into the full length vivapain fragment in the T vector (Fig. 3.12).  This shows that 
the mutant AHN coding fragment was successfully ligated into to the BsgI sites of the full 
length vivapain coding fragment rendering the ∆FLVp. This clone was, therefore, used in 
the remainder of the study.  
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    10        20        30        40        50        60        70        80                
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CTCCAGACTTTATCGACTCACTATAGGGAAAGCTTGCATGCAGGCCTCTGCAGTCGACGGGCCCGGGATCCGATTAAAGA 80    
 L  Q  T  L  S  T  H  Y  R  E  S  L  H  A  G  L  C  S  R  R  A  R  D  P  I  K  E  
         90       100       110       120       130       140       150       160     
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ATTCTACATGGCGGTGCTGCGCGCGGAGGGGCCCGTGGAGCCGCTGTTTGCGGCGTTCAAGCAGAAGTACGGCAGGTCGT 160   
  F  Y  M  A  V  L  R  A  E  G  P  V  E  P  L  F  A  A  F  K  Q  K  Y  G  R  S  
        170       180       190       200       210       220       230       240        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ACGGGACCGCGGCGGAGGAGGCGTTCCGCCTGCGCGTATTCGAGGACAACATGCGCCGGTCGCGGATGTACGCGGCGGCA 240   
Y  G  T  A  A  E  E  A  F  R  L  R  V  F  E  D  N  M  R  R  S  R  M  Y  A  A  A  
        250       260       270       280       290       300       310       320        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AACCCGCACGCGACGTTCGGTGTCACGCCGTTCTCGGACCTCACGCCCGAGGAGTTCAGGACACGCTACCACAACGGCGA 320   
 N  P  H  A  T  F  G  V  T  P  F  S  D  L  T  P  E  E  F  R  T  R  Y  H  N  G  E  
        330       340       350       360       370       380       390       400        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
GCGCCACTTCGAGGCAGCGCGGGGGCGCGTGAGGACGCTGGTGCAGGTGCCGCCGGGCAAGGCGCCCGCCGCCGTGGACT 400   
  R  H  F  E  A  A  R  G  R  V  R  T  L  V  Q  V  P  P  G  K  A  P  A  A  V  D  
        410       420       430       440       450       460       470       480        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
GGCGCCGCAAGGGTGCGGTGACGCCCGTCAAGGACCAGGGCAGGTGCGGCTCCGCCTGGTCCTTCTCCGCCATTGGGAAC 480   
W  R  R  K  G  A  V  T  P  V  K  D  Q  G  R  C  G  S  A  W  S  F  S  A  I  G  N  
        490       500       510       520       530       540       550       560        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ATCGAGGGCCAGTGGGCGGCTGCCGGCAACCCGCTGACGAGTCTGTCGGAGCAGATGCTTGTGTCGTGCGACACCACGGA 560   
 I  E  G  Q  W  A  A  A  G  N  P  L  T  S  L  S  E  Q  M  L  V  S  C  D  T  T  D  
        570       580       590       600       610       620       630       640        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TAGTGGTTGCAGTGGTGGCCTGATGGACAACGCATTCGAGTGGATCGTGAAGGAGAACAGTGGCAAGGTGTACACGGAGA 640   
  S  G  C  S  G  G  L  M  D  N  A  F  E  W  I  V  K  E  N  S  G  K  V  Y  T  E  
        650       660       670       680       690       700       710       720        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
AGAGCTATCCCTACGTCTCTGGCGGTGGCGAGGAGCCGCCCTGCAAGCCGCGTGGGCACGAGGTCGGTGCCACGATCACC 720   
K  S  Y  P  Y  V  S  G  G  G  E  E  P  P  C  K  P  R  G  H  E  V  G  A  T  I  T  
        730       740       750       760       770       780       790       800        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
GGCCACGTGGACATCCCGCACGACGAGGACGCCATCGCCAAGTACCTCGCCGACAACGGCCCGGTCGCTGTGGCCGTGGA 800   
 G  H  V  D  I  P  H  D  E  D  A  I  A  K  Y  L  A  D  N  G  P  V  A  V  A  V  D  
        810       820       830       840       850       860       870       880        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
CGCCACCACCTTCATGTCGTACAGTGGCGGTGTGGTGACGTCCTGCACCTCCGAGGCGCTGAACCACGGCGTGCTCCTCG 880   
  A  T  T  F  M  S  Y  S  G  G  V  V  T  S  C  T  S  E  A  L  N  H  G  V  L  L  
        890       900       910       920       930       940       950       960        
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TCGGCTACAACGACAGCAGCAAGCCGCCGTACCGGATCATCAAGAACCCGTGGAGCTCGTCGTGGGGCGAGAAGGGCTAC 960   
V  G  Y  N  D  S  S  K  P  P  Y  R  I  I  K  N  P  W  S  S  S  W  G  E  K  G  Y  
        970       980       990       1000      1010      1020      1030      1040       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
ATCCGCATCGAGAAGGGCACGAATCAGTGTCTGGTGGCGCAGCGCGCGTCGAGTGCTGTTGTTGGTGGCCCCGGTCCCAC 1040  
 I  R  I  E  K  G  T  N  Q  C  L  V  A  Q  R  A  S  S  A  V  V  G  G  P  G  P  T  
        1050      1060      1070      1080      1090      1100      1110      1120       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
GCCCACGCCCACGCCCACGCCAACAACAACAACAACAACGACCGCACCTGGCCCATCGTCAAGCTTCACGAAGACGCTTT 1120  
  P  T  P  T  P  T  P  T  T  T  T  T  T  T  A  P  G  P  S  S  S  F  T  K  T  L  
        1130      1140      1150      1160      1170      1180      1190      1200       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
GCAGCGGTGATGATTGCGCCGACAACTGTTCAGCGACTGTCTACAACACGAACACGTGCATCCGGCTGGGCGCGCTTGGC 1200  
C  S  G  D  D  C  A  D  N  C  S  A  T  V  Y  N  T  N  T  C  I  R  L  G  A  L  G  
        1210      1220      1230      1240      1250      1260      1270      1280       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
TCGATGGTGGCCACGTGCGGCGCGGGGGTGCTTGAGCTGAAGGCCTACATGCAGAATGAGCAGTGCACTGGCACCCCGGA 1280  
 S  M  V  A  T  C  G  A  G  V  L  E  L  K  A  Y  M  Q  N  E  Q  C  T  G  T  P  E  
        1290      1300      1310      1320      1330      1340      1350      1360       
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
GCGGCTCAGCCTGCCGCTGGACAAGTGCCTGGCGTCGCTCAGCGTGTCGGCAACGTACCACTGCAACTATGGCGCACCGG 1360  
  R  L  S  L  P  L  D  K  C  L  A  S  L  S  V  S  A  T  Y  H  C  N  Y  G  A  P  
        1370      1380       
....|....|....|....|....|. 
CGTAAGAACAGCGGCCGCCCCTTTGG 1386  
A  *  E  Q  R  P  P  L  W  
 
Figure 3.12 Sequence of the full length mutant vivapain (∆FLVp), showing the amino acids in the active site, which 
are the “AHN” triad (blue) and the DNA sequence coding for each of these amino acids (pink).  
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3.3.2 Subcloning of full length inactive mutant of vivapain (∆FLVp) into pET-32a and 
pPic9 expression vectors 
Since the ∆FLVp fragment was successfully cloned into the T vector, the next step was to 
subclone the fragment into the bacterial expression vector, pET-32a, and the yeast 
expression vector expression vector, pPic9. The purified ∆FLVp fragment and the two 
expression vectors prepared and cut with EcoRI and NotI was analysed on an agarose gel to 
determine their relative quantities for use for ligation (Fig. 3.13 A and B). Figure 3.13 A 
shows the pET-32a expression vector at approximately 6 kb (lane 2) and the ∆FLVp 
fragment at approximately 1.3 kb (lane 4). Figure 3.13 B shows the pPic9 expression vector 












Figure 3.13 Agarose gel (1%) analysis of the purified ∆FLVp fragment and the expression vectors cut 
with EcoRI and NotI. A) the pET-32a expression vector and the ∆FLVp insert and B) the pPic9 expression 
vector and ∆FLVp insert in order to determine the relative quantities of DNA to use for ligation. A) Lane 1, 
FastRuler™ DNA Ladder High Range; lane 2, pET-32a expression vector (1 µl) and lane 3 ∆FLVp insert (1 
µl). A) Lane 1, FastRuler™ DNA Ladder High Range; lane 2, pPic9 expression vector (1 µl) and lane 3 
∆FLVp insert (1 µl). Gel was stained with ethidium bromide.  
 
The colonies obtained from ligating the ∆FLVp insert with the expression vectors and the 
transformation into E. coli JM 109 cells were screened for recombinants using colony PCR 
with C-term Fw and pET Rv primers (Fig. 3.14). All nine colonies that were chosen from 
the pET-32a-∆FLVp transformation were positive (Fig. 3.14 A) due to the presence of a 
0.456 kb band (made up from 0.360 kb from the C-terminal extension of ∆FLVp and 0.096 
kb from the pET-32a plasmid). The recombinant pET-32a-∆FLVp plasmid DNA was used 
as template DNA with the pET primers as a positive control for this PCR and, 
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consequently, a band at approximately 750 bp was obtained (Fig. 3.14 A, lane 12). Both 
colonies chosen from the pPic9-∆FLVp transformation were positive since a PCR product 
of 0.360 kb was observed (Fig. 3.14 B), which is the expected size for the amplification of 














Figure 3.14 Agarose gel (1%) showing the screening of recombinant pET-32a-∆FLVp and pPic9-
∆FLVp after transformation into E. coli  JM 109 cells. A) recombinant pET-32a-∆FLVp clones: lane 1, 
FastRuler™ DNA Ladder High Range; lanes 2-10, PCR product for the screening of the nine colonies (20 µl); 
lane 11, negative control (no DNA template) (20 µl); lane 12, positive PCR control (recombinant pET-32a 
vector plasmid DNA used as the template with pET primers) (20 µl). B) recombinant pPic9-∆FLVp clones: 
lane 1, FastRuler™ DNA Ladder High Range; lanes 2-3, PCR product for the screening of the two colonies 
(20 µl); lane 4, positive PCR control (T. vivax genomic DNA as template) (20 µl); lane 5, negative control (no 
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The plasmid DNA of one clone from each of the transformations was isolated, and 
subjected to restriction digests using EcoRI and NotI. This restriction showed the presence 




















Figure 3.15 Agarose gel (1%) analysis of EcoRI and NotI restriction of pET-32a containing ∆FLVp and 
pPic9 containing ∆FLVp. A) Lane 1, FastRuler DNA Ladder High Range; lane 2, cut pET-32a-∆FLVp 
miniprep DNA (10 µl). B) Lane 1, FastRuler DNA Ladder High Range; lane 2, cut pPic9-∆FLVp miniprep 
DNA (10 µl).  The arrow in (A) and in (B) represents the ∆FLVp insert in pET-32a and pPic9, respectively. 
The gel was stained with ethidium bromide.   
 
3.3.3 Expression of the recombinant full length mutant of vivapain (∆FLVp) in pET-
32a  
The recombinant plasmid DNA (pET-32a vector containing the ∆FLVp fragment) was 
transformed into BL21 (DE3) and expression was performed in terrific broth. Analysis of 
the lysed cell pellet and supernatant on SDS-PAGE (Fig. 3.16) revealed that majority of the 
expressed protein is found in the pellet as insoluble inclusion bodies at approximately       
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Figure 3.16 Analysis by a 12.5% reducing SDS-PAGE gel of recombinant ∆FLVp expression from 
bacterial lysate. Lane 1, Molecular weight markers; lane 2, pET-32a-∆FLVp pellet (20 µl); lane 3,             
pET-32a-∆FLVp supernatant (20 µl); lane 4, pET-32a-BL21 (DE3) (20 µl). Arrow indicates the size of 
∆FLVp at 70 kDa in lane 2. Each of the samples were mixed with an equal volume of reducing treatment 
buffer and boiled for 2 minutes prior to loading. Proteins were stained with Coomassie R-250. 
 
Since attempts to purify the recombinantly expressed ∆FLVp under denaturing conditions 
failed (results not shown), it was decided to renature the protein. Following renaturation, 
the protein sample was analysed on a SDS-PAGE gel (Fig. 3.17). Results of the 
renaturation are inconclusive because a clear shift in size between that of the renatured and 
non-renatured protein is not visible (Fig. 3.17). The renaturation process also led to a 
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Figure 3.17 Analysis by 12.5% SDS-PAGE of the renaturation of full length mutant vivapain (∆FLVp) 
expressed in pET-32a. Lane 1, molecular mass markers; lane 2, non-renatured ∆FLVp (5 µl reduced and 
boiled); lane 3, renatured ∆FLVp (5 µl reduced and boiled); lane 4, non-renatured ∆FLVp (5 µl non-reduced 
and boiled); lane 5, renatured ∆FLVp (5 µl non-reduced and boiled); lane 6, non-renatured ∆FLVp (5 µl non-
reduced and non-boiled); lane 7, renatured ∆FLVp (5 µl non-reduced and non-boiled). Protein bands were 
stained with Coomassie R-250. 
 
A western blot was carried out using anti-congopain N-terminal peptide antibody to 
confirm the recombinant expression of ∆FLVp. The positive control used in this blot was 
C2, which is detected at approximately 27 kDa (Fig. 3.18, lane 5). The anti-congopain      
N-terminal peptide antibody also detected a 70 kDa band in lane 2 (∆FLVp solubilised) and 
lane 2 (∆FLVp after renaturation), which is the expected size of ∆FLVp expressed in 
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Figure 3.18 Western blot analysis of recombinant expression of ∆FLVp. Proteins were electrophoresed on 
a 12.5% SDS-PAGE gel and electroblotted onto a nitrocellulose membrane. Transferred protein was 
incubated with anti-congopain N-terminal peptide antibody (1 µg/mL). Secondary antibody was rabbit      
anti-chicken HRPO-conjugate (1:10000). The reaction was developed with 4-chloro-1-naphthol/H2O2. Lane 1, 
Fermentas Rainbow Marker ; lane 2, ∆FLVp after solubilisation; lane 3 ∆FLVp after renaturation; lane 4, the 
catalytic domain of vivapain (Vp); lane 5, catalytic domain of congopain (C2). 
 
3.3.4 Expression of ∆FLVp in pPic9  
3.3.4.1 Transformation into P. pastoris GS 115 cells 
The recombinant plasmid DNA (pPic9 vector containing the ∆FLVp fragment) was 
linearised with Sall in preparation for transformation into P. pastoris GS 115 cells. SacI 
could not be used to linearise the plasmid DNA since sequencing revealed that a SacI site 
was present in the ∆FLVp gene. A positive control pPic9-C2 (H43W) transformed into JM 
109 cells was also transformed and expressed in P. pastoris GS 115 cells. The pPic9-C2 
(H43W) clones were screened using AOX primers (Fig. 3.19 A). In this colony PCR two 
prominent bands were obtained at approximately 0.96 and 2.2 kb, which correspond to the 
C2 (H43W) insert gene and the native AOX gene of P. pastoris respectively. The          
pPic9-∆FLVp clones were screened using the C-term forward primer and the AOX reverse 
primers (Fig. 3.19 B). This colony PCR revealed the presence of a 0.470 kb band in lanes   
2-4 that correspond to the C-terminal extension portion of the ∆FLVp insert gene (0.36 kb) 
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and the portion of the pPic9 vector amplified (0.11 kb). The positive control used in this 
PCR was pPic9-∆FLVp plasmid DNA, which also produced a band at 0.470 kb. The band 


















Figure 3.19 Agarose gel (1%) showing the screening of the pPic9-C2 (H43W and pPic9-∆FLVp clones 
after transformation into GS115 P. pastoris yeast cells. A) Six [pPic9-C2 (H43W)] clones after 
transformation into GS115 P. pastoris yeast cells using AOX primers. Lane 1, FastRuler™ DNA Ladder 
Middle Range; lanes 2-7, PCR product for the screening of the six colonies (20 µl); lane 8, negative control 
(no DNA template) (20 µl); lane 9, positive PCR control (recombinant pPic9-C2 (H43W) vector plasmid 
DNA used as the template with AOX primers ) (20 µl). B) Four (pPic9-∆FLVp) clones after transformation 
into GS115 P. pastoris yeast cells using  the C-term forward primer and the AOX reverse primers.  Lane 1, 
FastRuler™ DNA Ladder Middle Range; lanes 2-5, PCR product for the screening of the four colonies (20 
µl); lane 6, positive PCR control (recombinant pPic9-∆FLVp vector plasmid DNA used as the template with 
C-term forward primer and the AOX reverse primers) (20 µl); lane 7, negative control (no DNA template) (20 
µl).Gel was stained with ethidium bromide.  
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3.3.4.2 Expression in P. pastoris GS 115 cells 
A small scale recombinant expression of ∆FLVp and C2 (H43W) was performed in          
P. pastoris. Three phase partitioning (TPP) was used to concentrate the recombinantly 
expressed proteins from the culture supernatant and expression was analysed by using 
chicken anti-N-terminal peptide antibodies (Fig. 3.20). The blot revealed that the ∆FLVp 
was not expressed since the antibody did not detect any band in lanes 2 and 3 (∆FLVp 
before and after TPP) (Fig. 3.20). This is further verified by the observation that the 
primary antibody recognised bands at approximately 27 kDa in lanes 4 and 5 [C2 (H43W 
before and after TPP)] (Fig. 3.20), which was used as a positive control in this experiment. 




















Figure 3.20 Western blot analysis of recombinant expression of ∆FLVp in P. pastoris. Proteins were 
electrophoresed on a 12.5 % SDS-PAGE gel and electroblotted onto a nitrocellulose membrane. Transferred 
protein was incubated with anti-congopain N-terminal peptide antibody (1 µg/mL). Secondary antibody was 
rabbit anti-chicken HRPO-conjugate (1:10000). Reaction was developed with 4-chloro-1-naphthol/H2O2. 
Lane 1, Fermentas Rainbow Marker ; lane 2, ∆FLVp supernatant culture from day 5 of expression (25 µl); 
lane 3, ∆FLVp after TPP (10 µl); lane 4, C2 (H43W) supernatant culture from day 5 of expression (25 µl); 














3.3.5 Production of antibodies against the recombinantly expressed ∆FLVp (in E. coli 
JM 109 cells) in mice and chickens  
Mice and chickens were injected with ∆FLVp separated on a gel and the production of 
antibodies was monitored by ELISA. The ability of the antibodies to recognise the 
recombinant ∆FLVp and native vivapain in a T. vivax lysate was evaluated by western blot.  
3.3.5.1 Evaluation by ELISA of anti-∆FLVp antibody production in chickens 
The first ELISA was performed to analyse the progression of antibody production during 
the 12 week period (Fig. 3.21). The ELISA showed that for chicken 1 antibody production 
peaked at weeks five, nine and eleven. Antibody production for chicken 2 peaked at weeks 
four, six and nine. Chicken 2 seemed to produce slightly higher antibody levels (Fig. 3.21).  
 
 
Figure 3.21 ELISA showing antibody production in chicken 1 () and chicken 2 ( X ) immunised with 
recombinant ∆FLVp. ELISA plates were coated with 1 µg/mL ∆FLVp. Primary antibody used was the IgY 
isolated from each chicken from weeks 1 to 12 at a concentration of 100 µg/mL. The interaction between 
∆FLVp and the primary antibody were detected using rabbit anti-chicken IgY HRPO-conjugate (1:10000) and 
ABTS/H2O2. Absorbance of the reactions was read at A405, which represent the average of duplicate readings. 
Arrows indicate when the booster immunisations were administered. Microsoft excel 2007 was used to 

















The second ELISA was performed in order to determine antibody titre for each chicken 
using serial dilutions for the antibodies produced during each week (Fig. 3.22). The results 
from this ELISA revealed that chicken 2, once again, produced higher levels of antibodies 
(Fig. 3.22 B). The ELISA also shows that all the antibodies produced from week 6 in the 
case of chicken 1 and  week 4 for chicken 2 were comparable and at significantly higher 
levels than the non-immune control. The titration curves suggest that a concentration of    
































Figure 3.22 ELISA showing the antibody titre for chickens immunised with recombinant ∆FLVp. 
ELISA plates were coated with 1 µg/mL ∆FLVp. Primary antibody used was the IgY isolated for each 
chicken for chicken 1 (A) or chicken 2 (B) weeks 1 to 12 at a concentrations ranging from 100 µg/mL to 
0.001 µg/mL. The interaction between ∆FLVp and the primary antibody were detected using rabbit anti-
chicken IgY HRPO-conjugate (1:10000) and ABTS/H2O2. Absorbances of the reactions were read at A405, 





3.3.5.2 Evaluation by ELISA of anti-∆FLVp antibody production in mice 
Two ELISAs were performed to analyse the antibody production in mice against the 
recombinant ∆FLVp over the eight week immunisation schedule. The first ELISA was 
conducted to monitor antibody production over the eight week immunisation period       
(Fig 3.23). This ELISA was performed using sera from samples collected three, four, five 
six, seven and eight weeks after the first immunisation. High antibody levels were observed 
four weeks after the first immunisation for both mice. Antibody production seemed to be 
constant from weeks four to six in mouse 1 and weeks four to five in mouse 2, thereafter, 
antibody production peaked at week 7 for mouse 1, and week six for mouse 2, which means 
that there was an increase in antibody production after the second booster (week six) for 
both mice (Fig. 3.23). It was decided to perform the big bleed on the mice at week eight. 
This serum was used for the subsequent ELISAs and western blots. 
 
Figure 3.23 ELISA showing the antibody production in mice against ∆FLVp. Sera from mouse 1 () and 
mouse 2 () were diluted 1:200 and incubated in ELISA plates coated with 1 µg/mL ∆FLVp. The interaction 
between ∆FLVp and the primary antibody were detected using horse anti-mouse IgG HRPO-conjugate and 
ABTS/H2O2. Absorbances of the reactions were read at A405, which represent the average of duplicate 
readings. Arrows indicate when the booster immunisations were administered. Microsoft excel 2007 was used 























The second ELISA was carried out to determine which concentration would be the best to 
use in western blots and possibly diagnostic tests (Fig. 3.24). This was done by using serial 
dilutions of the mice sera collected after the eight week of the immunisation period. The 
ELISA revealed that serum from mouse 2 had slightly higher antibody levels than that of 
mouse 1 and the serum dilutions of 1:1000 or 1:2000 would be suitable for use in western 
blots (Fig. 3.24).  
 
Figure 3.24 ELISA showing the antibody titre in mice. Sera from for mouse 1 (non-immune) (), mouse 1 
(), mouse 2 (non-immune) (), mouse 2 ( X ) were serially diluted in a range from 1:667 to 1:118 098 000 
incubated in ELISA plates coated with 1 µg/mL ∆FLVp .The interaction between ∆FLVp and the primary 
antibody were detected using horse anti-mouse IgG HRPO-conjugate (1:10000) and ABTS/H2O2. Absorbance 
of the reactions were read at A405, which represent the average of duplicate readings. Microsoft excel 2007 















Serial dilutions of mice sera
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3.3.5.3 Detection of recombinant ∆FLVp and native vivapain in T. vivax lysate by 
antibodies in a western blot 
The chicken anti-∆FLVp antibodies and mouse anti-∆FLVp sera were used in a western 
blot to detect recombinant ∆FLVp (Fig. 3.25) and native vivapain in a T. vivax lysate    
(Fig. 3.26). The antibodies collected at week eight from chicken 2 and serum from mouse 2 
were used in the western blots. The chicken anti-∆FLVp antibodies and mouse anti-∆FLVp 
sera were able to detect the recombinant at approximately 70 kDa (Fig. 3.25 A and B). The 
chicken anti-∆FLVp antibodies did not detect native vivapain in parasite lysate (results not 
shown). The mouse serum detected a band at approximately 55 kDa (Fig. 3.26, lanes 3 and 











Figure 3.25 Western blot detection of recombinant ∆FLVp by chicken anti-∆FLVp antibodies and 
mouse anti-∆FLVp sera. Proteins were electrophoresed on a 12.5% SDS-PAGE gel and electroblotted onto a 
nitrocellulose membrane. Transferred protein was incubated with A) chicken anti-∆FLVp antibodies          
(2.5 µg/mL) and non-immune chicken antibody in lane 2 (2.5 µg/mL) and with B) mice sera (1:5000) and a 
non-immune serum in lane 2 (1:5000). Secondary antibody in A) rabbit anti-chicken HRPO-conjugate 
(1:10000) and B) horse anti-mouse HRPO-conjugate (1:10000). Reaction was developed with 4-chloro-1-
naphthol/H2O2. Lane 1, Fermentas Spectra™ multicolour Broad range protein ladder ; lanes 2-3, recombinant 
∆FLVp; lane 4, recombinant ∆FLVp renatured. The pencil lines were drawn in to indicate the expected 
positions of ∆FLVp.  
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Figure 3.26 Western blot detection of native vivapain in T. vivax lysate. T. vivax lysate (1 x 105 parasites 
per well) proteins were electrophoresed on a 12.5% SDS-PAGE gel and electroblotted onto a nitrocellulose 
membrane and membrane was cut in strips for incubation with different mouse serum samples. The antibody-
vivapain interaction was detected using horse anti-mouse HRPO-conjugate (1:10000). Reaction was 
developed with 4-chloro-1-naphthol/H2O2. Lane 1, Fermentas Rainbow Marker; lane 2, non-immune serum; 
lane 3, mouse two serum (1:1000); lane 4, mouse two serum (1:2000). Arrow indicates the detection band of 
the native vivapain at 55 kDa.   
 
3.4 DISCUSSION 
The diagnosis of trypanosomosis is a very important aspect since it gives insight into the 
disease and allows for the correct use of chemotherapeutics. This study was performed to 
produce a recombinant antigen that will be useful in the field diagnosis of T. vivax in the 
sera of the infected animals. The most promising technique is the serological ELISA 
technique. There are two types of ELISA techniques that can be used; the antigen-detection 
ELISA and the antibody-detection ELISA. For the first method, the recombinant antigen 
will be used to produce antibodies that will be used to detect the antigen in infected sera 
and the second would use the antigen directly to detect antibodies in infected animals.  
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The cloning and expression of the full length inactive mutant of vivapain (∆FLVp) was 
undertaken for possible use in diagnostic tests for T. vivax. It is not possible to express a 
full length (FL) active form of vivapain that would be useful for the detection of antibodies 
in T. vivax infected animals due to prior investigations with the full length active form of 
congopain from Trypanosoma congolense (Boulangé A, University of KwaZulu-Natal, 
personal communication). The expression levels of the full length active form of congopain 
were very poor and the expressed protein was very unstable.  Therefore, for this study 
attempts were made to clone and recombinantly express ∆FLVp in bacterial and yeast 
expression systems.  
The 1.3 kb ∆FLVp fragment was obtained from a full length active vivapain fragment 
cloned into the pTZ57R/T vector (T vector) and mutant catalytic domain of vivapain 
fragment (∆CAVp) in a pPic9 vector. The full length active vivapain fragment that was 
cloned in the T vector was obtained by using the touch down PCR method. The full length 
vivapain gene was amplified from T. vivax genomic DNA extracted from T. vivax parasites. 
The full length vivapain gene was ligated into a T vector and successfully transformed into 
E. coli JM 109 cells.  The transformation was verified by performing a colony PCR with 
primers that amplify the C-terminal extension coding sequence. Bands corresponding to the 
amplified C-terminal portion coding region of the full length vivapain fragment were 
present, confirming the presence of the full length vivapain fragment in the T vector. The 
mutant catalytic domain of vivapain fragment (∆CAVp) in a pPic9 vector was obtained 
from Professor Theo Baltz (University of Victor-Segalen, Bordeaux, France). The ∆CAVp 
fragment has an alanine coding sequence substituted for a cysteine coding sequence in the 
catalytic triad, thus coding for an active site Ala25, His159 and Asn175 (papain numbering)  as 
compared to active vivapain, which has Cys25, His159 and Asn175 (papain numbering) in the 
active site. The ∆FLVp fragment was obtained by using a unique double cutter restriction 
enzyme, BsgI, which was unique to both the full length active vivapain coding fragment 
cloned into the T vector and mutant vivapain catalytic domain coding fragment (∆CAVp) 
in pPic9. Therefore, this enzyme was able to remove both the active site (CHN) coding 
sequence from the full length active vivapain fragment and the inactive AHN coding 
123 
 
sequence from the ∆CAVp fragment. Thereafter, the AHN coding fragment was ligated 
into the BsgI restriction sites of the full length active vivapain fragment which was in the          
T vector, leading to the production of an inactive form of FLVp (∆FLVp). The ∆FLVp in 
the T vector was transformed into E. coli JM 109 cells. Once again, the transformation 
efficiency was examined by colony PCR using C-terminal extension primers. The presence 
of the ∆FLVp fragment in the T vector was verified by the presence of the band 
corresponding to the C-terminal extension coding portion of the full length inactive 
vivapain fragment. The presence of the ∆FLVp fragment in the T vector was further 
verified by sequencing.  
For preparation of expression in the methylotrophic Pichia pastoris yeast expression 
system, the ∆FLVp fragment was sub-cloned into the pPic9 expression vectors via the 
EcoRI and NotI restriction sites. The recombinant pPic9 colony plasmid DNA linearised 
with SalI containing the open reading frame (ORF) coding for the full length mutant form 
of vivapain was transformed into P. pastoris GS115 cells. A positive control, pPic9-C2 
(H43W) in JM 109 cells was also transformed into P. pastoris GS115 cells. The pPic9-C2 
(H43W) plasmid DNA was linearised with SacI. A colony PCR was performed to detect 
the presence of either the pPic9-∆FLVp or the pPic9-C2 (H43W) DNA in the yeast 
genome. For the pPic9-∆FLVp the C-terminal extension forward primer and the AOX 
reverse primer were used. These primers amplified a band that correlated to the positive 
control in the PCR. The AOX primers were used to detect the presence of the pPic9-C2 
(H43W) DNA. This PCR revealed the presence of a band that correlated to the insert DNA 
and to the wild-type AOX gene. Both colony PCR assays confirmed that the transformed 
yeast colonies were recombinant.  
The reason for choosing the methylotrophic P. pastoris yeast expression system was due to 
the simplicity of the technique and its ability to express high levels of foreign proteins, but 
most of all for its ability to produce multiple eukaryotic post translational modifications. 
These include disulfide bond formation, glycosylation, protein folding and proteolytic 
processing, which eliminates the need for renaturation of the protein after expression 
(Cereghino and Cregg 2000; Macauley-Patrick et al. 2005; Aloulou et al. 2006). However, 
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attempts made to express the recombinant ∆FLVp in the yeast expression system were 
unsuccessful. In contrast the C2 (H43W) positive control was successfully expressed as 
shown by the recognition by anti-congopain N-terminal peptide antibody before and after 
the three phase partitioning concentration step. Therefore, it can be concluded that it was 
not possible to express the ∆FLVp in the P. pastoris yeast expression system.  
Due to the inability to express the ∆FLVp in the P. pastoris yeast expression system, it was 
decided to attempt expression in a bacterial system. There is evidence of successful 
expression of cysteine peptidases in bacteria; such as, full length cruzipain, the major 
cysteine peptidase of T. cruzi, in E. coli (Eakin et al. 1993). The ∆FLVp fragment was sub-
cloned into pET-32a via the EcoI and NotI restriction sites. The pET-32a-∆FLVp plasmid 
DNA was transformed into E. coli JM 109 cells. The recombinant pET-32a-∆FLVp colony 
plasmid DNA was further transformed into the electrocompetent BL21 (DE3) cells before 
expression. The BL21 (DE3) strain was chosen due to the fact that it contains the T7 RNA 
polymerase and one of the key features of the DE3 lysogen is that is peptidase deficient 
(pET Expression System Manual). 
Very high levels of ∆FLVp were expressed in the pET-32a BL21 (DE3) bacterial 
expression system and detected by anti-congopain N-terminal peptide antibody. This 
antibody had a good chance of detecting the ∆FLVp due to the high sequence identity 
between congopain and vivapain (Fig 1.8, Section 1.8.5) Although the expected size of the 
∆FLVp is approximately 50 kDa, the protein was expressed as a 70 kDa protein as a result 
of 20 kDa sequence that is contributed by the pET-32a vector. The results of a solubility 
test revealed that the bacterial cells expressed the ∆FLVp as insoluble inclusion bodies. 
Attempts to purify the ∆FLVp under denaturing conditions failed. Therefore, it was decided 
to solubilise and renature the protein before further attempts were made to purify the 
expressed protein. The renaturation protocol was adapted from that used by Sijwali et al 
(2001) for the refolding of falcipain-2, a cysteine peptidase from Plasmodium falciparum. 
The renaturation process usually involves the use of a buffer which contains reduced and 
oxidised thiol agents such as glutathione, cysteine or cystamine for the formation of 
disulfide bonds (Singh and Panda 2005). In the present study, the renaturation buffer used 
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was based on the buffer optimised for the refolding of falcipain-2, which contained reduced 
and oxidised glutathione in a 1:0.5 ratio (Sijwali et al. 2001). The refolding buffer also 
contains EDTA, which prevents the metal-catalysed oxidation of the cysteine residues 
(Singh and Panda 2005). The buffer further contains the stabilising agent glycerol, which 
allows for the correct folding of the protein and prevents the aggregation of partially folded 
intermediates of the protein formed during the renaturation process (Jaspard 2000; Vallejo 
and Rinas 2004). 
The renaturation process involves the gradual dilution of the ∆FLVp protein after it had 
been solubilised. This was followed by incubation in the renaturation buffer for 
approximately 20 hours; thereafter, the solution is concentrated by ultrafiltration. Analysis 
of the renaturation of ∆FLVp using SDS-PAGE revealed that there was no shift in the size 
evident between the non-renatured and renatured ∆FLVp samples, and there was a drastic 
loss in amount of protein present after the renaturation process. Therefore, results were 
inconclusive for the renaturation of ∆FLVp. Since there was such a major loss in the 
amount of protein present after the renaturation process, it was not feasible to perform 
further purification steps.  
Since the ultimate goal of the recombinant expression of ∆FLVp was its use in diagnostic 
tests, it was decided to make antibodies against this recombinant preparation in both 
chickens and mice to use as positive controls in antigen detection ELISAs and to determine 
whether the antibodies could detect the peptidase in T. vivax lysates. Such antibodies would 
also be useful to follow vivapain gene silencing in RNAi and gene knockout studies. Strong 
antibody responses against the recombinant ∆FLVp were observed in both mice and 
chickens. An ELISA to determine the progression of antibody production in chickens over 
the 12 week period revealed that antibody production peaked from week five for chicken 
one and weeks four for chicken 2 with slight fluctuations in antibody levels over the 
subsequent weeks to week 11 for which analyses were performed. The titres of the 
antibodies produced after 5 weeks did not differ significantly.  
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The general trend for both mice serum samples showed that antibody production peaked 
four weeks after the first immunisation. Thereafter, antibody production was relatively 
constant. The antibody titre revealed that mouse 2 produced higher levels of antibodies.  
The antibodies produced in chickens and mice were able to detect the recombinant ∆FLVp 
used to produce these antibodies. The antibodies were tested on a T. vivax lysate in a 
western blot. Antibodies produced in chicken 2 and mouse 1 was used for the blot since the 
ELISA revealed that they produced higher levels of antibody. In contrast to the chicken 
antibodies, the mice serum was able to detect native vivapain in a T. vivax lysate. 
In this study, the ∆FLVp gene was successfully cloned into the pTZ57R/T vector (T vector) 
and sub-cloned into the pPic9 and pET-32a expression vectors. The ∆FLVp was only able 
to be successfully expressed in the bacterial expression system. Antibodies were made 
against the recombinantly expressed ∆FLVp in both mice and chickens. The mice serum 
was able to detect the native vivapain in a T. vivax lysate. Therefore, the ability of the 
∆FLVp to detect the native vivapain is a good indication that this antigen will be useful in 
detecting the T. vivax infections in the sera of infected animal for field diagnosis, using 










Appendix 1: The sequence alignment of FLVp with the vivapain sequence obtained from the database 
The sequence alignment was performed using Clustal W2 program 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). The areas shaded in black shows where the sequences align  
Tviv255b07.q1k_3    1 CATGGCGGTGCTGCGCGCGGACGGGCCCGTGGAGCCGCTGTTTGCGGCGTTCAAGCAGAAGTACGGCAGGTCGTACGGGA 
FLVp                1 TATGGCGGTGCTGCGCGCGGAGGGGCCCGTGGAGCCGCTGTTTGCGGCGTTCAAGCAGAAGTACGGCAGGTCGTACGGGA 
 
 
Tviv255b07.q1k_3   81 CCGCGGCGGAGGAGGCGTTCCGCCTGCGCGTATTCGAGGACAACATGCGCCGGTCGCGGATGTACGCGGCGGCAAACCCG 
FLVp               81 CCGCGGCGGAGGAGGCGTTCCGCCTGCGCGTATTCGAGGACAACATGCGCCGGTCGCGGATGTACGCGGCGGCAAACCCG 
 
 
Tviv255b07.q1k_3  161 CACGCGACGTTCGGTGTCACGCCGTTCTCGGACCTCACGCCCGAGGAGTTCAGGACACGCTACCACAACGGCGAGCGCCA 
FLVp              161 CACGCGACGTTCGGTGTCACGCCGTTCTCGGACCTCACGCCCGAGGAGTTCAGGACACGCTACCACAACGGCGAGCGCCA 
 
 
Tviv255b07.q1k_3  241 CTTCGAGGCAGCGCGGGGGCGCGTGAGGACGCTGGTGCAGGTGCCGCCGGGCAAGGCGCCCGCCGCCGTGGACTGGCGCC 
FLVp              241 CTTCGAGGCAGCGCGGGGGCGCGTGAGGACGCTGGTGCAGGTGCCGCCGGGCAAGGCGCCCGCCGCCGTGGACTGGCGCC 
 
 
Tviv255b07.q1k_3  321 GCAAGGGTGCGGTGACGCCCGTCAAGGACCAGGGCAGGTGCGGCTCCTGCTGGTCCTTCTCCGCCATTGGGAACATCGAG 
FLVp              321 GCAAGGGTGCGGTGACGCCCGTCAAGGACCAGGGCAGCTGCGGCTCCTGCTGGTCCTTCTCCGCCATTGGGAACATCGAG 
 
 
Tviv255b07.q1k_3  401 GGCCAGTGGGCGGCTGCCGGCAACCCGCTGACGAGTCTGTCGGAGCA----GATGCTTGTGTCGTGCGACACCACGGATA 
FLVp              401 GGCCAGTGGGCGGCTGCCGGCAACCCGCTGACGAGTCKGTCCGAGARCAAGAATGCTWGTGTCGTGCGAMMCCAAGGWCA 
 
 
Tviv255b07.q1k_3  477 GTGGTTGCAGTGGTGGCCTGATGGACAACGCATTCGA-GTGGA-TCGTGAAGGAG-AACAGTGGCAAGGTGTACACGGAG 
FLVp              481 ATGGRTGCGGTGGTGGCCTGATGGACAACGCATTCGAAGTGGAATCGTGAAGGAGGAACAGTGGCARGGTGTACACSGAG 
 
 
Tviv255b07.q1k_3  554 AAGAGCTATCCCTACGTCT-CTGGCGGTGGCGAGGAGCCGCCCTGCAAGCCGCGTGGGCACGAGGTCGGTGCCACGATCA 
FLVp              561 AAGAGCTATCCCTACGTCTTCTGGCGGTGGCGAGGAGCCGCCCTGCAAGCCGCGTGGGCACAAGGTCGGTGCCACGATCA 
 
 
Tviv255b07.q1k_3  633 CCGG-CCACGTGGACATCCCGC-ACGACGAGGACGCCATCGCCAAGTACCTCGCCGACAACGGCCCGGTCGCTGTGGCC- 
FLVp              641 CCGGGCCACGTGGACATCCCGCCACGACGAGGACGCCATCGCCAAGTACCTCGCCGACAACGGCCCGGTCGCTGTGGCMC 
 
 
Tviv255b07.q1k_3  710 GTGGACGCCACCACCTTCATGTCGTACAGTGGCGGTGTGGTGACGTCCTGCACCTCCGAGGCGCTGAA-CCACGGCGTGC 
FLVp              721 GTGGACGCCACCACYT-CATGTCGTACAGTGGCGGTGTGGTGACGTCCTGCACCTYCGAGGCGCTGWRACCACGGCGTGC 
 
 
Tviv255b07.q1k_3  789 TCCTCG-TCGGCTACAACGACAGCAGCAAGCCGCCGTACTG-GATCATCAAGAACTCGTGGAGCTCGTCGTGGGGCGAGA 
FLVp              800 TCCTCGGTCGGCTAMMACGAMMGCAGCAAGCCGCCGTACTGCRATCATCAAGAACTCGTGGAGCTCGTCGTGGGGCGAGA 
 
 
Tviv255b07.q1k_3  867 AGGGCTACATCCGCATCGAGAAGGGCACGAATCAGTGTCTGGTGGCGCAGCTCGCGTCGAGTGCTGTTGTTGGTGGCCCC 
FLVp              880 AGGGCTACATCCGCATCGAGAAGGGCACGAATCAGTGTCTGGTGGCGCAGCGCGCGTCGAGTGCTGTTGTTGGTGGCCCC 
 
 
Tviv255b07.q1k_3  947 GGTCCCACGCCCACGCCCACGCC------AACAACAACAACAACAACGACCGCACCTGGCCCATCGTCAAGCTTCACGAA 
FLVp              960 GGTCCCACGCCCACGCCCACGCCCACGCCAACAACAACAACAACAACGACCGCACCTGGCCCATCGTCAAGCTTCACGAA 
 
 
Tviv255b07.q1k_3 1021 GACGCTTTGCAGCGGTGATGATTGCGCCGACAACTGTTCAGCGACTGTCTACAACACGAACACGTGCATCCGGCTGGGCG 
FLVp             1040 GACGCTTTGCAGCGGTGATGATTGCGCCGACAACTGTTCAGCGACTGTCTACAACACGAACACGTGCATCCGGCTGGGCG 
 
 
Tviv255b07.q1k_3 1101 CGCTTGGCTCGATGGTGGCCACGTGCGGCGCGGGGGTGCTTGAGCTGAAGGCCTACATGCAGAATGAGCAGTGCACTGGC 
FLVp             1120 CGCTTGGCTCGATGGTGGCCACGTGCGGCGCGGGGGTGCTTGAGCTGAAGGCCTACATGCAGAATGAGCAGTGCACTGGC 
 
 
Tviv255b07.q1k_3 1181 ACCCCGGAGCGGCTCAGCCTGCCGCTGGACAAGTGCCTGGCGTCGCTCAACGTGTCGACGAGGTACCACTGCAACTATGG 
FLVp             1200 ACCCCGGAGCGGCTCAGCCTGCCGCTGGACAAGTGCCTGGCGTCGCTCAGCGTGTCGGCAACGTACCACTGCAACTATGG 
 
 
Tviv255b07.q1k_3 1261 CGCACCGGCGGAGGCGCGCCGCCCTGCGATGCACAAC--TGA-------------------------------------- 
FLVp             1280 CGCACCGGCGAAGGCGCGCCGCCCTGCGATGCACAACATCGAGGGTAGGGCGGCCGCTTAATCGGATCCCGGGCCCGTCG 
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4. GENERAL DISCUSSION 
Animal trypanosomosis is a major disease affecting livestock in sub-Saharan Africa. The 
trypanosome parasite causing the disease is transmitted by the Glossina spp. tsetse fly 
(Hursey 2001; Krafsur 2003; Antoine-Moussiaux et al. 2009). This disease is responsible 
for economic losses of US $4.5 billion annually in sub-Saharan Africa (Antoine-Moussiaux 
et al. 2009). Therefore, there is a great need for quick and effective diagnosis as well as 
methods for control of this devastating disease.  
Current control measures that are being used for African animal trypanosomosis are tsetse 
fly eradication, the use of trypanocidal drugs and trypanotolerant cattle (McDermott and 
Coleman 2001; Naessens et al. 2002; Aksoy 2003; Holmes et al. 2004). Due to the negative 
impact that the trypanocidal sprays used for the eradication of tsetse flies have on the 
environment, the emergence of drug resistant parasites and the decreased used of 
trypanotolerant cattle because of their limited productivity, there is a great demand for 
improved control measures. The ability of the trypanosome to continually change its 
variable surface glycoprotein (VSG) coat, by a process known as antigenic variation, has 
made it extremely difficult to produce vaccines, especially one based on the VSGs 
(Vickerman 1978). For this reason, chemotherapy seems to be one of the key approaches 
for the control of trypanosomosis (McDermott and Coleman 2001; Antoine-Moussiaux et 
al. 2009). An interesting point to make is that diagnostic tools may also be used to monitor 
tsetse fly control and eradication methods, and provide information on the efficiency of 
chemotherapy and the development of trypanocidal drug resistance (Eisler et al. 2004).   
The chemotherapeutic approach is based on targeting molecules that are essential for 
parasite survival and hence kill the parasites. The parasite cysteine peptidases are promising 
targets for chemotherapeutic drug design since they play an important role in the biology of 
trypanosomes (Sajid and McKerrow 2002; Antoine-Moussiaux et al. 2009). The cysteine 
peptidases assist the parasite in differentiation at the different stages of the life cycle, 
invading the host by parasite migration through tissue barriers and altering the host immune 
defence (Chagas et al. 1997; McKerrow et al. 2006).  
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Chemotherapy based on targeting the parasite cysteine peptidases has been introduced for 
many other parasitic diseases such as Chagas disease (McKerrow et al. 1995), malaria 
(Rosenthal 1998; Rosenthal 2004), schistosomiasis (Abdulla et al. 2007) and leishmaniasis 
(Croft and Coombs 2003). The backbone of this approach is to produce synthetic inhibitors, 
targeting the cysteine peptidase, which could potentially be used in the production of new 
drugs. This approach has been very promising in the last decade since the synthetic peptide 
inhibitors against the cysteine peptidases have been able to reduce and in some cases even 
cure Plasmodium, Leishmania and Trypanosoma  infections (McKerrow et al. 1999). 
Synthetic inhibitors that proved to be promising as trypanocidal agents were the irreversible 
vinyl sulfones, the peptidyl ketones; namely, chloromethylketones, diazomethylketones and 
fluromethylketones (Anene et al. 2001). These inhibitors were trypanocidal against           
T. brucei (Scory et al. 1999; Troeberg et al. 1999), T. congolense (Mbawa et al. 1992) and    
T. cruzi infections (Ashall et al. 1990; Bonaldo et al. 1991; Harth et al. 1993; Engel et al. 
1998). These findings brought about the need for this part of the study, which involved 
recombinantly expressing and enzymatically characterising a cysteine peptidase from        
T. vivax, known as vivapain. To date, there has been no published data on the enzymatic 
characterisation of this enzyme as compared to the cysteine peptidases of T. brucei,           
T. congolense, T. cruzi. By enzymatically characterising these cysteine peptidases, and 
more importantly, acquiring information on the amino acid residues preferred in the P1 and 
P2 positions of substrates, this would give the necessary information for the production of 
synthetic irreversible inhibitors. These inhibitors would be comprised of the preferred 
amino acid residues linked to vinyl sulfones or peptidyl ketones. 
The trypanosomal cathepsin L-like cysteine peptidases belong to the C1 family of clan CA 
papain superfamily (Barrett and Rawlings 2004; Caffrey and Steverding 2009). This family 
of peptidases is characterised by the presence of a Cys25, His159 and Asn175 (papain 
numbering) catalytic triad in the active site. The primary structure of these cysteine 
peptidase possess a pre-region, pro-region and a catalytic domain. The peptidases also 
contain a C-terminal extension, which is unique to parasite cysteine peptidases (Authié et 
al. 2001). The C-terminal extension of congopain and trypanopain are proline rich, while 
130 
 
that of vivapain is threonine rich. The exact function of this region is unknown; however, 
since it has proven to be very immunogenic it could potentially play a role in altering the 
host’s immune defences. The presence or absence of this region does not affect the activity 
of the peptidase in any way (Robertson et al. 1996).  
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) is the irreversible inhibitor 
for all clan CA cysteine peptidases. This inhibitor was able to irreversibly inhibit vivapain 
in the present study and was used as the active site titrant. The substrate specificity of 
cysteine peptidases is determined by the occupation of the S2 pocket on the peptidase 
(Sajid and McKerrow 2002; Rosenthal 2004; Caffrey and Steverding 2009). Cysteine 
peptidases belonging to this family prefer bulky hydrophobic amino acid residues such as 
phenylalanine in P2 (Alves et al. 2001; Lecaille et al. 2001) and a wide range of amino 
acids are accepted in P1; however, there is a preference for basic amino acids such as 
arginine in this position (Alves et al. 2001). Most of the peptidases belonging to the papain 
family possess endopeptidase activity (Mbawa et al. 1992), while Vp was also shown to 
have exopeptidase activity.   
Since there has been no published data on vivapain, it was decided to use congopain as a 
positive control in this study. Both the catalytic domains of vivapain (Vp) and congopain 
(C2) were successfully expressed in the P. pastoris yeast expression systems and purified. 
Purification of Vp was conducted using the TPP method and molecular exclusion 
chromatography. Evidence of their expression was verified by detection with suitable 
antibodies in western blots. Interesting to note is that the mature vivapain has a 
glycosylation site at position Asn288 [determined using a prediction program; NetNGlyc 1.0 
Server (www.cbs.dtu.dk/services/NetNGlyc)], since the double band characteristic of the 
vivapain sample was present before and after activation at pH 4.2. This is not a 
characteristic of cruzipain and rhodensain, for example, since these cysteine peptidases do 
not contain a glycosylation site in the mature region of the protein (Eakin et al. 1993; 
Caffrey et al. 2001). Both recombinantly expressed proteins, Vp and C2, were catalytically 




The enzymatic studies performed revealed that Vp and C2 were able to hydrolyse synthetic 
substrates with a phenylalanine residue (hydrophobic) in P2 and an arginine residue (basic) 
in P1, which was expected. Literature revealed that other cysteine peptidase were also able 
to hydrolyse the same substrates such as native congopain from T. congolense (Authié et al. 
1992; Mbawa et al. 1992; Chagas et al. 1997), trypanopain from T. b. brucei (Troeberg et 
al. 1996), native and recombinant falcipain-2 from Plasmodium falciparum (Shenai et al. 
2000), native and recombinant cruzipain from T. cruzi (Cazzulo et al. 1990; Serveau et al. 
1996), mammalian cathepsin L (Brömme et al. 1989), cathepsin L-like cysteine peptidase 
from Fasciola hepatica (Wijffels et al. 1994), and a cysteine peptidase from L. infantum 
(Salvati et al. 2001). Both Vp and C2 were also able to hydrolyse substrates with a 
hydrophobic residue (leucine) in P2 and a basic residue (lysine) in P1. Trypanopain from T. 
brucei was also able to hydrolyse these substrates (Troeberg et al. 1996). Interesting to note 
is that Vp and C2 were only able to hydrolyse synthetic peptides if position P2 was 
occupied by a hydrophobic amino acid residue such as Phe and Leu. These peptidases were 
also unable to hydrolyse peptides with a hydrophobic residue in P1.  
The hydrolysis of Z-Phe-Arg-AMC or D-Val-Leu-Lys-AMC by Vp and C2 was reversibly 
inhibited by the low molecular weight leupeptin, antipain and chymostatin. Native 
trypanopain from T. b. brucei, native and recombinant cruzipain from T. cruzi, native 
congopain from T. congolense, native and recombinant falcipain-2 from P. falciparum and 
a cathepsin L-like cysteine peptidase from F. hepatica (Cazzulo et al. 1990; Eakin et al. 
1992; Mbawa et al. 1992; Wijffels et al. 1994; Troeberg et al. 1999; Shenai et al. 2000) 
were also inhibited by these reversible inhibitors. The hydrolysis of Z-Phe-Arg-AMC and 
D-Val-Leu-Lys-AMC by Vp and C2 was irreversibly inhibited by iodoacetic acid (IAA) 
and iodoacetamide (IAN). By analysing the interaction of an enzyme with its potential 
inhibitor, the reaction kinetic constants can be determined. These constants may be used to 
compare different inhibitors in order to find the best inhibitor for a particular peptidase. The 
kinetic constant values can give an indication of how much inhibitor to use and how much 
time should be allocated for the inhibition to take place (Salvesen and Nagase 1989).  
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The pH optimum obtained for Vp was pH 7.0 and for C2 was pH 6.5. This is surprising 
since most of the cysteine peptidases are located in the lysosome and the pH in this 
environment is usually acidic (Rosenthal 1999) and it would thus be expected that the pH 
optimum should be lower. Cysteine peptidases such as congopain are believed to be 
involved in intracellular proteolytic processing (Mbawa et al. 1991a). Due to the pH 
optimum of C2 being very close to neutral, it can be deduced that this peptidase may have 
roles outside the lysosome, and the same could, therefore, be said for Vp. Most other 
parasite cysteine peptidases also have a pH optimum in the same range of between 6 and 
7.5 (Wijffels et al. 1994; Serveau et al. 1996; Troeberg et al. 1996; Shenai et al. 2000), 
which contributes to their role in the pathogenesis of the diseases. 
The results obtained for the enzymatic studies performed gives insight and vital information 
such as the amino acid residues that Vp prefers in P1, P2 etc which could be used for 
potential future design of synthetic inhibitors for the development of chemotherapeutic 
drugs that could be potentially trypanocidal to T. vivax. The work would involve producing 
synthetic peptide inhibitors that would have the chemical groups such as the vinyl sulfones 
and the peptidyl ketones attached to the preferred amino acid residues in P1, P2 etc and 
testing for their inhibitory action on Vp. Since trypanosomal cysteine peptidases are similar 
to the host peptidases, care must be taken to allow for the least amount of toxicity to the 
host (Steverding et al. 2006; Pink et al. 2005).  
The diagnosis of African animal trypanosomosis can be performed by a number of 
techniques, such as clinical, parasitological, molecular and serological. In most cases, the 
animals affected by trypanosomosis are found in areas that have poor physical and 
economic conditions; therefore, the diagnostic methods used should be suitable for use in 
the field. Other requirements for a diagnostic test are that the diagnosis needs to be specific 
and sensitive. The results obtained from the diagnostic tests should also be easy to interpret 
(Luckins 1992). One of the main reasons for diagnosis is to provide information to 
determine the most suitable method of therapeutic application (Eisler et al. 2004).  
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The most suitable serological diagnostic techniques to be used in conjunction with  
parasitological techniques for the diagnosis of T. congolense, T. vivax and T. brucei 
infections is the ELISA (Luckins 1992). This is due to the sensitivity, simplicity, accuracy 
and reliability of the technique as well as the fact that it does not require extremely 
specialised equipment and many samples can be tested at one time due to the automation of 
the equipment used (Nantulya 1990; Rebeski et al. 1999; Eisler et al. 2004). The antibody-
detection ELISA and the antigen-detection ELISA are the two forms of ELISA that can be 
used for diagnosis. The most important requirement for these ELISAs is a species-specific 
antigen. These antigens can be used in the antibody-detection ELISA and they can also be 
used to produce antibodies that can be used in the antigen-detection ELISAs. There is, 
however, a lack of available recombinant trypanosome antigens required for the detection 
and production of antibodies for both ELISA techniques. Until recently, the antigens used 
in these ELISAs were based on crude preparations of whole parasite lysate. In one such 
study, the antigen used for the antibody-detection ELISA was obtained from tissue culture 
preparations of the procyclic and blood stream forms of T. brucei trypanosomes (Greiner et 
al. 1997). The use of native antigen preparation from whole parasite lysate for the ELISAs 
made it difficult to optimise and standardise the diagnostic tests (Greiner et al. 1997; Eisler 
et al. 2004; Tran et al. 2009). 
The invariant surface glycoprotein ISG75 of T. brucei, full length mutant of congopain, 
FL28 and RoTat 1.2 variable surface glycoprotein recombinant antigens have been 
produced and used to detect T. brucei (Tran et al. 2008), T. congolense (Davita, 
2009)(MSc) and T. evansi (Verloo et al. 2001; Lejon et al. 2005), respectively.  
Recombinant invariant surface glycoprotein ISG75 of T. evansi has also been expressed 
and was also able to detect T. evansi infections (Tran et al. 2009). However, none of these 
antigens were specific for the diagnosis of T. vivax infections (European Commission 6th 
Framework Research grant, Trypadvac2). Due to the high amount of cross-reaction that 
occurs in the ELISA methods when testing sera of animals infected with trypanosomosis, it 
is important for diagnostic sensitivity that sera is tested against an array of trypanosome 
species-specific antigens. The main pathogens causing disease in the African livestock are 
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T. congolense, T. vivax and to a lesser extent T. brucei. There are recombinant antigens; 
namely, the invariant surface glycoprotein ISG75 of T. brucei and full length mutant of 
congopain, FL28 specific for T. brucei and T. congolense infections, respectively. 
Therefore, there is a need to produce an antigen that would be specific in detecting T. vivax 
infections, since these three parasites are the main causative agents of bovine 
trypanosomosis.   
For this reason, this study also focussed on the production of a recombinant antigen derived 
from the T. vivax that could potentially be used for specific diagnosis of T. vivax infections. 
The antigen that was produced was the full length (FL) inactive mutant form of vivapain 
(ΔFLVp). The decision to express the ΔFLVp instead of full length active form of vivapain 
was based on prior studies which showed that the expression of the full length active form 
of congopain resulted in a very low yield and that the expressed protein was very unstable 
(Boulangé A, University of KwaZulu-Natal, personal communication). 
The ∆FLVp clone was obtained by firstly cloning a FL active form of vivapain, obtained by 
PCR using specific FL primers and T. vivax genomic DNA as the template, into a 
pTZ57R/T vector. Thereafter, the Cys25 residue from the catalytic domain of the FL active 
form was replaced with an Ala25 residue from an already existing mutated catalytic domain 
(C25A) clone which was present in the pPic9 vector. This mutation changes the 
conventional Cys25, His159, Asn175 (papain numbering) catalytic domain of the FL active 
form of vivapain to Ala25, His159, Asn175. This mutation was made possible by using a 
specific restriction enzyme, i.e. BsgI that was specific to the full length active clone and the 
mutated catalytic clone. The restriction sites for this enzyme were present on either side of 
CHN coding domain in the full length active clone and the ANH coding domain on the 
mutated catalytic clone. Therefore, the use of this restriction enzyme allowed for the 





from the full length active clone as well as the surrounding residues with the Ala, His and 
Asn and surrounding residues from the mutated catalytic domain clone.  
This FL mutant was cloned into a yeast expression vector, pPic9, and a bacterial expression 
vector, pET32, but expression of the ∆FLVp was only successful in the bacterial expression 
system. Although this expression system resulted in very high yields of the recombinant 
ΔFLVp, the expressed protein was insoluble. This made purification difficult; hence 
attempts were made to renature the protein first. The method used for renaturation was 
based on that used for the refolding of falcipain-2 (Sijwali et al. 2001). The recombinant 
ΔFLVp solubilised in and treated with renaturation buffer that contained 100 mM Tris-Cl,  
1 mM EDTA, 20% Glycerol, 1 M KCl, 1 mM GSH, 0.5 mM GSSG. The results from the 
renaturation were inconclusive since there was no clear shift in size between the renatured 
and non-renatured protein as was seen for falcipain-2 (Sijwali et al. 2001). This process 
also led to a drastic loss of the recombinant ΔFLVp. If this work were to be repeated then 
expression of the mutant should be performed under different conditions such as lowering 
the temperature at which the culture is grown. Studies have shown that lowering the 
incubation temperature leads to a decreased amount of inclusion bodies and an increase in 
the production of soluble protein (Shirano and Shibata 1990). By obtaining more soluble 
protein, this would alleviate the need to renature the protein and hopefully prevent such a 
drastic loss of protein in the purification steps.   
Antibodies were produced against the recombinant solubilised ΔFLVp in both mice and 
chickens as indicated by ELISA. The antibodies from both chickens (IgY) and mice (sera) 
detected the recombinant ΔFLVp in western blots. The blots showed significant levels of 
non-specific antibody binding. This could have been due to the fact that the chicken and 
mouse antibodies were not affinity purified. It could also be due to the possibility that too 
much protein was loaded on the SDS-PAGE gel. A very positive and interesting point to 
note from a diagnostic point of view is that the serum from one of the mice was able to 
detect native vivapain in a T. vivax lysate. This suggests that the antibodies produced 
against the ΔFLVp antigen could potentially be used to detect T. vivax in sera of infected 
animals.   
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In this study, the catalytic domain of vivapain (Vp) was expressed in a yeast expression 
system and enzymatically characterised. This information could provide insight for future 
work to synthesise synthetic inhibitors which targets vivapain and could potentially be 
trypanocidal to the T. vivax parasite. This study also involved the expression of ΔFLVp in 
the bacterial expression system. The ΔFLVp was expressed for use as an antigen or it could 
be used to produce antibodies, which ultimately could be useful in the ELISA diagnostic 
tests. Since the ΔFLVp was expressed as an insoluble protein, future work will be based on 
attempting to express the mutant cultures at lower incubation temperatures, which could 
potentially lead to the production of more soluble protein. Antibodies against the ΔFLVp 
recombinant protein were produced in both mice and chickens. The mouse serum was able 
to detect the native vivapain from a T. vivax lysate.  
The findings from enzymatic studies of Vp gives information that is vital for the future 
production of new chemotherapeutic drugs, which could potentially aid in the control of 
this disease. The ΔFLVp antigen could finally be used to specifically diagnose T. vivax 
infections as well as be used in conjunction with other antigens specific for T. congolense 
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